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Abstract 
Background 
The increased detection of pT1 colorectal cancers (CRC) in the National Health 
Service Bowel Cancer Screening Programme (NHSBCSP) raises new concerns for 
clinicians.  The aim of this study is to investigate the phenotypic features and biology 
of screened and symptomatic pT1 CRC and to assess current and new high risk 
features associated with lymph node metastasis (LNM).  The second aim of this 
study is to investigate the inter-observer variation of reporting screened pT1 CRC 
between pathologists.  
 
Methods 
Symptomatic and screened pT1 CRC were identified from two databases (Northern 
and Yorkshire Cancer Registry and Information Services [NYCRIS] and NHSBCSP 
database).  Phenotypic features of the pT1 CRC were evaluated and compared from 
both cohorts.  
The second part of the study investigated the inter-observer variability in the 
qualitative and quantitative assessments of screened pT1 CRC.  Participating 
pathologists were asked to perform quantitative and qualitative assessments on 41 
screened pT1 CRC.  The level of agreement was determined using Fleiss Kappa 
statistics and intraclass correlation coefficient testing.  
 
 
  
iii 
Results 
Symptomatic CRC with LNM had a significantly wider area of invasion (p=0.001), a 
greater area of submucosal invasion (p < 0.001) and a higher proportion of tumour 
stroma (p = 0.005) compared to CRC without LNM. Symptomatic pT1 CRC were 
also significantly bigger in size than screened pT1 CRC. 
The inter-observer variation study showed that quantitative factors had better levels 
of agreements than qualitative factors. 
 
Conclusion 
This study has shown that screened pT1 CRC are quantitatively smaller to their 
symptomatic counterparts suggesting that the NHS BCSP detects earlier pT1 CRC.  
This study also showed that novel quantitative factors such as width of invasion, 
area of submucosal of invasion and PoTS could be used as valid parameters in 
determining the rate of LNM.  Finally, this study highlights the need for better 
guidelines/definitions in the evaluation of screened pT1 CRC. 
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Chapter 1: Colorectal cancer 
Colorectal cancer (CRC) is the third most common cancer worldwide after lung and 
breast cancer with 60% of all CRC presenting in more developed countries.  CRC is 
an important public health problem as nearly 1.36 million new cases are diagnosed 
worldwide each year with around 694,000 deaths.  In the UK, CRC is the fourth most 
common cancer in the UK where around 41,600 people are diagnosed with CRC 
each year (CRUK 2015a). 
In England and Wales, the overall five-year survival rate for CRC has improved over 
the last 30 years.  The 5-year survival rate for males and females are 59.2% and 
58.2% respectively (CRUK 2015b).  Much of the improved survival rate is attributed 
to earlier cancer detection, improved surgical techniques, the use of therapy post-
operatively and for pre-operative down staging by radiotherapy and chemotherapy.  
Endoscopy (colonoscopy and/or flexible sigmoidoscopy) and imaging modalities 
such as computer tomography (CT) and magnetic resonance imaging (MRI) scans 
have helped detect and stage CRC and also dictate the best treatment options 
(Salerno, Daniels and Brown 2006, Levin et al 2008, Beets-Tan and Beets 2011).  
Advancing surgical techniques (Heald 1988, Ptok et al 2007, Guerrieri et al 2008, 
Hohenberger et al 2009) sometimes with CRT (IMPACT 1995) have reduced the 
recurrence rate of CRC and have helped increase the survival rates in patients with 
favourable staging.  However, there are associated morbidity and mortality risks with 
surgery (Canivet et al 1989, Brown et al 1991, Bokey et al 1995, Wolpin et al 2007) 
and CRT (Ooi et al 1999, Andre et al 2004, De Dosso et al 2009).  In everyday 
clinical practice, it is difficult to balance the risks of morbidity and mortality 
associated with surgery and CRT versus the potential risk of under treating the 
  
2 
malignancy.  This is highlighted most in the area of early cancer, stage pT1, where 
there is a difficult decision making process in determining local endosopic or surgical 
excision versus a major surgical excision. 
 
1.1 Anatomy of the large bowel 
1.1.1 Gross anatomy of the large bowel 
The large bowel is the most distal segment of the gastrointestinal tract.  It is around 
1.5 meters in length and originates in the lower right quadrant of the abdominal 
cavity, starting at the ileocaecal valve.  The large bowel can further be divided into 
different sections namely the caecum, ascending, transverse, descending and 
sigmoid colon.  The large bowel eventually terminates at the rectum.  The rectum is 
the terminal part of the large bowel and is located within the pelvic cavity.  The 
contents of the large bowel are then evacuated via the anal canal.  
The large bowel can be differentiated from the small bowel by its wider transverse 
diameter, sacculations of the wall (haustra), thickened longitudinal muscle bands 
(taeniae coli) and the presence of omental appendages (appendices epiplociae).  
The transverse diameter diminishes continually towards the distal end of the 
gastrointestinal tract except for the dilatation known as the rectal ampulla. 
The arterial supply to the large bowel is from the superior and inferior mesenteric 
arteries arising from the aorta.  The arterial supply from the rectum is via the inferior 
mesenteric artery and also branches of the internal iliac arteries (middle and inferior 
rectal arteries).  The main venous drainage of the large bowel is by the way of the 
portal venous system into the liver where absorbed nutrients are metabolised.  
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There is also a secondary drainage system for the large bowel in the form of the 
lymphatic system.  The lymphatic system is composed of network lymphatic vessels 
and channels that subsequently drain lymph via lymph nodes into the cisterna chyli 
in the upper abdomen.  The lymph circulates from the cisterna chyli via the thoracic 
duct into the left subclavian vein. 
 
1.1.2 Microscopic anatomy of the large bowel 
The architecture of the large bowel wall is similar to the organisation of the entire 
gastrointestinal tract as observed from proximal oesophagus to the anus.  It contains 
five distinctive layers; the mucosa, sub-mucosa, muscularis propria, subserosa and 
serosa.  
 
1.1.2.1 Mucosa 
The colonic mucosa lines the inner surface of the large bowel and appears smooth 
at the gross level due to the absence of villi (figure 1.1).  The mucosa is lined by a 
single layer of columnar epithelium composed of a variety of cell types such as 
goblet cells, absorptive colonocytes and neuroendocrine cells.  The composition of 
the cells depends on the location within the large bowel and position in the crypt.  
The crypt has a basement membrane and on the lamina propria side a thin layer of 
myofibroblasts.  The colonic glands are maintained within a connective tissue matrix 
(lamina propria), which in turn is bounded by a thin smooth muscle layer, the 
muscularis mucosae, a layer that defines the lower limit of the mucosa. 
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1.1.2.2 Muscularis Mucosae 
The muscularis mucosae represents the lower border of the mucosa and consists of 
a thin layer of smooth muscle fibres with mixed transverse, oblique and longitudinal 
orientation.  Vascular and lymphatic structures as well as neural branches traverse 
this muscle layer.  The muscularis mucosae is an important pathological structure as 
the breach of this structure by neoplastic colorectal epithelium indicates invasive 
carcinoma (figure 1.1) (Walsh and Carey 2013). 
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Figure 1.1: The mucosa composed of crypts and lamina propria. The blue arrow 
indicates the crypts of the colonic mucosa and the red arrow indicates the lamina 
propria. The black arrow indicates the muscularis mucosae at the lower border of the 
mucosa. Magnification is at 100x. 
 
1.1.2.3 Submucosa 
The submucosa underlies the muscularis mucosae and consists of loose connective 
tissue such as blood vessels, lymphatics, smooth muscle fibres, collagen and 
adipose tissue (figures 1.1 and 1.2).  It also contains two enteric neural plexi; the 
inner submucosal plexus (Meissner’s plexus) and the outer submucosal plexus 
(Schabadasch’s or Henle’s plexus).  The enteric nervous system serves to transmit 
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central, sympathetic and parasympathetic nerve signals to the large bowel in order to 
regulate its function.  
 
 
Figure 1.2: The submucosa occupies the area between the muscularis mucosae and 
the muscularis propria as indicated by the arrow.  Magnification is at 40x.  
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1.1.2.4 Muscularis propria 
The muscularis propria comprises of an inner circular smooth muscle layer and an 
outer longitudinal layer (figures 1.3).  In between the muscle layers is the third plexus 
of the enteric nervous system, the myenteric plexus (Auerbach’s plexus) that 
provides motor innervations to both muscles and secretomotor innervations to the 
mucosa.  The muscularis propria also contains blood vessels and lymphatics.  
 
1.1.2.5 Sub-serosa, serosa and peritoneum  
The sub-serosa is the outermost layer of the large bowel and its outermost surface is 
covered by the serosa consisting of connective tissue with a surface of mesothelium 
(figure 1.3).  The sub-serosa has the same composition as the mesentery.  Within 
the peritoneal cavity, the serosa is also known as the visceral peritoneum and 
continues over the abdominal wall as the parietal peritoneum. 
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Figure 1.3: Microscopic view of the layers of the colon. Magnification is at 10x.  
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1.2 Epidemiology of colorectal cancer (CRC) 
Around 110 new cases of CRC are diagnosed each day in the UK and it is the fourth 
most common cancer.  In 2011, there were 41,600 new cases of CRC registered in 
the UK with 95% of CRC occurring in people aged 50 years and over.  Most of the 
CRC are diagnosed in the left side of the colon with around 60% occurring in the 
sigmoid colon, recto-sigmoid junction and rectum (CRUK 2015a) (figure 1.4). 
 
Figure 1.4: Distribution of cancers within the colon, Great Britain, 2007 – 2009. 
Diagram obtained from Cancer Research UK website 
[http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/bowel-cancer/incidence#heading-Zero] 
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CRC is the third most common cancer in both males and females separately. Up to 
the age of 50, men and women have similar proportions for CRC, but later in life, the 
male proportion increases (figure 1.5).  The lifetime risk for men and women being 
diagnosed with CRC in the UK is approximately to 1 in 14 and 1 in 19 respectively 
(CRUK 2015b). 
 
Figure 1.5: Average new number of CRC cases per year and age-specific incidence 
rates, UK 2009 – 2011. Diagram obtained from Cancer Research UK website 
[http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/bowel-cancer/incidence#heading-Zero] 
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1.3 Development of CRC 
CRC is a complex disease that arises from a sequence of genetic and molecular 
events. It has been recognized that normal colonic mucosa produces adenomas that 
progress onto carcinomas if left untreated.  This pathway is most commonly known 
as the adenoma – carcinoma sequence (Morson 1974).  CRC are sporadic, familial 
(inherited) or associated with inflammatory bowel disease.  Sporadic CRC accounts 
for 70 – 80% of colorectal malignancies.  Progression from normal colonic epithelium 
through to adenoma and finally to carcinoma requires several genetic alterations to 
normal tumour suppressor genes and proto-oncogenes (Hardy, Meltzer and 
Jankowski 2000).  
Hanahan and Weinberg proposed six biological hallmarks that contribute to the 
development of cancer in general which can be applied to CRC (Hanahan and 
Weinberg 2011).  The six hallmarks that were proposed are: 
 Self-sufficiency in growth signals 
 Insensitivity to antigrowth signals 
 Ability to evade apoptosis 
 Limitless replicative potential 
 Sustained angiogenesis 
 Tissue invasion and metastasis 
The first four hallmarks are acquired through genomic instability by alterations to 
proto-oncogenes, tumour suppressor genes and DNA mismatch repair genes. 
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1.3.1 The adenoma – carcinoma pathway 
CRC is a heterogeneous disease with multiple molecular pathways leading to 
different phenotypes   As a result of germ line defects or damage and changes in the 
somatic DNA, normal colonic mucosa epithelium can transform into a benign 
neoplasm (adenoma) and subsequently into invasive carcinomas (Markowitz and 
Bertagnolli 2009, Pritchard and Grady 2011).  The progression of tubular, tubullo-
villous and villous adenomas into CRC has long been recognized, but there is 
evidence that another pathway to malignancy exists; the serrated neoplasia 
pathway.  This serrated pathway involves a small percentage of hyperplastic polyps 
progressing to serrated lesions and eventually to CRC (Pritchard and Grady 2011).  
The serrated adenoma pathway will be discussed further later in this chapter. 
Currently, there are three distinct molecular pathways that lead to the transformation 
of normal colonic mucosa to an adenomatous lesion and subsequently CRC.  The 
three molecular pathways are the chromosomal instability pathway, microsatellite 
instability pathway and the CpG Island Methylator Phenotype (CIMP) pathway.   
 
1.3.1.1 Chromosomal instability pathway 
Chromosomal instability is the most common cause of genomic instability in CRC 
and is found in up to 85% of sporadic CRCs (Pritchard and Grady 2011). 
Chromosomal instability results from defective chromosomal segregation leading to 
aneuploidy, telomere dysfunction or defects in DNA damage response mechanism 
(Pino and Chung 2010).  This most frequently results in loss of heterozygosity at the 
tumour suppressor gene loci and chromosomal rearrangements.  Tumours with 
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chromosomal instabilities are distinguished with the accumulation of mutations in 
specific oncogenes (KRAS, BRAF, PIK3CA) and tumour suppressor genes (APC, 
TP53), thereby triggering the development of CRC.   
The most common gene implicated in chromosome instability is the APC gene.  The 
function of the APC is to regulate the spindle microtubule formation and is required 
to detect misaligned chromosomes during mitosis (Caldwell and Kaplan 2009).  The 
autosomal condition familial adenomatous polyposis, in which numerous 
adenomatous colonic polyps develop leading to a 100% lifetime risk of developing 
CRC (Woods et al 2010, Kastrinos and Syngal 2011) is the consequence of the 
alteration to the APC gene. 
The other important example of tumour suppressor gene loss is the TP53 gene.  
TP53 gene is a key tumour suppressor gene that is mutated/altered in about half of 
all CRCs (Pritchard and Grady 2011).  The TP53 gene has multiple functions.  It has 
been shown to be involved in cell cycle regulation, apoptosis, DNA excision repair 
and chromosomal segregation (Wsierska-Gadek and Horky 2003, Ewing et al 2014).  
Loss of function of the TP53 gene often results in the malignant transformation of 
colonic adenomas (Markowitz and Bertagnolli 2009, Pritchard and Grady 2011).   
All or most oncogenes are alterations of normal genes called proto-oncogenes.  
Proto-oncogenes are normal genes that encode proteins that are responsible for the 
control of key functions of cell growth, division and development.  The proto-
oncogenes normally facilitate signal transmission of extracellular growth signals to 
the nucleus of the cell and also regulate cellular signal transduction.  The mutated 
proto-oncogene is called an oncogene.  Oncogenes typically exhibit increased 
function or production of proteins that are vital in cellular development thus leading to 
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unregulated cell growth and division.  An example of an oncogene often implicated in 
CRC is the KRAS oncogene which occurs relatively early in the adenoma-carcinoma 
sequence (Pritchard and Grady 2011).  There are two types of KRAS oncogenes 
that are found in CRC; the normal (wild-type) KRAS oncogene and the abnormal 
mutated KRAS oncogene.  In CRC, up to 60 – 70% of patients have the wild type 
KRAS oncogene and the remaining 30 – 40% have the mutant version of the 
oncogene (Schuch, Kobold and Bokemeyer 2009). 
The BRAF gene is another proto-oncogene often implicated in CRC and other 
cancers such as malignant melanoma, papillary thyroid and lung cancers.  The 
BRAF gene encodes for the protein B-raf which is a member of the Raf kinases 
family of phosphorylating enzymes that control cell differentiation and division.   
Mutations or alterations to the BRAF gene results in BRAF acting as an oncogene.  
 
1.3.1.2 Microsatellite instability (MSI) pathway 
Microsatellites are repeated sequences of DNA found throughout the entire genome.  
The repetitive nature of microsatellites makes them a vulnerable target to 
transcription errors during replication.  The development of CRC with microsatellite 
instability (MSI) involves the inactivation of genes responsible for DNA mismatch 
repair (MMR) through either through germline, somatic mutation or aberrant 
methylation (Pritchard and Grady 2011).  The somatic inactivation of the MMR genes 
is found in approximately 15% of cases of sporadic CRC and associated with older 
age, the female sex and the proximal distribution of the CRC (Markowitz and 
Bertagnolli 2009, Bogaert and Prenen 2014).  
  
15 
The germline mutation/ alteration of MMR genes is responsible for Lynch syndrome 
or hereditary non-polyposis colorectal cancer (HNPCC).  Loss of function in the 
MMR gene has been identified in four genes: MLH1, MSHS2 (accounting for majority 
of cases), MSH6 and PMS2 (Woods et al 2010, Kastrinos and Syngal 2011).  Lynch 
syndrome is inherited in an autosomal dominant fashion and is the most common 
hereditary CRC syndrome amounting to 2 – 3% of all cases (Kastrinos and Syngal 
2011).  Affected individuals have an 80% lifetime risk of developing CRC (Woods et 
al 2010) and are also at risk of developing extra-colonic malignancy that includes 
endometrial and ovarian cancers (Al-Sohaily et al 2012).  
 
1.3.1.3 CpG Island Methylator Phenotype (CIMP) Pathway 
Changes to gene expression or function without changing the DNA sequence of that 
particular gene can happen with epigenetic alteration.  Epigenetic alteration is 
usually caused by aberrant DNA methylation. In particular, the aberrant methylation 
occurs within the promoter-associated CpG islands leading to the loss of function of 
the MMR gene hMLH1 (Issa 2004, Markowitz and Bertagnolli 2009).  The 
hypermethylation of promoters containing CpG islands is known as the CpG island 
methylator phenotype (CIMP) (Pritchard and Grady 2011) and is observed in 15% of 
CRCs where there is loss of MLH1 expression resulting in MMR deficiency and 
associated MSI (Donehower, Creighton and Schultz 2013). 
Another gene involved in DNA repair is the MGMT gene.  The MGMT gene encodes 
for the MGMT protein (methylated DNA protein cysteine methyltransferase) that is 
  
16 
involved in repair of DNA.  This MGMT gene can be inactivated by hypermethylation 
of its promoter sequence and thus impair its DNA repairing properties. 
 
1.3.2 Serrated colorectal lesions  
The significance of colonic serrated lesions and their importance as an alternate 
pathway to the development of CRC have long been recognised.  First used in 1990, 
Longacre and Fernoglio-Preiser had described the term ‘serrated adenoma’ for 
colonic polyps that had features of a conventional adenoma and a hyperplastic 
polyp.  This lesion had subsequently been termed as the ‘traditional serrated 
adenoma (TSA) (Longacre and Fernoglio-Preiser 1990).  A few years later, 
Torlakovic and Snover had identified polyps that showed a constellation of features 
that were specific for hyperplastic poylps and TSAs and this led to the recognition of 
the entity of sessile serrated lesions (SSL) (Torlakovic and Snover 1996).  
The terminology of serrated lesions is complex as there are differences in opinion 
between UK, European and US pathologists in regards to the constitution of a 
serrated lesion.  In the UK, it has been proposed that serrated lesions are given one 
of the following names based on their morphological features: hyperplastic polyp, 
sessile serrated lesion, sessile serrated lesion with dysplasia and traditional serrated 
adenoma (Bateman and Shepherd 2015).  These lesions will be described in detail 
in the next headings.  
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1.3.2.1 The spectrum of sessile serrated lesions 
A spectrum of colonic polyps with partial or wholly serrated architecture is now 
recognised.  The spectrum of these polyps ranges from polyps with no dysplasia 
(hyperplastic polyps, sessile serrated lesions without dysplasia) to polyps with 
definite dysplasia (sessile serrated lesions with dysplasia, traditional serrated 
adenomas) (Bateman 2014).  
 
1.3.2.2 Hyperplastic polyp 
Hyperplastic polyps are very commonly encountered by both the endoscopist and 
pathologist.  They constitute approximately 25 – 30% of all resected colonic polyps 
and have an estimated prevalence of 10 – 20% in the Western adult population 
(Bettington et al 2013).  Hyperplastic polyps occur at all site of the large bowel but 
are more common distally.  Three morphological variants exist – microvesicular, 
goblet cell and mucin poor types (Bateman 2014).  
Despite possessing both the BRAF and KRAS mutations, the malignant potential of 
hyperplastic polyps are considered to be low and under current UK guidelines, no 
additional surveillance is required (Bettington 2013, Bateman and Shepherd 2015).  
 
1.3.2.3 Sessile serrated lesions (SSL)  
SSLs share similar histological features with the microvesicular variant of 
hyperplastic polyps (Torlakovic and Snover 1996).  However, SSLs are bigger than 
hyperplastic polyps and contain several other key histological features such as an 
  
18 
irregular distribution of crypts, dilatation of crypt bases, presence of serration at crypt 
bases, branched crypts, horizontal extension of crypt bases, dysmaturation of crypts 
and herniation of crypts though the muscularis mucosae (Bateman and Shepherd 
2015).  
Similarly to hyperplastic polyps, SSLs are associated with BRAF gene mutations and 
therefore, it is possible that hyperplastic polyps and SSLs are part of the same 
spectrum of serrated lesions with small hyperplastic polyps at one end and large 
SSLs at the other (Bateman 2014).  
 
1.3.2.4 SSL with dysplasia 
Dysplasia can arise in a SSL and the dysplasia can be low or high grade in nature. It 
is also believed that SSLs with dysplasia are associated with a quicker progression 
to adenocarcinoma compared to the ‘classical’ adenoma (Bettington et al 2013).  In 
SSL with dysplasia, there is loss of function of the DNA mismatch repair gene, 
hMLH-1, increased DNA methylation (the CpG island methylator phenotype) as well 
as mutation to the BRAF gene (Bettington et al 2013).  
 
1.3.2.5 Traditional serrated adenomas (TSA) 
TSAs are uncommon lesions and are distinct from SSL.  TSA frequently occur more 
within the left side of the large bowel and their histological features include 
tubulovillous architecture, eosinophilic cytoplasm, elongated (‘pencillate’) nuclei and 
the presence of multiple tiny crypts extending from the primary crypts (ectopic crypts) 
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that give a serrated appearance to the lesion  (Longacre and Fenoglio-Preiser 1990).  
These serrated areas are usually mixed with areas displaying a more ‘classical’ 
adenoma growth pattern and transition between these areas is abrupt.  Dysplasia 
may occur within a TSA and progression to adenocarcinoma can take place 
(Makinen 2007). 
 
1.3.3 The serrated carcinoma pathway 
The serrated carcinoma pathway currently has two main mechanisms that involve 
BRAF and KRAS mutations.  The BRAF pathway is further subdivided into two 
further pathways depending on its MSI status.  
SSLs are associated with an early BRAF mutation followed by in some cases, loss of 
MLH1 expression.  The resulting CRC contains BRAF mutations,are CIMP-high and 
exhibit MSI.  This type of CRC tends to occur in elderly women and is most common 
in the proximal large bowel.  Another characteristic of this CRC is that it frequently 
presents with a high tumour stage but without nodal or distant metastasis (Bettington 
et al 2013). 
The second alternative BRAF pathway occurs in SSL in which MLH1 is not lost but 
may otherwise show silencing of p16 function or MGMT loss.  The ensuing CRC 
again contains the BRAF mutation, is CIMP-high but may only display low levels of 
MSI or none at all.  These tumours occur more proximally in the large bowel but are 
more aggressive as they are often poorly differentiated, mucin producing and have 
higher rates of tumour budding, lympho-vascular invasion and perineural invasion 
(Bettington et al 2013).  
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The other serrated carcinoma pathway involves mutation of the KRAS gene.  TSA 
are commonly associated with KRAS gene mutations and wnt abnormalities.  This 
results in CRCs with KRAS mutations, CIMP-low and is microsatellite stable (Jass et 
al 2006, Bettington et al 2013).  A summary of the serrated carcinoma pathway is 
shown in figure 1.6.  
 
 
Figure 1.6: Flow diagram of the serrated carcinoma pathways (Figure adapted from 
Bettington et al 2013). 
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1.4 Staging and grading of CRC 
Staging of CRC describes how far the cancer has progressed and the extent of its 
spread within the body.  Cancer staging aids clinicians in determining the most 
appropriate treatment for each patient.  Staging also gives a reasonable indication of 
prognosis with an increasing stage denoting a poorer prognosis.  In the UK, CRC is 
staged using the two main systems: the Dukes’ and TNM staging systems.  
 
1.4.1 Dukes’ and TNM staging system 
The Dukes’ staging system for CRC was first proposed in 1932 by the British 
pathologist Cuthbert Dukes (Dukes 1932).  At first, the Dukes’ staging system 
consisted of 3 stages; A, B and C but it was later modified to include a subdivision of 
stage C (stages C1 and C2) (Dukes and Bussey 1958) and further revised by 
Turnbull to include a stage D (Turnbull et al 1967) (Table 1.1).  
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Stage Definition Expected 5 yr cancer specific 
survival rate 
A Tumour invades through the muscularis 
mucosae into the submucosa but not through 
the muscularis propria. 
No lymph node involvement. 
>90% 
B Tumour invading through the muscularis 
propria. 
No lymph node involvement. 
60 – 75% 
C1 Spread of tumour to local lymph node(s). 40 – 60% 
C2 Spread of tumour to apical lymph node. 20 – 40% 
D Spread of tumour to other organs 5 – 40% 
Table 1.1: Modified Dukes’ staging of CRC and expected 5 year cancer specific 
survival rate 
 
The TNM staging system was developed by Denoix between 1943 and 1952 (Denoix 
and Schwartz 1959) and is the most commonly used staging system.  This system 
incorporates depth of invasion along with nodal and metastatic disease status (Table 
1.2).  Currently, in the UK, the Royal College of Pathologists recommends that CRC 
staging should be based on the fifth edition of the TNM manual (TNM 5) (Greene et 
al 2002). 
“T” describes the depth of invasion of the tumour through the bowel wall 
“N” indicates whether or not there is spread to lymph nodes and if so, how many 
lymph nodes are involved. 
“M” describes the presence of distant metastasis (commonly to the liver or lungs) 
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Tumour Stage (T) Definition 
T0 No evidence of carcinoma 
Tis Carcinoma in-situ 
T1 Invasion of the submucosa but no further 
T2 Invasion into the muscularis propria 
T3 Invasion through the muscularis propria and into the 
subserosal layers but not through them 
T4 Tumour has invaded through the serosal layer and there is 
direct invasion into other organs or there is perforation of 
the visceral peritoneum 
Nodal Stage (N)  
N0 No regional lymph node metastasis 
N1 Metastasis into 1 to 3 regional lymph node(s) 
N2 Metastasis into 4 or more regional lymph nodes 
Distant Metastasis 
(M) 
 
M0 No distant metastasis 
M1 Distant metastasis present 
Table 1.2: Description of each component to the TNM staging system (version 5) 
(Sobin and Fleming 1997) 
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1.5 Treatment of CRC 
Curative treatment for CRCs consists of 3 options: major surgery, oncological 
treatment (chemotherapy and/or radiotherapy) and increasingly, local excision for 
early CRC.  All these options can be used in isolation or in combination with each 
other depending on the CRC stage.  For example, in advanced rectal cancers, a 
patient may initially receive radiotherapy and/or chemotherapy before surgical 
resection.  After surgical resection, the patient then may receive further 
chemotherapy if there is any evidence of lymph node spread. 
 
1.5.1 Surgery 
Surgery is the mainstay of curative treatment and in the UK approximately 80% of 
patients with CRC undergo surgery (CRUK 2015a).  The type of surgery that is 
offered depends on tumour location.  Surgery involves resection of the bowel 
containing the tumour and its mesentery that contains the vascular supply and 
draining lymph nodes.  If possible, the remaining bowel is re-anastomosed to restore 
intestinal continuity.  However, in certain cases where rectal cancer is low-lying, a 
permanent stoma is needed due to involvement of the anal sphincter complex.  
After resection, the bowel containing the tumour and its respective mesentery are 
examined by a pathologist.  This will accurately determine the completeness of 
resection, the stage of the cancer and finally the grade of differentiation of the 
cancer.  This information will then further assist clinicians in terms of further 
treatment if needed. 
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Risks of surgery include those relating to age and co-existing morbidity and 
operative and anaesthetic risk.   Most common operative risk includes bleeding, 
infection (wound, chest or intra-abdominal infections), wound dehiscence, thrombo-
embolic event, post-operative cardiac event and anastomosis leaks.  Overall, 
morbidity and mortality of colorectal cancer surgery varies from 28% - 37.2% and 
3.4% - 5.9% respectively (Bokey et al 1995, Longo et al 2000, Alves et al 2005, 
Morris et al 2011).  
 
1.5.2 Local procedures 
With the increasing number of pT1 CRCs detected within the screening programme, 
avoidance of major invasive surgery by use of local excision procedures like 
polypectomy, endomucosal resection (EMR) and transanal endoscopic microsurgery 
(TEMS) would be ideal. 
Polypectomy and EMR are possible for pT1 cancers throughout the bowel and can 
be done by a trained endoscopist or surgeon.  Polypectomy is a technically easier 
procedure compared to EMR but EMR has the advantage of removing flat or sessile 
lesions.  EMR also identifies lesions that are invading or tethered to the deep 
submucosa or muscle layer (non-lifting sign) which are unlikely suitable for 
endoscopic removal and confirms the need for a more radical procedure.  
TEMS was first introduced by Buess et al in 1983 (Buess et al 1984, Buess et al 
1985; Buess et al 1987, Buess et al 1988a; Buess et al 1988b).  TEMS is most 
commonly done on pT1 cancers affecting the rectum.  TEMS is possible due to the 
accessibility and locality of the cancer within the rectum. Many studies have been 
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done on the effectiveness of TEM in treating rectal cancers.  In 1996, Winde 
published a prospective randomized trial where TEM (n=24) was compared to 
anterior resections (n=26) in the treatment of T1N0 rectal cancers (Winde et al 
1996).  The study showed no statistically significant difference for local recurrence or 
5-year survival rates. Langer et al showed that TEM (n=79) had lower rate of 
recurrence when compared to conventional local excision techniques (n=76) and a 
lower incidence of complications and less impairment of life quality when compared 
to radical resection (n=27) (Langer et al 2003).  
Ptok et al also showed that local resection (conventional transanal approach and 
TEMS) were associated with fewer general and specific post-operative 
complications.  However, they showed that the patients with local resections had a 
significantly higher 5-year local tumour recurrence rate compared to the patients who 
underwent radical resection.  Interestingly, 5-year tumour-free survival and overall 
survival rate did not differ for both cohorts (TEMS vs radical resection) (Ptok et al 
2007).  In a prospective study done by Guerrieri et al, they showed that 51 patients 
who had undergone TEMS did not have any local recurrence or metastasis.  The 
survival rate was 100% at a median follow-up period of 81 months (25th – 75th 
percentile = 44 – 121 months) (Guerrieri et al 2008). 
 Local excision procedures like these are optimal as they have lower rates of 
morbidity (4% - 17%) and mortality (0% - 1.3%) compared to major resections (de 
Graaf et al 2002, Maslekar et al 2006, Bretagnol et al 2007).  However, local 
excisions do not accurately stage the cancer as lymph node status is unknown.  This 
will have an impact as treatment can be inadequate and the risk of local/distant 
recurrence will be high. 
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1.5.3 Chemotherapy and radiotherapy (CRT) 
CRT is used as an adjunct to major surgery or local procedures.  CRT is also used in 
isolation as palliation for inoperable cancers.  As mentioned already, CRT may be 
commenced prior to surgery to help reduce tumour size and also downstage the 
cancer.  Post-operative or adjuvant chemotherapy is often administered to patients 
with node positive disease (stage III) based on the results of the IMPACT trial  
(IMPACT 1995).  The IMPACT trial studied the efficacy of adjuvant 5-flurouracil (5-
FU) and folinic acid in treating patients with Dukes’ B and C CRC.  The results 
showed a significant reduction in mortality by 22%, increasing 3-year event free 
survival by 11% and overall survival from 78% to 83%.  The successor to the 
IMPACT trial, the MOSAIC trial showed improvement in the 6-year overall-survival 
rate with the addition of oxaliplatin to 5-FU (Andre et al 2009).  The benefits of 
adjuvant chemotherapy in stage II (node negative) CRC was investigated by the 
QUASAR trial (Gray et al 2007) and showed that there is an absolute overall 
improvement in survival by 3.6%.  
Currently in the UK, there are different types of chemotherapy regimens for stage III 
and high risk stage II colorectal cancers.  The more common regimens include: 
 Intravenous 5-FU with or without folinic acid 
 Combination of folinic acid with intravenous 5-FU and oxaliplatin 
 Oral Capecitabine (Capecitabine is an orally administered precursor of 5-FU) 
 Combination of Capecitabine and oxaliplatin 
 The decision of commencing chemotherapy requires a full discussion with the 
patient with respect to the inconvenience and side effects.  Sometimes, 
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chemotherapy is contraindicated as the risk/side effects outweigh the possible 
benefits.  
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1.6 Conclusion 
We are slowly beginning to understand the biology and molecular genetics of CRC.  
This knowledge is being used to help better stratify an individual’s risk of developing 
CRC and also helps clinicians provide a more personalized treatment regimen to 
specific types of CRC.  This knowledge has also help improve the ability to predict 
the benefits from new biological agents. 
Therefore, the role of pathologist remains integral in the management of patients 
with CRC.  The role of pathologist have expanded vastly from issuing an accurate 
tissue diagnosis to assessing prognostic parameters such as surgical margins, 
lymphatic and vascular invasion and assessing therapeutic effects in patient who 
have received neoadjuvant therapy.  Pathologist also play a central role in identifying 
histological features that are suggestive of MSI and selecting the appropriate tissue 
sections for molecular testing. 
The role of pathologist in CRC screening is also important and vital in the treatment 
of early CRC.  CRC screening and the role of pathologist in screening will be 
discussed further in the chapters below. 
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Chapter 2 Lymph node metastasis in pT1 colorectal 
cancers 
 
2.1 Standard predictors of lymph node metastasis (LNM) in symptomatic 
presentation pT1 CRC 
LNM occurs in approximately 8.4 to 24.0% of patients with symptomatic pT1 CRC 
(Tanaka et al 1995, Nascimbeni et al 2002, Suzuki et al 2003, Shimomura et al 
2004, Yasuda et al 2007, Kobayashi et al 2012, Caputo et al 2014, Bosch and 
Nagtegaal 2014) (see table 2.2 and 2.3).  LNM is significant, as persistent malignant 
disease within the lymph nodes would require the individual to undergo radical 
resection.  LNM is also of prognostic importance as it indicates that the carcinoma 
possesses the propensity to metastasize and upstages the patient from stage I to 
stage III.  
With the potential of LNM apparent in pT1 cancers, it is essential that the most 
appropriate treatment is provided be it a local excision or a radical resection.  
However, such treatment options have their pros and cons in balancing the benefits 
of a potential cure to the risks of recurrence, morbidity, mortality and disease spread.  
Therefore, the key to successful treatment is to identify and balance the high risk 
factors of LNM and systemic metastasis versus the possible mortality and morbidity 
associated with the treatment. 
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There are several described risk factors of LNM in pT1 CRC.  These include site of 
carcinoma, grade of differentiation of carcinoma, lymphatic and vascular invasion, 
depth, width and area of invasion and tumour budding. 
 
2.1.1 Site of carcinoma 
Studies have shown that the site of the carcinoma within the bowel plays a factor in 
the risk of LNM.  The rectum is the location that is often associated with LNM and 
adverse prognostic outcomes (Haggitt et al 1985, Nascimbeni et al 2002).  Okabe et 
al compared the risk of LNM between the locations within the bowel and showed that 
LNM were more common within the rectum when compared to the left colon (p=0.04) 
or right colon on univariate analysis (p=0.003) (Okabe et al 2004).  Nascimbeni et al 
showed that the lower third of the rectum had higher risk of LNM compared to the 
rest of the colon (p=0.007) (Nascimbeni et al 2002).  
However, when Nascimbeni compared the risk of LNM between the rectum, left and 
right colon, there was no difference.  Several other studies have also confirmed that 
the site of carcinoma is not prognostic factor in LNM (table 2.1). 
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Author Number of cases p-value 
Left colon Right colon Rectum Total 
Nascimbeni et al 
2002 
234 119 353 0.243 
Sakuragi et al 
2003  
119 63 96 278 0.9 
Chok and Law 
2007  
28 44 72 0.89 
Choi et al 2008  54 18 96 168 0.529 
Table 2.1: Studies showing that the site of carcinoma is not a risk factor for LNM 
 
2.1.2 Grade of differentiation of carcinoma 
Tumours are normally graded on how differentiated they appear.  Differentiation is 
primarily based on the architecture and specifically gland or tubule formation.  The 
criteria for poor differentiated tumours are either irregularly folded, distorted and 
often small tubules or the absence of any tubular formation (Loughrey, Quirke and 
Shepherd 2014). 
Normally, the grading of differentiation of the tumour can be divided into 4 groups; 
well-differentiated, moderately-differentiated, poorly-differentiated and 
undifferentiated (Bosman et al 2010).  Most commonly, the grades are split into 2 
groups; low-grade (well-differentiated/moderately-differentiated) and high-grade 
(poorly-differentiated/ undifferentiated) (Loughrey, Quirke and Shepherd 2014). 
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In general, the higher the tumour grade, the poorer the prognosis.  In a pooled-data 
analysis, Hassan et al showed that the presence of poorly differentiated carcinoma is 
associated with a higher cancer-related mortality (odds ratio 9.2, p<0.05) (Hassan et 
al 2005). In terms of LNM, several studies have shown that poor differentiation/ high 
tumour grade is a predictor of LNM in early stage CRC (Wang et al 2005, Ricciardi et 
al 2006, Rasheed et al 2008, Tateishi et al 2010).  
 
2.1.3 Lymphatic and vascular invasion 
Even though pT1 CRC are considered ‘early’ carcinomas, they do have potential to 
spread because the submucosa of the large bowel contains a rich lymphatic and 
vascular supply.  Invasion of the lymphatic and/or vascular system is generally 
regarded as a significant risk factor for regional involvement and spread of 
malignancy to the surrounding lymph nodes and distant organs is a very important 
prognostic factor in CRC.  Table 2.2 and 2.3 summarises the studies that have 
investigated lympho-vascular invasion as a predictive factor for LNM. 
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Author Total 
patients 
Lymph Node Metastasis (LNM) 
Total 
LNM 
cases, n 
(%) 
Vascular 
invasion 
absent, n 
(%) 
Vascular 
invasion 
present, 
n (%) 
p-
valu
e 
Lymphatic 
invasion 
absent, n 
(%) 
Lymphatic 
invasion 
present, n 
(%) 
p-value 
Tanaka 
et al 
1995  
177 21 (12) Not assessed 6 (3.3) 15 (8.5) <0.01* 
Sakura
gi et al 
2003  
271 21 (7.7) 16 (5.9) 5 
(1.8) 
0.025 2 (0.7) 19 (7) <0.001* 
Wang 
et al 
2005  
159 16 
(10.1) 
15 (9.4) 1 
(0.6) 
0.192 9 (5.7) 7 (4.4) 0.023* 
Yasuda 
et al 
2007 
86 21 (24) 3 (3.5) 18 
(20.9) 
0.001* Not assessed 
 
Sugimo
to et al 
2014 
102 14 
(13.7) 
6 (5.9) 8 
(7.8) 
0.03 3 (2.9) 11 
(10.8) 
0.25 
Table 2.2: Studies investigating lymphatic and vascular invasion as a predictive 
factor for LNM. * indicates multivariate analysis. 
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Author Total 
patients 
Lymph Node Metastasis (LNM) 
Total LNM 
cases, n 
(%) 
Lymphovascular 
invasion absent, n 
(%) 
Lymphovascular 
invasion present, n 
(%) 
p-value 
Nascimbeni 
et al 2002  
353 46 (13) 37 (10.5) 9 (2.5) 0.001* 
Okabe et al 
2004 
428 43 (10) 15 (3.5) 28 (6.5) 0.003* 
Choi et al 
2008  
168 24 (14.3) 18 (10.7) 6 (3.6) 0.019 
Kye et al 
2012 
55 8 (14.5) 4 (7.3) 2 (3.6) 0.232* 
Kobayashi et 
al 2012 
68 6 (8.8) 1 (1.5) 5 (7.4) 0.074* 
Caputo et al 
2014 
48 6 (12.5) 5 (10.4) 1 (2.0) 1.000* 
Table 2.3: Studies investigating lympho-vascular invasion as single qualitative 
predictive factor for LNM. * indicates multivariate analysis. 
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2.1.4 Depth of invasion 
Many studies have investigated the risk that is associated with the depth of invasion 
of pT1 CRC.  Depth of invasion of pT1 CRC has been assessed by three methods.  
The first two methods were investigated by Haggitt and Kikuchi and were based on 
the shape of the lesion.  The third method developed by Japanese researchers 
involved measuring the vertical depth of invasion from the muscularis mucosae of 
the lesion (or from the luminal surface if muscularis mucosae is not present) 
(Watanabe et al 2012). 
Haggitt et al first described the levels of invasion within a pedunculated polyp that 
contained carcinoma. Haggitt described 4 levels of invasion; level 1 invasion involves 
limited invasion into the head of the polyp, level 2 involves invasion extending to the 
neck of the polyp, level 3 involves invasion into the polyp stalk and level 4 denotes 
invasion beyond the stalk into the muscularis propria.  Haggitt showed that level 4 
invasion is an adverse prognostic factor in terms of local disease spread and 
mortality (Haggitt et al 1985). 
For sessile lesions, Kudo had initially classified the relative level of submucosal 
invasion into 3 distinctive levels; the superficial, middle and deep thirds of the 
submucosa (sm1, sm2 and sm3) (Kudo 1993).  Based on this classification, Kikuchi 
et al had showed that the deepest level of invasion was a significant risk factor for 
the development of LNM and local recurrence (Kikuchi et al 1995). 
Nascimbeni et al studied the carcinoma-related variables that were deemed as risk 
factors of LNM and one of these variables was depth of invasion. In this study, the 
depth of invasion was based on Kikuchi’s system and they showed that in both 
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univariate and multivariate analysis, sm3 invasion was a significant predictor of LNM. 
showed that the risk of LNM did increase with deeper sm level invasion with sm1, 
sm2 and sm3 having 2%, 8% and 23% risk respectively (Nascimbeni et al 2002). 
As mentioned above, the risk of LNM is thought to rise with increasing depth of the 
invading tumour.  Interestingly, the rate of LNM is almost comparable for the different 
depths of invasion in pT1 CRCs.  Table 2.4 summarises the studies that have 
investigated the risk of LNM in relation to depth of submucosal invasion. 
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Depth Author LNM Rate Univariate 
analysis 
Multivariate analysis 
p – value p - value Odds ratio 
≥ 1000 μm Kitajima et al 
2004  
87/865 (10.1%)  0.006 5.4 
Tateishi et al 
2010  
46/322 (14.3%) 0.05 NS  
Nakadoi et al 
2014 
38/322 (11.8%) <0.005 NS  
≥ 1800 μm Nakadoi et al 
2012  
41/499 (8.2%) <0.0001 0.0077 3.27 
≥ 2000 μm Sakuragi et al 
2003  
21/278 (7.6%) <0.001 0.022 13.1 
Ueno et al 2004  33/254 (13%) 0.0045   
Egashira et al 
2004  
13/140 (9%) 0.01 <0.05 1.45 
Tominaga et al 
2005  
19/155 (12.3%) 0.035 NS  
Yasuda et al 
2007  
11/86 (13%) 0.003 NS  
Yamauchi et al 
2008  
16/64 (9.8%) 0.007 NS  
≥ 2700 μm Sugimoto et al 
2014 
14/102 (13.7%) 0.02   
≥ 3000 μm Okabe et al 
2004  
43/428 (10%) 0.018 <0.05 2.7 
≥ sm 2 Hase et al 1995  11/79 (13.9%) 0.01 NS  
sm 3 Kikuchi et al 
1995  
13/182 (7.1%) 0.0001 NS  
Nascimbeni et 
al 2002  
46/297 (13%) 0.001 <0.001 5 
Choi et al 2008  24/168 (14.3%) <0.001 0.018 7.1 
Table 2.4:  Summary of investigations looking at depth of invasion and risk of LNM. 
(NS – not significant) 
  
  
39 
2.1.5 Width/Area of invasion of carcinoma 
As pT1 CRC are classed as early invasive carcinomas, the width of the invading 
carcinoma has often been studied to determine the risk of LNM and to verify whether 
a local excision would be sufficient in providing cure.  Ueno et al showed that the 
incidence of nodal involvement in a tumour with a width less than 4000µm was much 
lower than when compared to tumours with width of equal or more than 4000µm 
(p=0.0005) (Ueno et al 2004).  
This had also been shown earlier by a study by Suzuki et al where the width of 
submucosal invasion was significantly greater in lymph node positive tumours 
compared to lymph node negative ones (p=0.001) (Suzuki et al 2003).  Suzuki had 
also measured the area of submucosal invasion in 65 cases using an image 
analyzer but demonstrated that there were no significant differences in between 
node positive and node negative patients (p=0.09).  
 
2.1.6 Tumour budding 
Tumour budding is defined as the presence of isolated carcinoma cells or small 
carcinoma cell clusters (less than 5 cells per cluster) scattered in the stroma at the 
invasive margin of the tumour.  Morodomi and colleagues believed that budding 
would be a valuable factor in predicting LNM when used alongside the degree of 
differentiation of the carcinoma and evidence of lymphatic invasion (Morodomi et al 
1989). 
Hase et al studied budding in 663 patients who had curative resections of their CRCs 
that ranged from Dukes’ A to C.  The degree of budding was divided into 2 groups: 
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non/mild budding and moderate/severe budding. Hase’s study showed that 
moderate/severe budding was associated with a poorer 5 and 10-year survival 
outcome compared to the non/mild budding group where 71% of patients in the 
moderate/severe budding group had developed recurrences.  Hase concluded that 
budding provides valuable prognostic information independent of Dukes’ 
classification (Hase et al 1995). 
Ueno et al also studied budding in rectal cancer and showed that rectal carcinomas 
with high-grade intensity budding (defined as ≥ 10 foci within a microscopic field) had 
lower 5-year survival rate as compared to patients with low-grade intensity budding 
(p<0.0001).  On multivariate analysis, tumour budding was shown to be a significant 
independent variable in assessing the aggressiveness of rectal carcinomas.  Ueno 
also showed that grading tumour budding using his system is reproducible (Ueno et 
al 2002). 
Yasuda et al specifically studied the relationship between tumour budding and pT1 
CRC and showed that on multivariate analysis, tumour budding is an independent 
risk factor for LNM (p=0.003) (Yasuda et al 2007).  Tateishi et al also studied tumour 
budding as a risk factor and showed that it was also an independent risk factor in 
LNM (p < 0.01) when compared to other well established risk factors such as 
lymphatic invasion and poor differentiation (Tateishi et al 2010). 
More recently, studies by Kye, Nakadoi and Nishida have also demonstrated the 
significance of tumour budding in predicting LNM in pT1 CRCs (Kye et al 2012, 
Nakadoi et al 2014, Nishida et al 2014). Table 2.5 summarises studies looking at 
tumour budding in pT1 CRC with LNM. 
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Author Total patients Total LNM 
cases (%) 
Lymph node metastasis p - value 
Tumour 
budding 
absent/ Low 
grade (%) 
Tumour 
budding 
present/ High 
grade (%) 
Hase et al 
1993 
79 11 (13.9) 0 (0) 11 (100) p < 0.005 
Yasuda et al 
2007 
86 21 (24.4) 4 (4.7) 17 (19.8) p < 0.01 
Tateishi et al 
2010 
322 46 (14.3) 18 (5.6) 28 (8.7) p < 0.01 
Kye et al 
2012 
55 8 (14.5) 1 (1.8) # 5 (9.1) p < 0.05 
Nakadoi et al 
2014 
322 38 (11.8) 21 (6.5) 17 (5.3) p < 0.001 
Nishida et al 
2014 
265 31 (11.7) 8 (3.0) 23 (8.7) p < 0.001 
Table 2.5: Summary of studies investigating tumour budding. # Information regarding 
2 patients could not be found. 
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2.2 Research objectives 
The primary aim of this research is to increase the understanding of the prediction of 
the presence of lymph node metastasis in pT1 CRC. 
The objectives of the research include: 
1. Investigating the utility of subjective and quantitative features in predicting 
LNM. 
2. Increasing our understanding of the relationship between invasion of the 
submucosa and the presence of LNM. 
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2.3: Materials and methods 
2.3.1 Analysis of phenotypic features of symptomatic pT1 CRC 
2.3.1.1 Database searches 
Staged pT1 CRC were selected from the Northern and Yorkshire Cancer Registry 
and Information Service (NYCRIS).  All radical resections of primary CRC within 
Yorkshire region between 1st January 2000 and the 31st December 2009 were 
identified by the NYCRIS. Radical resections were included in this study as lymph 
node status could be confirmed from the surgical procedure.  Local exicision and 
piecemeal excisions of pT1 CRC were excluded in this study. 
 
2.3.1.2 Clinicopathological data  
Histopathological staging data was obtained from NYCRIS or official hospital 
pathology reports.  The data included the age, gender of patient, site of cancer, 
stage of cancer, lymph node involvement, distant metatstasis and lymphatic and 
vascular invasion status. 
 
2.3.1.3 Quantitative analysis 
All microscopy slides were retrieved with the help of the local laboratory technicians.  
The slide that showed the widest and deepest tumour invasion was selected for 
digital scanning.  These slides were scanned at x200 magnification with an 
automated digital scanner (Aperio XT Scanner, Aperio technologies, San Diego, Ca 
USA). Using a digital slide viewer (Imagescope v10.0, Aperio Technologies), 
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computer based morphometry of the tumours could be performed and analysed.  
Quantitative factors that were analysed as below: 
1) Maximum width of lesion. Lesion is defined as the summation of the adenoma 
and carcinoma component (Figure 2.1) 
2) Maximum width of invasive carcinoma (Figure 2.1) 
3) Maximum vertical depth of carcinoma from luminal surface (Figure 2.2) 
4) Maximum vertical depth of carcinoma from muscularis mucosae (Figure 2.2) 
5) Maximum depth of invasion within neck of polypoid/semi-pedunculated 
lesions (Figure 2.3) 
6) Minimum distance from resection margin (Figure 2.4) 
7) Minimum distance from muscularis propria if present (Figure 2.4) 
8) Total area of lesion (Figure 2.5) 
9) Total area of carcinoma (intramucosal and submucosal) (Figure 2.6) 
10) Total area of submucosal invasion by carcinoma (Figure 2.7) 
11) Length of invasive front (Figure 2.8) 
 Figure 2.1: Image of a digital slide showing the Imagescope measurements of the width of lesion (long bar) at 18.45mm (green 
label) and width of carcinoma (short bar) at 8.78mm (yellow label). 
  
46 
 
Figure 2.2: Image of a digital slide showing the Imagescope measurements of depth from the surface layer of the lesion (long bar) 
at 10.34mm (green label) and from the muscularis mucosae (short bar) at 8.226mm (yellow label). 
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Figure 2.3: For lesions with a stalk (pedunculated/semi-pedunculated), the depth of invasion within the stalk was measured from 
the reference line which is the boundary between the tumour head and stalk. Red arrow indicates the depth of invasion within the 
neck which was 684.7 µm. 
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Figure 2.4: Image of a digital slide showing the Imagescope measurements of minimum distance of invading lesion from the 
nearest muscularis propria (short bar) at 465.3 µm (green label) and resection margin (long bar) at 14.988 mm (yellow label). 
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Figure 2.5: Image of a digital slide showing the Imagescope measurements for total area of lesion (contained with the green area) 
of 75.28mm2. 
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Figure 2.6: Image of a digital slide showing the Imagescope measurements for thetotal area of carcinoma (intramucosal and 
submucosal) (contained within the yellow area) of 65.27mm2. 
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Figure 2.7: Image of a digital slide showing the Imagescope measurements for the estimated total area of submucosal invasion 
(contained within the red area) of 41.42 mm2. 
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Figure 2.8: Image of a digital slide showing the Imagescope measurements for the length of invasive front of 9.5 mm. 
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We have qualitatively divided the lesions into three types of shapes; 
pedunculated, semi-pedunculated and sessile.  We have used the relative 
measurements of the maximum width of the lesion and its base in determining 
the classification of the shapes of the lesions.  In pedunculated lesions, the 
width of the base is less than one third of the widest part of the body or the 
head of the lesion. In semi-pedunculated lesions, the base is greater than 
33% but less than 67% of the widest part of the body/head.  For sessile 
lesions, the base is equal or greater than 67% the widest part of the lesion. 
Figure 2.9 shows a summary of the shape classification of the lesions. 
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Figure 2.9: Demonstrations of the qualitative shape classification of the lesions.
   
 
Pedunculated: base is less than 33% 
of the widest part of body of the 
head.  
Semi-pedunculated: base is greater than33% but less than 80% of the widest 
part of the body of the head.  
Sessile: base is 80% or equal to the 
widest part of the body.   
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2.3.1.4 Qualitative analysis 
Information regarding qualitative factors such as vascular and lymphatic 
invasion and grade of differentiation were obtained from the original issued 
pathology reports.  Vascular invasion was defined as either the presence of 
intra- or extra-mural vascular invasion or both.  Lymphatic invasion was 
defined as the presence of carcinoma within a lymphatic vessel.  Grade of 
differentiation was divided into two groups: poorly differentiated vs non-poorly 
(well/ moderate) differentiated as per Royal College of Pathologist reporting 
guidelines (Loughrey, Quirke and Shepherd 2014).   
 
2.3.2 Inter/Intra-observer variation study 
To assess the reproducibility of the study, an inter-observer variation study 
was performed between the main and senior author (PQ).  Both authors had 
measured the quantitative factors in a random sample of 10 lesions. Intraclass 
correlation coefficient (ICC) values were calculated between the main and 
senior author.  
An intra-observer study was also performed by the main author (ET).  The 
same quantitative measurements were performed on 10 random lesions with 
a period gap of 4 weeks. The ICC values were then calculated. 
ICC values can be interpreted as follow: ≤ 0 indicates no agreement, 0.01 – 
0.20 indicates poor agreement, 0.21- 0.40 indicates fair agreement, 0.41-0.60 
indicate moderate agreement, 0.61 – 0.80 indicates strong agreement and > 
0.81 indicates almost perfect agreement. 
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2.3.3 Statistical analyses 
Statistical analyses were performed using the Statistical Package for the 
Social Sciences (SPSS v21.0, Chicago, IL, USA).  Statistical analyses of 
continuous variables between the symptomatic group with and without LNM 
were performed using the Mann-Whitney U test.  Associations between 
categorical data and LNM were performed using a Chi-Square test and 
Fishers exact tests.  A modified receiver operating characteristic (ROC) curve 
was generated with the recommendation of a biostatistician (P McShane 
2013, personal communication) to determine the cut-off values for significant 
quantitative factors that were analysed in the Mann-Whitney U test.   Logistic 
regression analysis was also used to investigate the significant quantitative 
factors that influenced LNM.  
Statistical analyses of continuous variables between symptomatic cases were 
performed using the non-parametric Mann-Whitney U test.  A p value of < 
0.05 for all the tests was considered significant. 
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2.4: Results 
2.4.1 Relationship of quantitative factors in symptomatic pT1 CRC and 
its association with LNM 
The NYCRIS database search identified 382 patients.  Out of the 382 
patients, 207 were used in this study as 105 patients’ microscopy slides were 
missing, 35 slides were damaged and were unsuitable for digital scanning and 
26 cases were rectal carcinomas which were down-staged to a pT1 stage 
after receiving pre-operative treatment.  Nine cases had synchronous tumours 
that were staged pT2 - 4 with lymph node metastasis.  All 207 patients had 
radical resections of their cancer and none had received pre-operative 
chemotherapy or radiotherapy. 
LNM was noted in 19 (9.2%) of the 207 cases. In the patients with LNM, 17 
(89.5%) were staged pN1 and 2 (10.5%) patients were staged pN2.  This did 
not correlate with gender, age or tumour site.   There were no significant 
differences in the occurrences of LNM between the shape of the lesions.   The 
summary of the clinico-pathological features is in Table 2.6. 
CRC with LNM had a significantly wider area of invasion (p=0.004) and a 
greater area of submucosal invasion (p=0.002) compared to CRC with no 
LNM.  Table 2.7 and 2.8 summarizes the other quantitative and qualitative 
factors that were analysed respectively.  The cut-off value for the width of 
invasion and area of submucosal invasion that was determined by the 
modified ROC curve were 11.5 mm and 35 mm2 respectively (Figures 2.10 
and 2.11). 
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 Lymph Node Metastasis p - value 
Negative (n = 
188) [%] 
Positive (n = 
19) [%] 
 
Sex Male 113[60.1] 14 [73.7] 0.247 
Female 75 [39.9] 5 [26.3] 
Age (Median, IQR) 71, 63 - 77 69, 57 - 75 0.536 
Site Caecum 12 [6.4] 0 0.439 
Ascending 
Colon 
12 [6.4] 0 
Transverse 
Colon 
5 [2.7] 0 
Descending 
Colon 
9 [4.8] 0 
Sigmoid Colon 66 [35.3] 9 [47.4] 
Rectum 83 [44.4] 10 [52.6] 
Unknown 1 [0.5] 0 
Shape of 
Lesion 
Pedunculated 48 [25.5] 3 [15.8] 0.537 
Semi-
pedunculated 
86 [45.7] 11 [57.9] 
Sessile 54 [28.7] 5[26.3] 
Table 2.6: Characteristics of pT1 carcinomas. p-values obtained using Chi-
Square test. 
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Quantitative Factors Lymph Node Metastasis 
Median (IQR: SD) 
p – value 
Negative  Positive 
Maximum width of lesion (mm) 15.14 (13.08 – 
19.26: 4.67) 
17.56 (14.85 – 19.74: 
3.77) 
0.209  
Maximum width of carcinoma 
(mm) 
11.46 (9.12 – 
14.50: 3.91) 
15.58 (12.18 – 17.04: 
2.56) 
0.001 
Maximum depth of invasion of 
carcinoma from surface (mm) 
5.80 (3.81 – 
8.96: 3.99) 
6.27 (.09 – 8.94: 2.30) 0.215 
Maximum depth of invasion of 
carcinoma from muscularis 
mucosae (mm) 
4.40 (3.21 – 
7.08: 3.05) 
5.62 (3.89 – 7.42: 2.24) 0.105 
Depth of invasion within neck 
(mm) 
 1.16 (0.45 – 
2.12: 1.07) 
 2.53 (1.94-4.77: 1.64) 0.002 
Distance of carcinoma to margin 
(mm) 
4.89 (3.44 – 
7.35: 3.22) 
4.93 (2.72 – 7.59: 3.88) 0.894 
Distance of carcinoma to 
muscularis propria (mm) 
1.69  (0.98 – 
3.27: 2.53) 
0.60 (0.25 – 4.77: 2.59) 0.14 
Total area of lesion (mm2) 74.16 (48.53 – 
108.27: 50.41) 
96.26 (66.88 – 116.27: 
42.87) 
0.211 
Total area of carcinoma (mm2) 64.38 (41.08 – 
105.78: 43.01) 
81.32 (63.99 – 111.60: 
45.74) 
0.064 
Total area of carcinoma within 
submucosal layer (mm2) 
36.16 (19.60 – 
56.21: 29.31) 
54.10 (39.97 – 77.86: 
28.32) 
< 0.001 
Length of invasive front (mm) 8.92 (6.99– 
10.97: 4.27) 
12.20 (6.57 – 12.51: 
3.52) 
0.49 
Table 2.7: Quantitative factors of symptomatic pT1 CRC that have been analysed. P-
values obtained using Mann-Whitney U test. Values in red identify significant factors. 
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Qualitative factor Lymph node metastasis p-value 
Negative, n = 
188 (%) 
Positive, n = 
19 (%) 
Vascular 
invasion 
No 182 (96.8) 16 (84.2) 0.039* 
Yes 6 (3.2) 3 (15.8) 
Lymphatic 
invasion 
No 184 (97.9) 16 (84.2) 0.018* 
Yes 4 (2.1) 3 (15.8) 
Grade of 
differentiation 
Non-poor 184 (97.9) 14 (73.7) < 0.0001* 
Poor 4 (2.1) 5 (26.3) 
Table 2.8: Qualitative factors of symptomatic pT1 CRC. p-values obtained 
using Fisher’s Exact Test. 
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Figure 2.10: Modified ROC curve showing the optimal value for maximum 
width of carcinoma. The optimal value is determined from the peak of the 
curve (indicated by the arrow) [Area under curve = 0.723]. 
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Figures 2.11 : Modified ROC curve showing the optimal value for the area of 
submucosal invasion of carcinoma. The optimal value is determined from the 
peak of the curve (indicated by the arrow) [Area under curve = 0.747]. 
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42.07, p=0.003) but not on multivariate analysis (OR=5.59, CI=0.92 – 34.12, 
p=0.062).  Area of submucosal invasion as chosen from the ROC curve with 
the maximum sensitivity and specificity was greater than 35mm2 and this was 
predictive of LNM on both univariate (OR=20.9, CI=2.73 – 159.74, p=0.003) 
and multivariate analysis (OR=12.48, CI=1.44 – 108.07, p=0.022) (Table 2.9). 
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Factors Lymph 
node 
metastais 
(LNM) 
positive 
(n=19) [%] 
Multivariate analysis 
p value Odds Ratio (CI) 
Width of 
Carcinoma 
<11.5mm 
(n=101) 
2[10.5] 0.062 5.59 (0.92 – 
34.12) 
≥11.5mm 
(n=106) 
17[89.5] 
Area of 
Submucosal 
Invasion of 
Carcinoma 
<35 mm2 
(n=102) 
1 [5.3] 0.022 12.48 (1.44 – 
108.07) 
≥ 35mm2 
(n=105) 
18 [94.7] 
Vascular 
invasion 
Yes (n=9) 3 [15.8] 0.08 5.51 (0.82 – 
37.18) 
No 
(n=198) 
16 [84.2] 
Lymphatic 
invasion 
Yes (n = 
7) 
3 [15.8] 0.02 12.86 (1.50 – 
110.02) 
No (n = 
200) 
16 [84.2] 
Grade of 
differentiation 
Non-poor 
(n = 198) 
14 [73.7] < 0.0001 28.36 (3.05 – 
263.50) 
Poor (n = 
9) 
5 [26.3] 
Table 2.9: Multivariate analysis of quantitative and qualitative factors affecting 
LNM. p-values obtained using logistic regression analysis. 
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2.4.2 Results for the inter/intra-observer variation study 
For the intra-observer variation study, the ICC values for the quantitative 
parameters showed almost perfect agreement (table 2.10).  Focusing on the 
significant quantitative parameters found in this study, the ICC for width of 
carcinoma is 0.95 (95% CI 0.81 – 0.99, p < 0.0001) and area of submucosal 
invasion is 0.89 (95% CI 0.63 – 0.97, p < 0.0001). 
For the inter-observer variation study, the ICC values for the quantitative 
measurements varied from 0.18 to 0.99 (table 2.11). The significant 
quantitative parameters did show strong agreement; the ICC for width of 
carcinoma is 0.76 (95% Confidence Interval 0.31 – 0.93, p= 0.004) and area 
of submucosal invasion is 0.95 (95% CI 0.81 – 0.99, p < 0.0001). 
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Quantitative Factors Intra-class Correlation Coefficient score 
(95% confidence interval, p – value) 
Maximum width of lesion 0.99 (0.97 – 0.99, p < 0.0001) 
Maximum width of carcinoma 0.95 (0.81 – 0.99, p < 0.0001) 
Maximum depth of invasion of carcinoma 
from surface 
0.99 (0.97 – 0.99, p < 0.0001) 
Maximum depth of invasion of carcinoma 
from muscularis mucosae 
0.97 (0.89 – 0.99, p < 0.0001) 
Depth of invasion within neck 0.97 (0.87 – 0.99, p < 0.0001) 
Distance of carcinoma to margin  0.98 (0.93 – 0.99, p < 0.0001) 
Distance of carcinoma to muscularis 
propria  
0.99 (0.95 – 0.99, p < 0.0001) 
Total area of lesion  0.99 (0.99 – 1, p < 0.0001) 
Total area of carcinoma  0.86 (0.57 – 0.96, p < 0.0001) 
Total area of carcinoma within 
submucosal layer  
0.89 (0.63 – 0.97, p < 0.0001) 
Length of invasive front  0.89 (0.64 – 0.97, p < 0.0001) 
Table 2.10: Results of intra-observer variation study involving the main author. 
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Quantitative Factors Intra-class Correlation Coefficient score 
(95% confidence interval, p – value) 
Maximum width of lesion 0.89 (0.63 – 0.97, p < 0.0001) 
Maximum width of carcinoma 0.76 (0.31 – 0.93, p < 0.0001) 
Maximum depth of invasion of carcinoma 
from surface 
0.85 (0.54 – 0.96, p < 0.0001) 
Maximum depth of invasion of carcinoma 
from muscularis mucosae 
0.83 (0.16 – 0.96, p < 0.0001) 
Depth of invasion within neck 0.18 (-0.45 – 0.70, p < 0.0001) 
Distance of carcinoma to margin  0.99 (0.97 – 0.99, p < 0.0001) 
Distance of carcinoma to muscularis 
propria  
Not assessed 
Total area of lesion  0.58 (0.14 – 0.87, p = 0.014) 
Total area of carcinoma  0.92 (0.69 – 0.95, p < 0.0001) 
Total area of carcinoma within 
submucosal layer  
0.95 (0.81 – 0.99, p < 0.0001) 
Length of invasive front  0.88 (0.70 – 0.94, p < 0.0001) 
Table 2.11: Results of inter-observer variation study between main author and 
senior author. 
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2.5 Discussion 
With the potential of LNM in pT1 cancers, it is essential that the most 
appropriate treatment is provided, be it a local excision or a radical resection 
of the cancer.  However, each treatment option has their pros and cons in 
balancing the benefit of a potential cure to the risks of spread of the disease 
and the mortality and morbidity that accompanies such treatments.  Therefore 
the key to success in providing successful treatment is to identify those 
patients at high risk of LNM.  
 
2.5.1 Suitability of Haggitt/ Kikuchi systems 
Both Haggitt and Kikuchi formulated treatment guidelines for early CRC.  
However, neither Haggitt (for pedunculated tumours) nor Kikuchi (for sessile 
tumours) systems are always simple to use in pathological practice and 
neither can be applied to all lesions.  For both Haggitt and Kikuchi systems to 
be applied, the lesions need to be removed whole and not in fragments.  The 
Haggitt system is of no value in lesions that are sessile in nature.  For the 
Kikuchi system, the lesion should be sessile and a definite muscularis propria 
needs to be identified so that the submucosal levels can be identified.  This is 
frequently not the case for patients who have undergone biopsy removal or 
submucosal excision of their lesion during colonoscopy.  Sub-pedunculated 
lesions are common and sometimes both systems are applied in the 
assessment of these lesions. 
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2.5.2 Issues in measuring depth and area of submucosal invasion 
The muscularis mucosae is an important structure as it signifies the beginning 
of the submucosal layer and Japanese researchers have used this structure 
as a reference point when measuring the depth of invasion.  In carrying out 
this study, there was a degree of difficulty in identifying the muscularis 
mucosae as it is commonly destroyed by the CRC.  This leads to increased 
variability when measuring the depth and area of submucosal invasion of the 
CRC.  In measuring the carcinoma width, we do not need to rely on the 
muscularis mucosae as a reference point and this would reduce the variability 
between pathologists when reporting pT1 CRC. 
Ueno et al demonstrated a relationship between the width and depth of 
invasion and the probability of LNM.  In this study, there was a significant 
difference in the rate of LNM between cases with depth of invasion ≥ 2000 µm 
and width of invasion ≥ 4000 µm compared to cases with depth of invasion < 
2000 µm and width of invasion <4000 µm (Ueno et al 2004).  Ueno suggested 
that cases with invasion depth of less than 2000 µm (and width of < 4000 µm) 
could be appropriately cured with endoscopic resection provided that there is 
an absence of other high risk features such as unfavourable grade of tumour, 
tumour budding and vascular invasion (Ueno et al 2004).  If a depth of 2000 
µm (2mm) or even 1000 µm (1mm) were to be used (Watanabe et al 2012) 
instead of sm3 or Haggitt 4 as one of the criteria for radical resection, this 
would lead to much higher rates of resection in symptomatic and screen 
detected pT1 CRCs than currently predicted.  This will further be reviewed in 
the discussion section of Chapter 3.   
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2.5.3 The lymphatic system within the submucosa and LNM 
In a recent study, Smith et al had showed that mucosal lymphatic vessels 
were present just above the muscularis mucosae and were significantly 
smaller than the submucosal vessels but interestingly, the study showed that 
lymphatic vessels were significantly more numerous within the sm1 level as 
compared to the sm3 level (Smith et al 2011).  How does this relate to the risk 
of LNM with depth and width of invasion?  As mentioned already, several 
studies have shown that LNM increases with deeper levels of invasion within 
the submucosal layer but in Smith’s study, the deeper levels (sm3) had fewer 
lymphatic vessels. 
This study has shown that lymph node positive pT1 cases have a significantly 
greater width of invasion (p=0.004) and area of submucosal invasion 
(p=0.002) compared to lymph node negative cases.  What are the potential 
implications of these findings in the risk of LNM in pT1 CRC?  This could be 
explained in terms of basic anatomy. Carcinoma cells develop within the 
mucosa and are termed invasive, because of the risk of metastatic spread, as 
soon as they breach the muscularis mucosae.  The first layer that the 
carcinoma invades is the superficial level of the submucosa (sm1).  With a 
wider and therefore greater area of invasion (figure 2.12), the chances of a 
carcinoma coming into contact and invading a lymphatic vessel would be 
higher due to the fact that lymphatic vessels are more numerous within the 
sm1 level as shown by Smith et al. 
How does this explain the increased rates of LNM in sm3 invasion as shown 
by Kikuchi and Ueno?  When comparing two pT1 CRC of equal width but 
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different depths of invasion, the area of submucosal invasion will typically be 
larger for the tumour with a deeper extent of invasion than that of a more 
superficial carcinoma (figure 2.13).  This could also explain why tumour 
budding is a risk factor for LNM as tumour budding increases the surface area 
of submucosal invasion but the relative significance of this is currently 
unknown and needs further investigation. 
 
 
Figure 2.12: Diagram illustrating pT1 cancers (indicated by the red boxes with 
different widths (x and y) but identical depths of invasion. The wider cancer 
has a bigger area of invasion compared to the cancer with the smaller width. 
Hence, with the greater area, the wider cancer has more chance of coming 
into contact and invading lymphatic vessels especially within the lymphatic 
rich superficial submucosa.  
  
71 
 
Figure 2.13: Diagram illustrating pT1 cancers with identical widths (x) but 
different depths of invasion. The pT1 cancer with SM3 invasion has 
progressed further in depth and has a greater area of invasion within the 
submucosa when compared to the pT1 cancer with the same extent of SM1 
invasion. The length of invasive front is also increased in wider and deeper 
cancers but this study has shown no significant difference in cases with and 
without LNM for this parameter. 
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2.6 Conclusion 
In this present study, we have found that the width and area of submucosal 
invasion can be considered as quantitative risk factors for LNM in pT1 CRC 
but the area of submucosal invasion in more predictive than width.  The area 
of submucosal invasion may replace the depth of invasion as a better 
predictor in routine practice.  With the advent of digital microscopy, this factor 
is more easily measurable and being quantitative, with a low inter- and intra-
observer variation, less variation would arise between reporting pathologists.  
In tumours where the muscularis mucosae has been destroyed, there is a 
need for a subjective assessment as to where it would have been.  This 
finding needs to be tested in a large prospective series and will hopefully help 
in determining the right type of treatment for patients with pT1 CRCs. 
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Chapter 3 Differences between screened and 
symptomatic pT1 colorectal cancers 
 
3.1 Screened pT1 CRC within the National Health Service Bowel Cancer 
Screening Programme (NHSBCSP) 
Screening is the process of detecting or identifying a disease in its early state, 
with the intention of halting its progression.  Screening is performed by means 
of tests, examinations and other procedures that can be applied rapidly.  The 
formal definition of screening is the process, by which unrecognized disease 
or defects are identified, using tests that can be applied rapidly and on to 
large numbers of people.  
A screening test should be able to distinguish a healthy individual from those 
who have the disease.  Normally, the screening process involves an initial test 
or examination that is not diagnostic and requires the appropriate follow up 
investigations and treatment.  Screening is warranted as early intervention or 
treatment of the disease is more successful and cost-effective to treat and 
thus lowering the mortality and morbidity from the disease.  
There are several types of screening, each with specific aims: 
 Mass screening involving large populations (for example chest x-rays 
for tuberculosis).  
 Multiple or multiphasic screening involving the use of several screening 
test on the same occasion (for example, annual health check ups). 
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 Targeted screening of groups with specific exposure to environmental 
and occupational hazards. 
 Proactive or systematic screening involving using population registers 
to invite members of the population at risk for screening at appropriate 
time intervals. 
 Case finding (or opportunistic screening) is a form of screening 
restricted to patients who consult a health practitioner for another 
purpose. 
 
In screening for a disease, there are principles that should be met before the 
screening programme is initialized.  These principles are based on the World 
Health Organization guidelines, which were adopted from the paper published 
by Wilson and Jungner (Wilson and Jungner 1968).  The principles are as 
below:  
1. The condition should be an important health problem. 
2. There should be a treatment for the condition. 
3. Facilities for diagnosis and treatment should be available. 
4. There should be a latent stage of the disease being screened. 
5. There should be a test or examination for the condition. 
6. The test should be acceptable to the population. 
7. The natural history of the disease should be adequately understood. 
8. There should be an agreed policy on whom to treat. 
9. The total cost of finding a case should be economically balanced in 
relation to the medical expenditure as a whole.  
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10. Case finding should be a continuous process, not just a “once and for 
all” project. 
 
Based on the principles outlined above, CRC is an ideal disease for which to 
provide screening.  CRC is ideal because it is a disease in which the natural 
history is sufficiently understood.  CRC also has an identifiable and treatable 
“pre-cancerous” stage (adenoma) with treatment in the form of removal of the 
adenoma preventing the development of CRC.  This has led to the 
introduction of the National Health Service Bowel Cancer Screening 
Programme, which will be discussed as below.  
 
3.1.1 National Health Service Bowel Cancer Screening Programme 
(NHSBCSP) 
In 2000, a pilot study was established in the UK to assess the feasibility of 
population based screening for CRC using faecal occult blood testing (FOBt) 
(UK Colorectal Cancer Screening Pilot Team 2003).  This was the UK pilot of 
Bowel Cancer Screening and consisted of two rounds. It was initially 
conducted at two sites; the West Midlands in England and Tayside, Grampian 
and Fife in Scotland.  Screening began at the Scottish and English sites in 
March and September 2000 respectively.  The first round of the UK pilot of the 
Bowel Cancer Screening demonstrated that screening for CRC using FOBt as 
shown by previous randomised trials (Towler et al 1998) could be replicated in 
a population-based pilot programme.  
  
76 
A second round of the pilot was then initiated with the aim of getting a clearer 
picture on how a screening programme would work where the population 
would be invited on a periodic basis.  Furthermore, the aims of the second 
round (or incidence round) could help determine the effects of the same 
process on a population who had already been invited to screening.  The 
second round of this pilot also had the advantage of being able to identify 
interval cancers from the first pilot round and to calculate the sensitivity of the 
FOBt. 
The second round of the pilot had begun in February 2003 and took place in 
Nottingham with invitations being sent to previous participants in the West 
Midlands.  The results from both rounds of the UK pilot of the Bowel Cancer 
Screening confirmed that CRC screening in the UK is feasible and worthwhile. 
Consequently, in England, the National Health Service (NHS) has devised 
and introduced the NHS Bowel Cancer Screening Programme (NHSBCSP).   
This screening programme was first piloted in July 2006 and was based in 
Coventry and North Warwickshire.  The pilot ended in March 2007 with 
271,646 participants.  The overall rate of detecting cancer was 1.62 per 1000 
people screened.  The positive predictive value was 10.9% for cancer and 
35.0% for adenoma.  In this pilot study, 552 cancers were detected by 
screening, 92 were polyp cancers and 48 per cent of all screened cancers 
were Dukes’ stage A.  At time of diagnosis, only 1 per cent of the cancers had 
metastasised (NHSBCSP 2011).   
Following this pilot study, the NHSBCSP has 58 local screening hubs and 
centres that cover all the regions in the England.  Currently, the NHSBCSP 
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offers screening every two years to men and women aged 60 – 69 and 
currently extending this age limit to 75 years old.  This specified age group 
was set as CRC increases with age with 85% of bowel cancer occurring in 
people over 60 years old. 
 
3.1.2 UK Flexible Sigmoidoscopy Screening Trial 
A multi-centre randomised controlled trial by Atkin et al (2010) which aimed to 
look at bowel cancer incidence and mortality reduction 11 years after a single 
screening examination.  The screening examination that was used was 
flexible sigmoidoscopy.  The trial recruited 170,000 people and the main 
objective was to examine the effectiveness of a once only flexible 
sigmoidscopy screen on people aged 55 to 64 years.  The trial involved 
removing any small colonic polyps (< 10mm) found during the screening 
process. If any high-risk adenomas (≥ 3 polyps, ≥ 10 mm, ≥ 25% villous, high 
grade dysplasia) were detected, the participant would then go on to have a full 
colonoscopy.  
The trial showed a reduced cumulative incidence in distal cancers (rectum 
and sigmoid) by 50% and a reduction of 33% for overall CRC incidence.  The 
trial also showed that CRC mortality was further reduced by 43%.  Most 
importantly, the trial proved that a once only flexible sigmoidoscopy for the 
population aged between 55 and 64 years old is a safe practical examination 
and offers a longstanding benefit in terms of reducing mortality and morbidity 
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from CRC (Atkin et al 2010).  This trial has now lead to a full roll out to two 
thirds of England by 2015. 
With the NHSBCSP in place and the roll out of the UK flexible sigmoidoscopy 
screening programme, there is an increase in the number of stage I cancers 
detected from the screened population as compared to the non-screened 
population (Steele et al 2011, Rajaskehar et al 2012, Morris et al 2012).  This 
has directly increased the number of pT1 CRC detected within the screened 
population.  This raises the important issue that we do not as yet know the 
optimal management for screened pT1 CRCs.  Does a screened pT1 have 
the same risk as a symptomatic pT1?  Should we be treating screened pT1 
CRC the same way as those that arise in the general population?  Over 
treatment of screened pT1 CRC may lead to a higher morbidity and mortality 
than is absolutely necessary.  This is important, as participating individuals 
are normally fit and healthy prior to entering the screening programme.  
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3.2 Research objectives 
This research will establish whether screened pT1 CRC are a different 
population and require different indicators for treatment when compared to 
symptomatic CRC.  Therefore, the objectives of the research include: 
1. To characterise pT1 CRC presenting in the NHS BCSP and comparing 
these cancers to symptomatic CRC to establish phenotypic differences.  
2. To identify clinically useful phenotypic features of pT1 CRC within the 
NHSBCSP that will help optimise decision making for patient 
management. 
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3.3: Materials and methods 
3.3.1 Database searches 
pT1 CRC were selected from the NHSBCSP and Northern and Yorkshire 
Cancer Registry and Information Service (NYCRIS). 
 
3.3.2 Symptomatic pT1 CRC 
All radical resections of primary CRC within Yorkshire between 1st January 
2000 and the 31st December 2009 were identified by the NYCRIS were 
included in this study.   
 
3.3.3 Screened PT1 CRC 
Screened pT1 CRC throughout the country were identified by the NHSBCSP 
database.  All but two of the screened pT1 CRC that were included in this 
study were local excision/ polypectomy specimens.  Piecemeal specimens 
were excluded from the study. 
 
3.3.4 Clinicopathological data  
Histopathological staging data was obtained from NYCRIS, NHSBCSP or 
pathology reports.  The data included the age, gender of patient, site of 
cancer, stage of cancer, lymph node involvement, distant metastasis and 
lympho-vascular invasion status (in symptomatic cases).  
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3.3.5 Quantitative analysis 
A local pathologist retrieved all microscopy slides.  The slide that showed the 
widest and deepest tumour invasion was selected for digital scanning.  These 
slides were scanned at x20 magnification with an automated digital scanner 
(Aperio XT Scanner, Aperio technologies, San Diego, Ca USA). Using a 
digital slide viewer (Imagescope v10.0, Aperio Technologies), computer-
based morphometry of the tumours could be performed and analysed.  
Quantitative factors that were analysed are identical to the ones that were 
used in the previous chapter and are listed as below: 
1) Maximum width of lesion. Lesion is defined as the summation of the 
adenoma and carcinoma component (Figure 2.1) 
2) Maximum width of invasive carcinoma (Figure 2.1) 
3) Maximum vertical depth of carcinoma from luminal surface (Figure 2.2) 
4) Maximum vertical depth of carcinoma from muscularis mucosae 
(Figure 2.2) 
5) Maximum depth of invasion within neck of polypoid /semi-pedunculated 
lesions (Figure 2.3) 
6) Minimum distance from resection margin (Figure 2.4) 
7) Minimum distance from muscularis propria if present (Figure 2.4) 
8) Total area of lesion (Figure 2.5) 
9) Total area of carcinoma (intramucosal and submucosal) (Figure 2.6) 
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10) Total area of submucosal invasion by carcinoma (Figure 2.7) 
11) Length of invasive front (Figure 2.8) 
 
The screened pT1 lesions were also divided into the 3 types of shapes that 
were described in the previous chapter (figure 2.9).  
 
3.3.6 Statistical analyses 
Statistical analyses were performed using the Statistical Package for the 
Social Sciences (SPSS v21.0, Chicago, IL, USA).  Statistical analyses of 
continuous variables between the screened and symptomatic cases were 
performed using the non-parametric Mann-Whitney U test.  A p value of < 
0.05 for all the tests were considered significant. 
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3.4 Results 
3.4.1 Relationship of quantitative factors in screened pT1 CRC and its 
comparison to symptomatic pT1 CRC 
164 screened cases have been collected.  2 out of the 164 cases were from 
radical resections and the remainder of the cases were excised via 
polypectomies or a local procedure.  Table 3.1 compares the shape of the 
pT1 CRC between the two groups showing an increase in semi –
pedunculated lesions and a reduction in sessile lesions.  
 pT1 Colorectal Carcinomas 
Screened 
(n=164) [%] 
Symptomatic 
(n=207) [%] 
p-value 
 
Shape of 
Lesion 
Pedunculated 42 [25.6] 51 [24.6] 0.015 
Semi-
Pedunculated 
100 [61.0] 97 [46.9] 
Sessile 22 [13.4] 59 [28.5] 
Table 3.1: Comparison of the shape of pT1 CRC between the screened and 
symptomatic groups. p-value obtained using Chi-Square test. 
 
The quantitative measurements are shown in Table 3.2.  Screened pT1 CRC 
were smaller in nearly all dimensions except for 1 measurement (maximum 
depth of invasion of carcinoma within the neck).  
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Quantitative Factors pT1 Colorectal Carcinomas p - value 
Screened 
(n=164), Median 
(IQR: SD) 
Symptomatic 
(n=207) Median 
(IQR: SD) 
Maximum width of lesion (mm) 11.98 (9.69 – 
16.25: 5.49) 
16.73(13.1 – 
21.57: 7.36) 
<0.0001 
Maximum width of carcinoma 
(mm) 
8.73 (6.15 – 
11.29: 3.86) 
11.55 (8.11 – 
14.84: 5.15) 
<0.0001 
Maximum depth of invasion of 
carcinoma from surface (mm) 
4.97 (3.59 – 
6.88: 2.79) 
5.82 (3.73 – 
8.71: 3.78) 
0.03 
Maximum depth of invasion of 
carcinoma from muscularis 
mucosae (mm) 
3.50 (2.50 – 
5.12: 2.01)  
4.36 (2.81 – 
8.96: 3.08) 
0.01 
Depth of invasion within neck 
(mm) 
1.02 (0.53 – 
1.91: 1.21) 
1.49 (0.96-2.36: 
1.21) 
0.44 
Distance of carcinoma to margin 
(mm) 
1.33 (0.58 – 
4.18: 2.58) 
5.31 (2.94 – 
8.21: 4.21) 
<0.0001 
Total area of lesion (mm2) 52.65 (34.78 – 
89.63: 58.00) 
79.63 (47.63 – 
124.47: 87.96) 
<0.0001 
Total area of carcinoma (mm2) 44.49 (27.76 – 
68.90: 43.00) 
70.71 (38.05 – 
109.30: 85.28) 
<0.0001 
Total area of carcinoma within 
submucosal layer (mm2) 
22.31 (14.93 – 
37.39: 22.00) 
34.98 (17.25 – 
54.39, 32.74) 
<0.0001 
Length of invasive front (mm) 6.48 (4.89 – 
9.04: 4.11) 
8.15 (5.01 – 
11.21: 4.94) 
0.009 
Table 3.2: Comparison of quantitative factors between screened and symptomatic 
pT1 CRCs. p-values obtained using Mann-Whitney U test. Values in red identifies 
significant factors 
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3.5: Discussion 
3.5.1 Implications for screened and symptomatic pT1 CRC based on the 
Japanese Society for Cancer of the Colon and Rectum (JSCCR) 
treatment guidelines 
The guidelines for the JSCCR have recommended that a pT1 CRC with a 
depth of submucosal invasion ≥ 1000μm would require a radical resection 
(Watanabe et al 2012).  If this recommendation was applied to the screened 
pT1 CRC in this study, all the pT1 CRCs would require a bowel resection if 
depth of invasion was measured from the luminal surface and 99.4% 
(163/164) would require a resection if the depth of invasion was measured 
from the muscularis mucosae (Table 3.3).  
If this recommendation were to be applied in the West, this would have major 
implications for all pT1 CRC.  Firstly, the rate of radical resections for both 
screened and symptomatic pT1 CRC will rise with nearly all lesions being 
resected.  This would lead to an unnecessary increase in the morbidity and 
mortality that are associated with these resections.  Secondly, with the 
increased number of radical resections performed, this will further burden the 
healthcare system financially.  Thirdly, this may have a negative impact on the 
NHSBCSP as it may deter the general public from entering screening with the 
fear of operative morbidity and mortality. 
Therefore, we again emphasised the importance of selecting the proper 
treatment for patients with pT1 CRCs. The decision on whether a patient 
should receive a radical resection or a local procedure should be made by a 
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multi-disciplinary team and aided by the histopathological features 
(quantitative and qualitative) of the pT1 CRC and the patient’s pre-operative 
state. 
  
 Depth of invasion ≥ 
1000 μm  
Depth of invasion ≥ 
2000 μm 
Depth of invasion ≥ 
3000 μm 
Luminal 
surface 
Muscularis 
mucosae 
Luminal 
surface 
Muscularis 
mucosae 
Luminal 
surface 
Muscularis 
mucosae 
Screened 
pT1 CRCs 
164/164 
(100%) 
163/164 
(99.4%) 
162/164 
(98.8%) 
147/164 
(89.6%) 
141/164 
(86%) 
104/164 
(63.4%) 
Symptomatic 
pT1 CRCs 
207/207 
(100%) 
198/207 
(95.7%) 
197/207 
(95.2%) 
180/207 
(87%) 
179/207 
(86.5%) 
151/207 
(72.9%) 
Table 3.3: Breakdown of depth of invasion from luminal surface and 
muscularis mucosae of screened and symptomatic pT1 CRCs 
 
3.5.2 Comparison between screened and symptomatic pT1 CRC 
This study has shown that screening pT1 CRC had a smaller width (lesion 
and carcinoma) and area (total area of lesion, total area of carcinoma and 
total area of submucosal invasion) of invasion and shorter length of invasive 
front.  There was also a significant difference in the depth of invasion from the 
muscularis mucosae and luminal surface between screened and symptomatic 
pT1 CRC.  Understandably, the distance of the invasive border to clear 
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margins were greater in symptomatic cases as all these cases had undergone 
radical resections.  
Screening pT1 CRC appear to have a different, possibly earlier morphological 
pattern.  They are quantitatively smaller than their symptomatic counterparts.  
Not surprisingly, it is clear that screening does not only help identify CRC in 
their earlier stages but also identifies CRC that are smaller in size within the 
pT1 staging and therefore potentially curable with local procedures.  The 
greater difference in depth from the neck of the lesion in screening cases is 
probably a reflection of the frequency of polypoid lesions in the screened 
population. 
However, it is worth noting that this study was performed using symptomatic 
pT1 CRC that had been resected through a radical resection.  Symptomatic 
cases that underwent a radical resection were chosen, as we wanted to know 
the lymph node status of each case.  This may have consequently introduced 
some biasness as the majority of screened pT1 CRC were resected by local 
procedures such as polypectomies, EMR and TEMS.  Ideally, it would have 
been better to compare the screened pT1 CRC to symptomatic pT1 CRC that 
have been resected through a local excision as this may help to reduce the 
biasness. 
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3.5.3 The value of local procedures in the treatment of screened pT1 
CRC 
Currently, the gold standard for treatment of early CRC is a radical resection 
but local procedures are becoming a suitable alternative especially for distal 
early CRC.  The main goal with performing a local procedure for a pT1 CRC is 
to achieve a curative outcome whilst reducing mortality, morbidity and 
maintaining a good quality of life for the patient.  Local procedures such as 
EMR and TEMS are an attractive alternative to radical resection for several 
reasons.  Local procedures are less invasive and are associated with less 
postoperative pain with a shorter length of inpatient stay including less post-
procedure morbidity.  Another advantage of a local procedure is that normal 
bowel function is preserved without the need for stoma formation.  
Furthermore, there have been great advances in both equipment technology 
and the endoscopist/surgeon skill set, leading to even less post-procedure 
complications and better surgical margins.   
However, the single most detrimental disadvantage of a local procedure is 
that the nodal status is not obtained, as lymph nodes are not excised.  This 
could mean that if lymph node metastasis was present, the local procedure 
was not considered a curative procedure and the patient will then need to 
undergo a further treatment.  This can then lead to an increase in morbidity 
and mortality in that patient as well as increased rates of local recurrence and 
a failure to salvage the patient, leading to death from cancer that may have 
been avoidable by the performance of a radical resection. 
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The key to a successful and potentially curative local procedure for an early 
CRC is to select the appropriate patient and to provide them with the correct 
local procedure.  Key factors that will help decide whether the early CRC 
would be appropriate or not for a local procedure includes location of the CRC 
within the rectum (Bhangu et al 2013, Althumairi and Gearhart 2015), poorly 
differentiated cancers (Nascimbeni et al 2002, Ueno et al 2004, Choi et al 
2008), lymphatic, and/or vascular invasion (Sakuragi et al 2003, Yamamoto et 
al 2004, Kitajima et al 2004, Yasuda et al 2007) and tumour budding (Ueno et 
al 2004, Kitajima et al 2004, Yasuda et al 2007).  Therefore, it is absolutely 
vital that patients who undergo a local procedure for their early CRC, should 
be selected based on the key factors mentioned above as this would minimise 
morbidity and mortality and help improve oncological outcomes.  
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3.6 Conclusion 
This study has shown that the NHS BCSP is identifying earlier pT1 CRCs that 
are smaller in terms of width and area and also less invasive in regards to the 
depth of invasion from the muscularis mucosae when compared to their 
symptomatic counterparts.  This should have been expected as one of the 
main objectives of the NHS BCSP is to detect early CRCs and the shift 
between stages from late to early should have been expected to generate 
earlier pT1 CRCs.   
 
 
 
 
 
 
 
 
 
‘; 
  
91 
Chapter 4 The significance of tumour stroma in pT1 
colorectal cancers 
 
Colorectal carcinomas are composed of malignant epithelial cells and non-
malignant cells.  These non-malignant cells create the tumour stroma that has 
various complex interactions with the cancer cells (Coussens and Werb 2002, 
Allen and Jones 2011, Pickup, Mouw and Weaver 2014).  The tumour stroma 
has been investigated extensively but as yet, it is still poorly understood.  The 
non-malignant cells of the stroma have a dynamic relationship with the tumour 
cells at all stages of carcinogenesis (Hanahan and Coussens 2012).  
Intracellular communication is driven by the complex network of cytokines, 
growth factors, receptors and inflammatory and matrix remodeling enzymes 
(Allen and Jones 2011, Pickup, Mouw and Weaver 2014). 
 
4.1 Cells of the tumour stroma 
The tumour stroma is composed of several different types of cells. These cells 
are described below. 
 
4.1.1 Cancer-associated fibroblasts 
Cancer-associated fibroblasts (CAF) are the most prominent cell type within 
the tumour stroma of many cancers.  CAF are different from host fibroblasts 
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as they express α-smooth muscle actin as cytoplasmic microfilaments and 
sometimes desmin.  Host or local fibroblasts express vimentin as intermediate 
filament proteins (Sappino, Schurch and Gabbiani 1990).  CAF are contractile 
and secretory cells that produce an extracellular matrix that is rich in type III 
and V collagen, which may be considered responsible for the hard 
consistency of many carcinomas (Liotta, Rao and Barsky 1983). 
CAF are believed to originate from multiple origins such as from resident/ 
local fibroblasts, bone marrow derived progenitor cells or trans-differentiating 
epithelial cells (Anderberg and Pietras 2008, Augusten 2014).  Resident/ local 
fibroblasts are activated to form CAF by cancer-derived growth factors such 
as Tumour Growth Factor – β (TGF-β), Platelet Derived Growth Factor 
(PDGF) and basic Fibroblast Growth Factor (bFGF).   
The second source of CAF is derived from the bone marrow progenitor cells.  
These cells are pluripotent and when recruited to tumour sites, are activated 
to form CAF by cytokines and growth factors such as Vascular Endothelial 
Growth Factor (VEGF), Epidermal Growth Factor (EGF), Hepatocyte Growth 
Factor (HGF), bFGF, PDGF and Monocyte Chemotactic Protein-1 (MMC-1) 
(Hall, Andreeff and Marini 2007, Dwyer et al 2007, Spaeth et al 2008, Feng 
and Chen 2009, Allen and Jones 2011).  
The third source of CAF is from epithelial cells and to a certain extent, tumour 
cells.  Tumour epithelial cells undergo transformation to CAF through the 
epithelial – mesenchymal transition (EMT) process.  EMT is a complex 
process in which the epithelial and tumour cells lose their innate 
characteristics and gain new mesenchymal properties (Augusten 2014).  CAF 
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play a vital role in tumour progression by providing a supportive environment 
for tumour growth and proliferation.  Once activated by tumour-secreted 
factors, CAF produces a whole host of growth factors (PDGF, VEGF, and 
HGF), proteases (matrix metalloproteases [MMP] 2, 9, 13 and 14) and 
cytokines (Stromal-Derived Factor - 1 [SDF-1], Interleukin [IL] 6, Chemokine 
Ligand 12 [CXCL12]) that are essential in tumour development, angiogenesis 
and metastasis (Owusu et al 2015). 
 
4.1.2 Pericytes 
Pericytes are contractile cells in close proximity to endothelial cells in 
capillaries and venules.  These cells are an integral component of tumour 
vasculature as they provide structural support to blood vessels during 
angiogenesis. (Armulik, Genove and Betsholtz 2011) 
The role of pericytes in tumour progression is still poorly understood.  Clinical 
studies in bladder and colorectal cancers (Yomenaga et al 2005, O’Keefe et al 
2008) suggest that low pericyte coverage around vessels correlated with poor 
prognosis and increased metastasis.  Using genetic mouse models and 
pharmacological inhibitors, pericyte depletion suppressed tumour growth at 
the early stages of tumour angiogenesis but metastasis is enhanced in the 
advanced stages of tumour angiogenesis (Cooke et al 2012).  This may 
suggest that the role of pericytes changes or evolves with the progression of 
the tumour.  
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4.1.3 Vascular endothelial cells 
Many angiogenic factors within the tumour stroma such as VEGF and platelet-
derived growth factors (PDGF) and chemokines stimulate endothelial cells 
and their associated pericytes to form new vessels.  These new vessels 
supply the tumour with nutrients that will aid cancer growth (Carmeliet and 
Jain 2011).   The vessels that are formed are usually abnormal with non-
uniform distribution, irregularly shaped and are variably ‘leaky’ (Jain 2005).  
This characteristic ‘leakiness’ of the vessel increases the tumour interstitial 
pressure leading to uneven blood flow and oxygenation and simultaneously 
creating poor nutrient and drug distribution within the tumour stroma.  This in 
turn leads to further hypoxia and facilitates tumour metastasis (Jain 2005).  
 
4.1.4 Cells of the immune system 
Most malignant processes induce an inflammatory response within the host 
and this response occurs via both the innate and adaptive pathways 
(Coussens and Werb 2002, Pickup, Mouw and Weaver 2014).  The 
inflammatory response generated by the tumour involves various pro-
inflammatory cytokines and cell mediated responses that play a role in 
modulating an individual’s response to the malignancy.  Therefore, it is 
common to see a variety of cells of the immune system within the tumour 
stroma (Quail Joyce 2013). 
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4.1.4.1 T-lymphocytes 
There are a variety of T-cell populations within the tumour stroma.  Among 
these, the cytotoxic CD8+ memory T cells are capable of killing tumour cells 
and are strongly associated with a good prognosis. CD8+ T cells are 
supported by CD4+ T helper 1 (TH 1) cells that produce cytokines IL-2 and 
interferon – γ (IF- γ).  High amounts of these cytokines correlate with a good 
prognosis (Fridman et al 2012).  
The CD4+ T cells associated with tumour growth are the immunosuppressive 
T regulatory cells (Tregs), which are recognized by their expression of FOXP3 
and CD25 (Hsieh, Lee and Lio 2012).  Tregs exert an immunosuppressive 
function through the productions of IL-10, TGF-β and cell-mediated contact 
through cytotoxic T-lymphocyte antigen 4.  This inhibits the recognition and 
clearance of tumour cells by the immune system (Campbell and Koch 2011).   
High amounts of Tregs within the tumour stroma have been correlated with 
worse prognosis in breast, ovarian and pancreatic cancer (Curiel et al 2004, 
Bates et al 2006, Hiraoka et al 2006).  Tregs can also be tumour suppressive 
in some B cell cancers as their presence in Hodgkin’s lymphoma indicates a 
good prognosis (Tzankov et al 2008, Koreishi et al 2010, Fozza and Longinotti 
2011).  
 
4.1.4.2 B-cell lymphocytes 
B-cell lymphocytes are normally found within the draining lymph nodes and 
lymphoid structures in the tumour stroma but can also be found at the 
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invasive margin of tumours.  Infiltration of B-cells in the tumour stroma is 
associated with a good prognosis in some breast and ovarian cancers 
(Coronella et al 2001, Milne et al 2009).  However, in studies involving mouse 
models, there is a contrast as B-cells inhibit tumour specific cytotoxic T-cell 
responses (Qin et al 1998) and more recently, Andreu et al and de Visser et al 
showed that B cells have a tumour promoting role (de Visser et al 2005, 
Andreu et al 2010). 
 
4.1.4.3 Natural Killer (NK) and Natural Killer T (NKT) cells 
NK and NKT cells also exist within the tumour stroma but are not normally 
found to be in contact with tumour cells.  The presence of NK and NKT cells 
appear to predict a good prognosis in many cancers such as colorectal, 
gastric, lung, renal and liver cancers (Tachibana et al 2005).  However, it is 
believed that NK and NKT cells may not be able to exert their full tumour 
killing ability due the effects of TGF-β that is released by the tumour cells 
(Fridman et al 2012). 
 
4.1.4.4 Tumour-associated macrophages and neutrophils  
Tumour-associated macrophages (TAMs) are abundant within the tumour 
stroma and are normally derived from monocytes that are recruited largely by 
monocyte chemotactic protein chemokines (Coussens and Werb 2002).  
TAMs are thought to have a dual role in tumourigenesis. TAMs have the 
potential to kill cancer cells following activation by IL-2, interferon and IL-12 
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(Brigati et al 2002, Tsung et al 2002, Quail and Joyce 2013).  However, TAMs 
are also believed to be pro-tumourigenic as they produce a number of 
angiogenic and lymphangiogenic growth factors, cytokines and proteases, all 
of which are potent mediators of tumour progression (Schoppmann et al 
2002).  TAMs also produce IL–10 which reduce the anti-tumour response by 
cytotoxic T cells.  
The role of tumour-associated neutrophils (TANs) in tumour growth and 
metastasis is still being researched.  There is evidence that TANs promote 
primary tumour growth by enhancing tumour angiogenesis (Nozawa, Chiu and 
Hanahan 2006, Shojaei et al 2008), increasing degradation of the extracellular 
matrix (De Larco, Wuertz and Furucht 2004) and reducing the immune 
response to the tumour (Youn and Gabrilovich 2010). 
Despite convincing evidence in support of TANs promoting tumour 
development, there is also evidence that TANs demonstrate anti-tumour 
activity. TANs possess cytotoxic granules that can be used to eliminate 
surrounding cancer cells (Borregaard, Sorenson and Theilgaard-Monch 
2007).  TANs are also considered indirect anti-tumour effector cells as they 
secrete cytokines and chemokines that may direct and activate other anti-
tumour effector cells (NK cells). 
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4.1.5 Role of tumour stroma in malignancies 
The role of tumour stroma in cancer progression is still being researched.  
Many investigators have studied the role of tumour stroma in the progression 
of different types of cancers and the interactions between tumour stroma and 
cancer cells are still unclear (Mesker et al 2007, Mesker et al 2009, West et al 
2010, Courrech Staal et al 2010, de Kruijf et al 2011, Wang et al 2012, 
Huijbers et al 2013).  
Recently, researchers have acknowledged the importance of tumour stroma 
in cancer growth, invasion and metastasis.  The complex interactions between 
tumour stroma and cancer cells have been investigated extensively through 
different types of methods. These methods vary from visual evaluation of the 
tumour stroma to analysis of the molecules of the tumour stroma itself. 
In trying to identify another marker for further adjuvant therapy to colorectal 
cancer treatment, Mesker studied the carcinoma-stromal components in 122 
patients with stage I – III colorectal cancer (Mesker et al 2007).  Mesker had 
visually estimated the carcinoma-stromal percentages on routine H & E 
stained histological sections.  They showed that patients with a high stromal 
percentage within the most invasive part of the primary tumour had lower 
overall (OS) and disease free (DFS) survival compared to patients with low 
stromal percentages (OS – 2.13 years vs 7.36 years, Hazard Ratio [HR] = 
3.73, p = <0.0001, DFS – 1.51 years vs 6.89 years, HR = 4.18, p < 0.0001).  
Mesker also showed that a high stromal percentage remained an independent 
variable after adjusting for tumour stage (OS: HR – 0.39, 95% CI = 0.22 – 
0.71, p <0.001; DFS: HR – 0.34, 95% CI = 0.19 – 0.60, p< 0.0001) and lymph 
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node status (OS: HR – 0.37, 95% CI = 0.20 – 0.68, p <0.001; DFS: HR – 
0.34, 95% CI = 0.19 – 0.61, p<0.0001).  They concluded that a high stromal 
percentage could be used as an extra parameter in identifying high-risk 
patients (Mesker et al 2007). 
In 2009, Mesker again used the similar method of calculating tumour stroma 
to further identify a sub-group of stage I - II colorectal cancer patients who 
may benefit from additional treatment.  In addition to calculating tumour 
stroma, Mesker had undertaken extra immunohistochemical staining to 
identify elements that are involved in the pathways of tumour stroma 
production (TGF – β – R2, SMAD4 and β – catenin).  This study analyzed 135 
patients and showed that patients with a high proportion of stroma (< 50% 
tumour cells) had poorer survival (OS: HR – 2.73, 95% CI = 1.73 – 4.30, p 
<0.001; DFS: HR – 2.43, 95% CI = 1.55 – 3.82, p < 0.001).  A further high-risk 
group was identified with high tumour stroma and SMAD4 loss.  This high-risk 
group showed a low 5-year survival rates for patients with low tumour stroma 
with positive SMAD4 staining (OS: HR – 7.98, 95% CI = 4.12 – 15.44, p = 
0.008; DFS: HR – 6.57, 95% CI = 3.43 – 12.56, p = 0.005) (Mesker et al 
2009).  
West et al (2010) further confirmed that a low proportion of tumour cells (high 
proportion of stroma) were related to a poor cancer-specific survival in 145 
patients of various stages (I – IV) of CRC.  In contrast to Mesker’s studies, 
tumour stroma was quantified digitally rather than estimated visually via a 
microscope.  Quantification of tumour stroma was performed by point 
counting using scanned tissue sections (this method will be described later in 
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the methods section).  West et al (2010) showed that patients with high 
tumour stroma (low proportion of tumour) had significantly lower cancer-
specific survival when compared to patients with low tumour stroma (high 
proportion of tumour) (HR = 2.087, 95% CI = 1.088 – 4.003, p = 0.024).  On 
multivariate analysis, high tumour stroma was an independent poor prognostic 
marker when the study model was adjusted for age, pT stage, pN stage and 
extramural vascular invasion (p = 0.017) (West el al 2010).  
More recently, Huijbers et al (2013) also confirmed that a high intra-tumour 
stroma percentage (proportion of tumour stroma > 50%) was a strong 
prognostic factor for stage II and III CRC patients within the VICTOR trial.    
Again the proportion of tumour stroma was evaluated and scored by simple 
microscopic visualization.  Huijbers et al had investigated 710 patients of 
stage II and III CRC and showed that OS and DFS times were significantly 
lower in stroma high groups (OS: HR = 1.96, 95% CI = 1.40 – 2.74, p  < 
0.001; DFS: HR = 2.15, 95% CI = 1.60 – 2.90, p < 0.001).  The 5-year OS 
was 69% versus 83.4% and DFS 58.6% versus 77.3% for stroma- high versus 
stroma-low patients (Huijbers et al 2013).  
The studies by Mesker, West and Huijbers have shown that tumour stroma 
could potentially become a valid prognostic factor in colorectal cancer.  
Equally useful is that information regarding tumour stroma is easily obtainable 
from normal H & E slides at no extra cost.  
To further reinforce the role of tumour stroma in tumourigenesis, Roepman et 
al had investigated the molecular and genetic differences in CRC and 
revealed a sub-type of CRC with a high EMT index.  This sub-type of CRC 
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showed increased mesenchymal gene expression and were termed 
‘mesenchymal type’ CRC (Roepman et al 2014).  Guinney et al further 
validated this by identifying four consensus molecular subtypes (CMS) of 
CRC.  The four CMS contain distinguishing features: CMS1 (microsatellite 
instability immune – hypermutated, microsatellite unstable and strong immune 
activation); CMS2 (canonical – epithelial, marked WNT and MYC signalling 
activation); CMS3 (metabolic – epithelial and evident metabolic dysregulation) 
and CMS4 (mesenchymal – prominent TGF-β activation, stromal invasion and 
angiogenesis) (Guinney et al 2015). 
Clinically, patients with CMS4 CRC have poorer relapse-free and overall 
survival amongst the other CMS CRC (Guinney et al 2015).  Previous studies 
by Yang, Roepman, Singh and Settleman have also shown poor 
chemotherapy responsed in ‘mesenchymal type’ CRC (Yang et al 2006, Singh 
and Settleman 2010, Roepman et al 2014). 
 
4.1.5.1 Tumour stroma in other malignancies 
The role of tumour stroma in other malignancies has also been investigated. 
Researches have shown that tumour stroma does play a prognostic role in 
breast and oesophageal cancers.  de Kruijf et al (2011) had investigated the 
tumour-stroma ratio in breast cancer and proved that it was an independent 
prognostic factor for the relapse free period in breast cancer patients 
especially in the triple negative subpopulation.  The research had shown that 
stroma-rich tumours had a shorter relapse free period (p=0.001) and overall 
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survival (p=0.025).  Within the triple negative subpopulation, patients with 
stroma rich tumours had a 2.92 times higher chance of relapsing (p=0.006) 
compared to their stroma poor counterparts.  Dekker et al (2013) further 
validated the prognostic importance of the tumour stroma ratio showing that 
stroma rich tumours had a higher disease relapse rate independent of other 
clinical parameters (P <0.001).  They also showed that tumour stroma ratio 
was independently associated with locoregional recurrence in younger 
patients (age ≤ 40 years old) (hazard ratio = 2.201, 95% CI 1.038 – 4.669, p = 
0.04) (Dekker et al 2013). 
Courrech Staal et al (2010) had evaluated the prognostic value of the tumour 
stroma ratio in patients with oesophageal adenocarcinoma.  They showed that 
patients with stromal rich oesophageal carcinomas had significantly poorer 
disease-free survival compared to stroma poor cancers.  In the multivariate 
analysis, the stroma rich characteristic was a highly significant prognostic 
factor for overall survival (hazard ratio = 2.0, 95% CI 1.181 – 3.407, p = 0.01) 
independent of other clinicopathological factors such as depth of tumour 
invasion, nodal status, TNM stage, histological grade and type of resection.  
Wang et al (2012) had investigated the prognostic value of tumour-stroma 
ratio in oesophageal squamous cell carcinoma.  They showed that 
oesophageal squamous cell carcinomas that were stroma rich (tumours with 
more than 50% tumour-stroma ratio) were associated with poorer prognosis 
and an increased risk of relapse.  Specifically, stroma rich tumours had lower 
3 year overall and disease-free survival rates.   
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4.2 Research objectives 
To assess whether the relative proportion of tumour stroma (PoTS) could be 
used as a prognostic factor for the prediction of the presence of lymph node 
metastasis (LNM) in patients with stage pT1 CRC. 
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4.3 Materials and Methods 
4.3.1 Patients and clinico-pathological data 
Patients with pT1 CRCs from the NYCRIS registry were used in this study.  
This cohort of patients was identical to the cohort used in the previous studies 
as described in chapters 2 and 3.  Clinicopathological data were extracted 
from official histopathology reports.  These data included histological 
information such as grade of differentiation, evidence of vascular and 
lymphatic invasion and lymph node involvement.  Other demographical data 
like gender and age of the patient were also obtained from the official 
histopathology reports.  
 
4.3.2 Measurement of proportion of tumour stroma (PoTS) 
The measurement of PoTS was based on the method employed by West et al 
(2010).  The H & E – stained slide that best represented each pT1 CRC were 
selected and scanned at X 400 magnification with an automated scanning 
system (Aperio XT, Aperio Technologies, Vista, CA, USA).  Using a digital 
slide software program (ImageScope v10.0, Aperio Technologies), slides 
were inspected after scanning.  An area of 9 mm2 was selected from the area 
that was deemed most invasive on digital microscopy.  A grid with systemic 
random sample of 300 points was superimposed on this 9 mm2  area using a 
virtual graticule software (RandomSpot, University of Leeds, Leeds, UK).  This 
grid/ virtual graticule was placed at the tumour invasive front and did not 
include any of the normal colonic submucosa (figure 4.1).  Each point was 
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scored using the following categories; tumour (the points fall onto a cancer 
cell), stroma, tumour lumen, necrosis, vessel, inflammation and non-
informative (unclassifiable) (figure 4.1 and table 4.1).  The main author (ET) 
was trained by an experienced pathologist (PQ) in recognizing the different 
categories and subsequently navigated through each point and categorized 
the material underneath the point while blinded to the lymph node status.  
After scoring, the informative points were then categorized into two groups: a 
tumour group and a stroma group (Table 4.1).  
The percentage of tumour stroma was calculated and expressed as a 
percentage fraction of all the informative points per case. 
 
 
Figure 4.1: A 9 mm2 boxed area is inserted at the invasive front of the cancer. 
This boxed area contained approximately 300 points. 
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Tumour 
    
Tumour Lumen Necrosis Mucin 
Stroma 
    
Stroma Muscle Inflammation Vessel  
Table 4.1: A summary of how each point was classified based on where the 
spot had landed. There is a 9th class for unclassifiable data if a spot landed on 
an area that is non-informative. 
 
4.3.3 Statistical analysis 
Statistical analyses were performed using the Statistical Package for the 
Social Sciences (SPSS v15.0, Chicago, IL, USA).  Using a modified receiver 
operating characteristic (ROC) curve recommended by a biostatician (P 
McShane – personal communication, 2013), the cut off for dichotomization of 
PoTS with the highest sensitivity and specificity regarding LNM was 
calculated.  With this approach, PoTS was classified as either PoTS – high or 
PoTS – low. 
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Statistical analyses of continuous variables between these two groups were 
performed using the Mann – Whitney U test.  Associations between 
categorical data (for example qualitative data) and LNM were performed using 
a Chi – Square test and Fishers exact tests where appropriate.  Multi-variable 
analyses were performed using binomial logistic regression analysis.  
A p value of < 0.05 for all tests was considered statistically significant. 
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4.4 Results 
4.4.1 Clinicopathological data 
Similar to the previous chapter, the NYCRIS database search identified 382 
patients and from this total, 207 patients were used in this study as 106 
patient’s microscopy slides were missing, 35 patients microscopy slides were 
damaged and were unsuitable for digital scanning and 25 cases were rectal 
carcinomas which were down-staged to a pT1 stage after receiving pre-
operative radiotherapy.  Nine cases had synchronous tumours that were 
staged pT2 – 4 with lymph node metastasis.  All 207 patients had primary 
resections of their cancers and none had received pre-operative chemo-
radiotherapy.  Table 2.6 shows the demographical data of the population of 
pT1 cases evaluated. 
 
4.4.2 Lymph node metastasis and relative proportion of tumour stroma  
The PoTS for the pT1 population followed a normal distribution with values of 
PoTS ranging from 9.38 to 84.46% (figure 4.2).  The median PoTS value was 
40.07% (interquartile range from 29.73 to 51.01%). 
LNM was noted in 19 (9.2%) of the 207 cases. In the patients with LNM, 17 
were staged pN1 and 2 patients were staged pN2.  Figure 4.3 displays the 
distribution of the pT1 CRCs with and without LNM. 
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Figure 4.2: The distribution of the percentage PoTS across the patient population. 
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Figure 4.3:  The distribution of the percentage of PoTS for the pT1 CRCs with and without LNM
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There were no statistical differences between the groups with and without 
LNM for gender, age and the site of the tumour (table 4.2).   However, pT1 
cancers with LNM had a higher PoTS compared to pT1 cancers without LNM 
and this was statistically significant.  This data is displayed in table 4.2. 
 
 Lymph Node Metastasis p-value 
Negative 
(n=188) [%] 
Positive (n=19) 
[%] 
Sex Male 113 [60.1%] 14 [73.7] 0.247 
Female 75 [39.9] 5 [26.3] 
Age Median, IQR 71, 63 - 77 69, 57 – 75 0.536 
Site of tumour Colon 104 [55.3] 9 [47.4] 0.439 
Rectum 83 [44.4] 10 [52.6] 
Unknown 1 [0.5] 0 [0.0] 
Proportion of 
tumour stroma 
(%) 
Median, IQR 39.50, (28.73 – 
49.83) 
48.31, (43.92 – 
56.61) 
0.005 
Table 4.2: Correlation between clinicopathological data, PoTS and lymph 
node metastasis status. p- values obtained using Fischers exact test. 
 
The modified ROC curves had generated a cut off value of PoTS of 43.5% 
(area under curve = 0.702, sensitivity = 0.789 and specificity = 0.612) (figure 
4.4).  
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Figure 4.4: Modified receiver operating characteristic curve used to determine 
the optimal cut-off value for PoTS to dichotomize the patient cohort. The area 
under the curve was 0.702.   
 
Using the cut off value that was generated by the modified ROC curve, the 
pT1 cancer population was dichotomized into a tumour stroma high group 
(PoTS ≥ 43.5%) and a tumour stroma low group (PoTS < 43.5%).  There was 
a significant difference between the two groups with regard to LNM where the 
majority of pT1 cancers with LNM (15/19 cases [78.9%]) had PoTS ≥ 43.5% 
(p = 0.001, OR = 5.78, 95% CI = 1.85 – 18.08) (table 4.3).  
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 Lymph node metastasis p-value Odds ratio (95% 
confidence interval) 
Negative 
(n=188) 
[%] 
Positive (n=19) 
[%] 
Tumour stroma < 
43.5% 
114 [60.6) 4 [21.1] 0.001 5.78 (1.85 – 18.08) 
Tumour Stroma ≥ 
43.5% 
74 [39.4] 15 [78.9] 
Table 4.3:  Univariate analysis of PoTS (low vs high) and lymph node 
metastasis. p- values obtained using Chi-Square test.  
 
When analysed on multivariate analysis with other established 
histopathological factors such as poor differentiation, vascular and lymphatic 
invasion, a PoTS ≥43.5% was predictive of LNM (p = 0.017, HR = 4.34, 95% 
CI = 1.30 – 14.47).  Both lymphatic invasion and poor differentiation were also 
significant in predicting LNM (p values 0.017 and 0.003 respectively).  Details 
of these data are in table 4.4. 
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Qualitative factor p-value, hazard ratio (95% confidence 
interval) 
Vascular invasion 0.054, 5.23 (0.97 – 28.16) 
Lymphatic invasion 0.017, 9.49 (1.51 – 59.74)  
Grade of differentiation 0.003, 11.6 (2.36 – 57.06)  
Proportion of tumour stroma 
≥43.5% 
0.017, 4.34 (1.3 – 14.47) 
Table 4.4: Multivariable analysis of well-established histopathological factors 
and high proportion of tumour stroma. p-values obtained using binomial 
logistic regression analysis.  
 
When the area of submucosal invasion ≥ 35 mm2 was included in the 
multivariate analysis with the PoTS ≥43.5% and the other established 
histopathological factors, the PoTS was still predictive of LNM (p = 0.002, HR 
= 9.30, 95% CI = 2.27 –38.12).  Details of these data are in table 4.5. 
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Qualitative factor p-value, hazard ratio (95% confidence 
interval) 
Vascular invasion 0.149, 4.84 (0.57 – 41.08) 
Lymphatic invasion 0.017, 14.70 (0.61 – 134.05)  
Grade of differentiation 0.004, 22.68 (2.69 – 191.31)  
Proportion of tumour stroma 
≥43.5% 
0.002, 9.30 (2.27 – 38.12) 
 
Area of submucosal invasion ≥ 
35 mm2 
0.001, 42.23 (4.44 – 460.63) 
Table 4.5:  Multivariate analysis of well-established histopathological factors, 
high proportion of tumour stroma and area of submucosal invasion greater 
than 35 mm2.  p-values obtained using binomial logistic regression analysis.  
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4.5 Discussion 
There is increased appreciation of the importance of tumour stroma and its 
relationship with colorectal cancer progression.  The tumour stroma promotes 
the proliferation and survival of cancer cells and facilitates epithelial-
mesenchymal transition (EMT) (Liu et al 2013).  Furthermore, the tumour 
stroma may play a role in local invasion and metastatic dissemination (De 
Weaver and Mareel 2003) and may provide resistance to chemotherapy 
agents (Petty et al 2009) however others differ (Hutchins et al 2015).  Not 
surprisingly, studies have already shown that a higher proportion of tumour 
stroma has been associated with a poorer survival outcome in patients with 
colorectal cancer (Mesker et al 2007, Mesker et al 2009, West et al 2010, 
Huijbers et al 2013, Hutchins et al 2015).  
There are several theories as to why a high PoTS within a tumour may 
increase the risk of LNM.  Tumour stroma contains a rich network of non-
malignant cells that produce key growth factors and cytokines such as VEGF, 
EGF, PDGF, IL-10, and TGF-β.  These appear vital in the development, 
maintenance and progression of the malignancy.  
 Secondly, the tumour stroma may play a role in helping tumour cells evade 
the host immune response directed towards them.  It is accepted that 
lymphocytes play a role in providing anti-tumour immunity (Titu, Monson and 
Greenman 2002). Researchers have shown that increased numbers of 
lymphocytes within the tumour stroma offer better survival in patients with 
CRC (Jass 1986, Ropponen et al 1997, Ogino et al 2009).  Lieubeau et al 
(1999) showed that cancer associated fibroblasts may prevent penetration of 
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immune cells such as lymphocytes within the tumour environment and create 
a physical barrier between the tumour cells and the immune cells.  Therefore, 
tumour growth and progression is not halted by actions of the immune cells 
(Lieubeau et al 1999).   A high density of cancer-associated fibroblasts has 
also been associated with tumour budding (Ueno et al 2004, Tsujino T et al 
2007), which is an adverse prognostic factor. 
Thirdly, a high tumour stroma may be indicative of how aggressive a cancer 
is.  In their cohort study, Mesker et al (2007) showed that there was a greater 
amount of patients with higher tumour stroma percentage in stage III patients 
compared to stage I patients (68.7% vs 7.7%).  Mesker et al (2009) further 
validated this by showing that in a tumour stroma high group, there was a 
greater amount of patients within stage II of the disease compared to stage I 
(94.1% vs 5.9%) (Mesker et al 2009).  Park et al (2014) also showed in their 
study of patients with primary operable CRC, there were a greater amount of 
pT3 and pT4 disease compared to pT1 and pT2 disease within the high 
tumour stroma percentage group (91% vs 9%).  In this study, we focused on 
pT1 CRC and showed that 78.9% of the pT1 CRC in the PoTS high group had 
LNM compared to 21.1% in the PoTS low group (p < 0.001).  This further 
substantiates the hypothesis that a high tumour stroma content within a 
cancer may be reflective of how aggressive it is in invading and spreading 
locally and distantly.  However, this needs to be validated with a study 
comprising of a bigger sample size. 
This study has focused on early CRC and showed that pT1 CRC with LNM 
had significantly higher PoTS compared to pT1 CRC without LNM.  This 
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would suggest that evaluation of the tumour stroma using routine pathological 
specimens might help identify high risk pT1 CRC.  Moreover, evaluating the 
tumour stroma is simple and adds no extra cost to the preparation of the 
pathological specimen.  It is hoped that when tumour stroma is assessed 
together with other well-known high-risk histopathological features, this will 
lead to better risk stratification for patients undergoing local or radical 
treatment for their pT1 CRC. 
 
4.5.1 Tumour stroma as a potential future treatment target 
Tumour cells are genetically unstable. This makes targeted chemotherapy 
towards tumour cells difficult and often gives unpredictable results.  In 
contrast to tumour cells, cells of the tumour stroma are genetically more 
stable thus making these cells an ideal target for chemotherapy agents and 
immune therapy.   
A successful example of therapy targeting the tumour stroma is bevacizumab, 
which is an anti-VEGF antibody (Presta et al 1997).  VEGF is a unique 
product generated by tumour stroma in conditions of hypoxia where VEGF 
promotes tumour angiogenesis.  Bevacizumab was first believed to exert its 
direct antiangiogenic effect on tumour vasculature (Willet et al 2004).  
However, it is now believed that bevacizumab alters tumour physiology 
(reducing tumour interstitial fluid pressure, potentially increasing tumour 
oxygenation and lowering extracellular pH (Wildiers et al 2003, Kramer and 
Lipp 2007, Los, Roodhart and Voest 2007).  These factors help to increase 
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the sensitivity of a tumour towards chemoradiotherapy (Willet et al 2005, 
Pavlidis and Pavlidis 2013). 
Another potential target within the tumour stroma are the CAF and its 
associated protein, fibroblast associated protein (FAP).  Therapeutic 
strategies that target CAF have shown promising results in animal models.  
However, these treatment strategies have not been widely used in the clinical 
setting due to lack of evidence within the human models (Brennen, Issacs and 
Denmeade 20112).  
The over expression of FAP is believed to lead an increase in tumour growth 
and metastasis (Brennen, Issacs and Denmeade 2012).  Loeffler et al  (2006) 
reported a 70% greater uptake of chemotherapeutic agents in carcinoma-
induced mice vaccinated specifically against fibroblast activation protein 
(FAP). In Loeffler’s study, the vaccinated mice showed a 3-fold prolongation 
of lifespan when vaccinated for FAP.  Wikberg et al (2013) have also shown 
high intra-tumoural FAP was associated with a poorer prognosis in CRC 
patients (HR = 1.72, 95% CI 1.07 – 2.77, p – 0.025).  However, more 
research is still needed in human studies. Several phase I and II studies 
targeting FAP with a humanized monoclonal antibody (sibrotiozumab) failed to 
produce clinical benefits in CRC (Scott el at 2003, Hofheinz et al 2013).  
We are slowly beginning to understand the complex relationship between 
tumour cells and their stroma.  There is no doubt that tumour stroma does 
play an integral role in tumour development and metastasis.  Therefore, the 
tumour stroma may prove to be a crucial target for future treatments of CRCs, 
especially higher staged CRCs.  
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4.6 Conclusion 
The understanding of the detailed roles of tumour stroma in the development 
and progression of CRC is important as it may help identify new prognostic 
and predictive factors.  The tumour stroma may also prove to be a target for 
new treatments for CRC and thus providing a more precise and personalized 
therapy. 
This study has shown that the calculation of PoTS by point counting on digital 
microscopy could potentially be a useful quantitative prognostic factor for LNM 
in pT1 CRC.  This low cost and reproducible method of calculating tumour 
stroma could be valuable in identifying high risk pT1 CRC and should be 
easily transferable to routine histological diagnostic practice.  Furthermore it 
could be automated increasing its value and likelihood of adoption. 
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Chapter 5 Inter-observer variations in the reporting of 
pT1 colorectal cancers 
 
With the NHS BCSP being fully rolled out, the pathology service plays a vital 
role in colorectal screening as the programme depends on high quality, 
accurate evaluation of the lesions found within the large bowel. Pathology 
also plays an important role in determining the type of treatment that a patient 
requires, be it a local excision or a radical resection and in determining the 
period of surveillance that a patient requires after screening.  
 
5.1 Reporting of lesions within the NHS BCSP 
Histopathological diagnosis of lesions discovered within the screening 
programme is mostly straightforward. However, there are times when the 
diagnosis of these lesions are difficult and may cause some discrepancy 
between pathologists. To aid in reducing these discrepancies, national 
guidelines have been produced for reporting lesions discovered through 
screening (NHSBCSP 2011, 2016).  The European recommendations 
appeared in 2011 (Quirke et al 2011).  
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5.1.1 Pathological reporting of lesions within the NHS BCSP 
Histopathological reporting of lesions within the screening programme should 
contain key diagnostic data that should help both pathologist and clinicians in 
making treatment decisions. For colorectal adenomas, the key diagnostic 
features that require reporting are as below: 
 
5.1.2 Site of lesion 
The origin of each lesion should be identified by the endoscopist and provided 
to the pathologist on the request form.  
 
5.1.3 Size of lesion 
The size of a lesion is an important objective measurement and is best 
performed during histopathological analysis.  Microscopic measurements of 
lesions are more accurate compared to endoscopic measurements.  Accurate 
measurements of these lesions are clinically important as these 
measurements would help dictate the period of surveillance colonoscopies 
and help decrease the burden on endoscopists (Taylor et al 2016).  Normally, 
the largest diameter of the lesion on the glass slide is taken as the 
measurement of the size and a hierarchy of measurements is recommended. 
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5.1.4 Type of lesion 
Three broad groups of lesion are commonly reported; classical adenomas, 
serrated lesions and other polyps. 
 
5.1.4.1 Classical adenomas 
Classical adenomas must show a degree of dysplasia and can further be sub-
divided into tubular, tubulovillous or villous types. Previously, the definitions of 
these sub-types are based on the ‘20% rule’ as described in the WHO 
classification (Hamilton 2000). For a polyp to be classified as a tubulovillous 
adenoma, at least 20% of the estimated volume of the adenoma should be 
villous.  In a villous adenoma, 80% of the volume must comprise of villous. All 
other lesions are classified as tubular.  However, the current guidelines (NHS 
BCSP 2016) now state that for a polyp to be classified as a tubulovillous 
adenoma, at least 25% of the estimated volume of the adenoma should be 
villous and in a villous adenoma, more than 75% of the volume of the polyp 
must comprise of villi.  
 
5.1.4.2 Serrated lesions 
These lesions have a common serrated pathology. The spectrum of lesions 
with a serrated growth pattern is subdivided into hyperplastic polyps, sessile 
serrated lesions, traditional serrated adenomas and mixed 
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hyperplastic/adenomatous polyps. The serrated lesion spectrum is still being 
researched and remains controversial in terms of their malignant potential. 
Hyperplastic polyps are common and have a very low malignant potential. 
These polyps are frequently found within the distal large bowel and are 
composed of simple elongated crypts with a serrated structure in the upper 
half. Hyperplastic polyps are only significant when they are numerous in 
numbers, proximally located within the large bowel and/or are of a large size (
≥ 10mm), features raising the possibility of serrated (formerly hyperplastic) 
polyposis syndrome.  
Sessile serrated lesions are lesions that show a serrated morphology with 
structural changes that are consistent with mucosal neoplasia.  If dysplasia is 
present then they are classified as sessile serrated lesions with dysplsia. 
Traditional serrated adenomas are histologically distinct from sessile serrated 
lesions. These poylps contain histological features that include eosinophilic 
cytoplasm, pencillate nuclei, ectopic crypts and variable degrees of dysplasia 
(Bateman and Shepherd 2015).  
Mixed hyperplastic/adenomatous polyps are lesions that have both non-
dysplastic hyperplastic type epithelium showing serrated glandular 
architecture and areas of adenomatous dysplastic epithelium (Jass et al 
2006).  In context to the screening programme, these lesions should be 
completely removed and if there is an adenomatous or dysplastic component, 
the lesion should be under surveillance in the same manner as for adenomas. 
A summary of the different type of polyps is provided in table 5.1. 
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Type Criteria 
Classical Adenomas Classification is based on the relative proportions of 
tubular and villous components 
Tubular Adenomas that contain a villous component less than 
25% 
Tubulo-villous Adenomas that contain more than 25% but less than 
75% villous component 
Villous Adenomas with a villous component more than 75% 
 
Serrated Lesions  
Hyperplastic polyps Characterized by serrated glandular profiles caused by 
variable degrees of epithelial hyperplasia, without 
dysplasia.   
Sessile serrated lesions 
(SSL) 
Morphologically similar to the microvesicular variant of 
the hyperplastic polyp, but with one or more key 
histological features that include irregular distribution of 
crypts, dilatation of crypt bases, serration present at 
crypt bases, branched crypts, horizontal extension of 
crypt bases, dysmaturation of crypts and herniation of 
crypts through the muscularis mucosa. 
SSL with dysplasia Similar histological features to SSL but containing 
cytological features of dysplasia (low or high grade).  
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Traditional serrated 
adenoma 
Histologically distinct from SSLs.  Histological features 
include the presence of dysplasia together with variable 
proportion of the lesion showing eosinophilic cytoplasm, 
pencillate nuclei and ectopic crypts (Bateman and 
Shepherd 2015).   
Mixed 
hyperplastic/adenomatous 
polyps 
Contain areas of both dysplastic adenomatous 
epithelium and hyperplastic polyp-type hyperplasia 
Table 5.1: Summary of the classical adenomas and serrated lesions (NHS BCSP 
2016, Bateman and Shepherd 2015). 
 
5.1.4.3 Other types of polyps 
There are other polyps that can be identified within the bowel cancer 
screening programme. These polyps include inflammatory polyps, juvenile 
polyps and Peutz-Jeghers polyps. There are also other different types of 
lesions found in the screening programme such as lipomas and leiomyomas. 
Rarely, unusual forms of stromal lesions, which include ganglioneuroma, 
neurofibroma, gastro-intestinal stromal tumour (GIST), various forms of 
vascular tumour, perineurioma, fibroblastic polyp and epithelioid nerve sheath 
tumour can present as polypoid lesions in the bowel. 
 
 
 
  
127 
5.1.5 Grading of dysplasia 
In reporting the grade of dysplasia, it is recommended that high grade 
dysplasia and low grade dysplasia are used instead of mild, moderate and 
severe dysplasia. By definition, adenomas have at least low grade dysplasia. 
Thus, an adenoma is classed as low grade dysplasia unless it has any 
features of high grade dysplasia.  
Adenomas with high grade dysplasia usually involve more than just one or 
two glands and should exhibit architectural abnormalities and appropriate 
cytological features. Architectural abnormalities include: 
 Complex glandular crowding and irregularity 
 Prominent budding 
 Cribiform appearance and ‘back to back’ glands 
 Prominent intraluminal papillary tufting 
Under low power microscopy, the epithelium appears thick, disorganised and 
‘dirty’. 
Cytological features that accompany the architectural abnormalities include: 
 Atypical mitotic figures 
 Loss of cell polarity or nuclear stratification to the extent nuclei are 
approximately equally 
 Significantly enlarged nuclei often with dispersed chromatin pattern and 
a prominent nucleolus 
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 Prominent apoptosis, giving the epithelium of the lesion a ‘dirty’ 
appearance 
 
5.2 Reporting of pT1 CRC within the NHS BCSP 
Meticulous and accurate assessment of pT1 colorectal cancer is an integral 
part in determining the appropriate treatment.  Reporting of the screened pT1 
colorectal carcinomas include similar key diagnostic features as described 
above, but there are extra features that need to be reported as well.  These 
features are as described below. 
 
5.2.1 Tumour grade 
As described earlier, tumours are graded on how differentiated they appear. 
Based on the NHS BCSP guidelines for reporting lesions, poorly differentiated 
carcinomas can be identified by either: 
 The presence of irregularly folded, distorted and small tubules or 
 The lack of any tubular formation 
When there is lack of the evidence as above, it is recommended that the 
grade of differentiation should be applied to the polyp carcinoma when any 
area of the lesion displays poor differentiation. Testing of such lesions for 
deficient mismatch repair is also now recommended to exclude this as a 
cause of poor differentiation. 
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5.2.2 Lymphovascular invasion 
Identifying lymphatics and vascular structures on microscopy can be 
challenging to pathologists. Blood vessels are usually more easily identified 
as they have a thicker muscular wall and contain red blood cells within their 
lumen. However, lymphatic vessels are thinned-walled, of irregular size (often 
smaller than blood vessels) and frequently have no visible contents at all. This 
makes detecting lymphatic vessels difficult and additional 
immunohistochemistry stains may be required.  These stains include D2-40 
and CD 34 stains. 
Any cases with uncertain lymphovascular invasion should be recorded and 
discussed by the multidisciplinary team. 
 
5.2.3 Margin involvement 
HIstopathological assessment should include the recording of deep 
(intramural) resection margin involvement by the invading carcinoma. It is also 
vital to record the mucosal resection margin that is involved by the carcinoma. 
There have been recent discussions and a change in recommendations 
(NHSBCSP 2016) regarding the degree of clearance that is acceptable. 
Previously a clearance of less than or equal to 1mm would be defined as 
margin involvement and would require further therapy. Recently this has been 
revised to any degree of histological tumour clearance, even less than 1mm, 
can be regarded as non-involvement of the margins unless there are 
infiltration of malignant glands into the diathermy zone associated with 
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morphological distortion to the extent that it is not possible to identify tumour 
clearance (NHSBCSP 2016).  
 
5.2.4 Sub-staging of pT1 CRC 
As already described, pT1 carcinomas can be further sub-staged based on 
their shapes; the Haggitt system for polypoid lesions and the Kikuchi system 
for sessile lesions respectively. However many case are semi-pedunculated 
and do not fall into these categories.  Each of these systems has their 
advantages and disadvantages and will be described in the chapter ahead. 
 
5.3 Inter-observer variations in reporting pT1 CRC 
Inter-observer variation in the reporting of colorectal polyp cancers has been 
studied in various ways and has been largely unsatisfactory. There is no 
formal training or selection process for histopathologists working within the 
NHS BCSP. However, quality assurance is maintained by a combination of 
annual training sessions, inspections and an online External Quality 
Assessment (EQA) scheme.  Currently, there are 150 pathologists within this 
scheme of whom all are consultant histopathologists (details of the GI and 
BCSP pathology EQA schemes available at 
http://www.gieqa.org.uk/overview).   
Most inter-observer variation studies have focussed on colorectal adenomas 
rather than colorectal carcinomas. Most of these inter-observer variation 
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studies have looked at the agreements in diagnosing the polyp histologic type, 
grade of dysplasia and completeness of the excision margin. Below, we will 
discuss these factors that have been studied and also studies that evaluated 
inter-observer variation in colorectal cancers.  
 
5.3.1 Inter-observer variations in polyp histologic type 
The inter-observer agreement in discriminating adenomatous and non-
adenomatous polyps is generally good. As part of a Dutch population-based 
randomized screening trial, van Putten (van Putten et al, 2011) had showed 
that there was a very good kappa value (κ) of 0.88 (95% confidence interval 
[CI] 0.83 – 0.94) between 23 general pathologists who had reviewed a total of 
440 polyps that were detected in the screening programme.  Equally 
impressive is a similar kappa value that was obtained when two expert 
gastrointestinal pathologist were asked to review the same 440 polyps (κ = 
0.85, 95% CI 0.73 – 0.98). 
More recently, Foss (Foss et al, 2012) studied the inter-observer agreement 
between two gastrointestinal pathologists who had reviewed a total of 239 
polyps that were detected within the NHS BCSP.  The discrimination between 
adenomatous and non-adenomatous polyps also showed very high levels of 
inter-observer agreement (κ = 0.83).  
The inter-observer agreement with respect to determining the histologic type 
of adenoma has ranged from fair to moderate. Within the screening 
population, Foss showed that there was moderate agreement in identifying 
  
132 
tubular adenomas (κ = 0.61, 95% CI = 0.51 – 0.71) but only poor and fair on 
the classification of villous sub types (tubulo-villous adenoma - κ =0.38. 95% 
CI 0.26 – 0.49, villous adenoma - κ =0.18, 95% CI 0.02 – 0.34). Other studies 
within a screening population (Denis et al 2009, van Putten et al 2011) have 
shown a moderate amount of inter-observer agreement (κ = 0.44 - 0.55) when 
distinguishing the histologic type of adenoma when there were 3 categories 
(tubular adenoma, tubulo-villous adenoma and villous adenoma).  
Turner (Turner et al 2013) had expanded the histologic types into 5 categories 
(hyperplastic polyp, serrated adenoma, tubular adenoma, tubullo-villous 
adenoma and villous adenoma). This study showed that there was still a 
moderate level of agreement (κ = 0.45, 95% CI 0.34-0.59) between BCSP 
pathologists in Wales.  
 
5.3.2 Inter-observer variation in grading of dysplasia 
Grading of dysplasia has produced satisfactory Kappa values. Studies have 
often categorised grading of dysplasia into two categories (low grade/ high 
grade) or three categories (no dysplasia/ low grade/ high grade or low grade/ 
high grade/ infiltrating carcinoma).  Kappa values for studies with two 
categories ranged from 0.59 to 0.69 (van Putten et al 2011, Foss et al 2012) 
and studies with three categories had kappa values of 0.54 to 0.67 (Costantini 
et al 2003, Denis et al 2003, Turner et al 2013).  
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5.3.3 Inter-observer variation in assessing excision margin status 
There has been great variability in the reporting of the completeness of a 
polyp excision margin. Turner (Turner et al 2013) had looked at the 
histological reporting of 28 pathologists based in Wales. The 28 pathologist 
had to report on 12 screened cases based on the BCSP recommended 
guidelines.  The kappa value for the histological reporting of the degree of 
excision (complete/incomplete/ uncertain) was only fair (κ= 0.24, 95% CI 0.07 
– 0.43). 
In contrast, an earlier study by Foss and colleagues (Foss et al 2012) showed 
that there was a higher level of concordance in determining the degree of 
excision (κ= 0.75, 95% CI 0.64 – 0.84) in screened polyps. However, Foss’s 
study only had two pathologists participating. Another study by Komuta 
(Komuta et al 2004) also showed that there was good agreement in assessing 
excision margin status within malignant colorectal polyps κ= 0.668.  
 
5.3.4 Inter-observer variation in the grading of CRC 
Chandler and Houlston (Chandler and Houlston 2008) had carried out a 
nationwide study looking at the inter-observer agreement in grading of 
colorectal cancers. This study had enlisted the participation of 104 consultant 
histopathologists. They were instructed to grade 20 carcinomas within three 
grades (well differentiated, moderately differentiated and poorly 
differentiated). The overall κ value for the grading results using the three 
grades was 0.351 indicating fair agreement. The study had also evaluated the 
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inter-observer agreement when the grading was reduced into two categories 
(low and high grade). The inter-observer agreement was still fair, κ value = 
0.358.  
Komuta et al evaluated the inter-observer variability in the histopathological 
assessment of malignant colorectal polyps. Three experienced 
gastrointestinal pathologists had reviewed 88 polyps. The inter-observer 
agreement was poor with respect to histopathological grading of these polyps 
(κ = 0.163) (Komuta et al 2004).  
The results from the studies above have shown that using both two and three 
grade system pathologists had only achieved fair levels of agreement. This 
implies that grading of cancers can be subjective and better definitions and 
criteria should be developed. 
 
5.3.5 Inter-observer variation in assessing lymphovascular invasion in 
CRC 
As mentioned already, assessment of lymphovascular invasion is often 
difficult and there is a high level of inter-observer variability. Komuta had 
looked into the inter-observer variability in assessing lymphovascular invasion 
in malignant colorectal polyps. The polyps were assessed on normal H & E 
slides and the inter-observer agreement was poor (κ = -0.017) (Komuta et al 
2004).  
The use of immunohistochemical stains was expected to lower inter-observer 
variability.  Harris et al evaluated the use of immunohistochemical stains in 
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identifying lymphovascular invasion. Six gastrointestinal pathologists 
assessed small and large vessel invasion based on 50 cases of colorectal 
cancers that were stained with H & E, CD31 and D2-40 stains. Inter-observer 
agreement was only fair for H & E small vessel invasion (κ = 0.28, 95% CI 
0.22 – 0.34) and poor for H & E large vessel invasion (κ = 0.18, 95% CI 0.11 – 
0.26). When the immunohistochemical stains were applied to the same 
cancers that were being assessed, agreement was not improved (CD31 
stains; large vessels κ value = 0.42 95% CI 0.2 – 0.63, small vessels κ value 
= 0.26, 95% CI 0.1 – 0.42; D2-40 stains, κ value = 0.32, 95% CI 0.21 – 0.42) 
(Harris et al 2008). 
Similar results were obtained in a study conducted by the Pathology Working 
Group of the Japanese Society for Cancer of the Colon and Rectum (Kojima 
et al 2013). This study had involved eight pathologists assessing 20 tumours 
for lymphatic and vascular invasion on H & E slides and on slides with 
immunohistochemical stains (D2-40 and elastic stains). Inter-observer 
agreement was only moderate in identifying vascular invasion (κ=0.574, 95% 
CI 0.441 – 0.606) and poor in lymphatic invasion (κ = 0.216, 95% CI 0.133 – 
0.209). This was no better when the cancers were prepared with 
immunohistochemical stains (κ value for vascular invasion = 0.502, 95% CI 
0.419 – 0.584, κ value for lymphatic invasion = 0.153, 95% CI 0.071 – 0.236). 
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5.4 Research objectives 
The main aim of this study is to investigate the reproducibility of qualitative 
and quantitative factors that may contribute to LNM in pT1 CRC and thus the 
decision as to whether a major resection is required.  
The secondary aim of this study is to assess the reproducibility of the novel 
quantitative factors that were studied (width of invasion and area of 
submucosal invasion).  
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5.5 Materials and methods 
5.5.1 Inter- and intra-observer variation studies 
H & E slides from the NHS BCSP were selected for the inter-observer and 
intra-observer study. NHS regional leads confirmed all the cases as stage pT1 
CRC. The screened pT1 cases were scanned in an identical fashion as 
described in section 4.3. In selecting the cases for the inter-observer study, a 
single digital image of the cancer was selected based on its best 
representation of the cancer as a whole. Digital images of these screened pT1 
cancers were uploaded to a web page. The web page is available for viewing 
at the address listed within the appendices. 
Regional lead pathologists who regularly reported within the bowel cancer 
screening programme were invited to participate in this study. An invitation 
was emailed to all pathologists together with instructions for the tasks to be 
performed and a proforma to complete (see appendix I). The proforma was a 
Microsoft Excel form that consisted of the selected cases (and the respective 
URL web page links) and tasks that the pathologists had to perform. The 
participating pathologist could access the cases through the web page.   
The participating pathologists were requested to perform the 10 key tasks 
listed as below:  
1. To define the shape of the lesion (pedunculated, semi-pedunculated, 
sessile or not assessable) 
2. To define the grade of differentiation (non-poor/poor) 
3. To identify the distance of the lesion to the nearest margin 
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4. To identify the presence of lymphatic invasion 
5. To identify the presence of vascular invasion 
6. To state whether the lesion can be assessed by Haggitt’s levels and 
identify the level of invasion (Level 1/ 2/ 3/ 4) 
7. To state whether the lesion can be assessed by Kikuchi’s levels and 
identify the level of invasion (SM1/ SM2/ SM3) 
8. To measure the width of the carcinoma 
9. To measure the depth of invasion of the carcinoma 
10. To state whether the lesion/ carcinoma is fully excised and/or should 
be resected 
The pathologist had to analyse 41 pT1 cases and were given a six week time 
limit to complete the analysis of the cases.  
For the intra-observer study, the pathologists were requested to repeat the 
study on the same cases 3 months after the first round. After the first round of 
the inter-observer study, new recommendations were formulated for the 
method of measuring the distance from the carcinoma to the nearest margin 
and the depth of invasion of the carcinoma. 
In this second round, the same cases as above were given to the pathologist 
but not in the same order as the first round. However, in the second round, 
the pathologists were asked to perform 11 instead of 10 tasks (see appendix 
II).  The 11 tasks are as below: 
1. To define the shape of the lesion (non-sessile/ sessile) 
2. To measure the width of the lesion and carcinoma 
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3. To identify the distance of the lesion to the nearest margin based on 
the recommendations from the first round of the inter-observer study 
4. To measure the depth of invasion of the carcinoma based on 4 
methods (epithelial surface to deepest tumour cell, virtual muscularis 
mucosae curved line method to deepest tumour cell [Figure5.1], virtual 
muscularis mucosae straight line method to deepest tumour cell 
[Figure 5.2] and from the muscularis mucosae that is visible)  
5. To measure the area of invasion by the carcinoma below the 
muscularis mucosae (submucosal invasion) 
6. To define the grade of differentiation (non-poor/ poor) 
7. To identify the presence of lymphatic invasion 
8. To identify the presence of vascular invasion 
9. To state the Haggitt’s level (level 1/ 2 /3/ 4) 
10. To state the Kikuchi’s level (SM1/ SM2/ SM3) 
11. To state whether the carcinoma should be resected based on the 
qualitative and quantitative features identified 
The pathologists were again given 6 weeks to complete the analysis of the 
cases.   
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Figure 5.1: Virtual muscularis mucosae curved line method. A virtual 
muscularis mucosae is created by estimating where the muscularis mucosae 
would have lain if not destroyed by tumour or eroded and the depth of 
invasion is measured from this virtual muscularis mucosae. 
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Figure 5.2: Virtual muscularis mucosae straight line method. A straight line is 
drawn from the highest point in the lesion where residual normal epithelium is 
seen containing normal muscularis mucosae to the same site on the opposite 
side. The depth of invasion is measured perpendicular to this straight line up 
to the deepest part of the invading cancer.  
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5.5.2 Statistical analysis 
The Kappa (κ) statistic was used to assess agreement between pathologists 
(inter-observer) for qualitative data. Specifically, the Fleiss’ κ was used as this 
method allowed for multiple assessors and categorical ratings. The Cohen’s κ 
was used to calculate the intra-observer agreement.  Both the Fleiss’ and 
Cohen’s κ were recommended by a senior biostatician (H Thygesen – 
personal communication, 2013).  A value of 0 indicates agreement no better 
than what would be expected by chance alone. Values of <0.20, 0.21 – 0.40, 
0.41 – 0.60, 0.61 – 0.80 and > 0.80 correspond to poor, fair, moderate, 
substantial and almost perfect agreement.  
For quantitative data, the inter-observer agreement was obtained using the 
intra-class correlation coefficient (ICC). The ICC is a popular method to 
assess agreement between quantitative measurements taken from different 
observers. The ICC was calculated using the Statistical Package for the 
Social Sciences (SPSS v21.0, Chicago, IL, USA).  Similar to the κ value, the 
ICC value can take on any value from 0 to 1 (values of <0.20, 0.21 – 0.40, 
0.41 – 0.60, 0.61 – 0.80 and > 0.80 correspond to poor, fair, moderate, 
substantial and almost perfect agreement). 
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5.6 Results 
A total of 19 histopathologists were invited to participate in the inter- and intra-
observer studies, however, only 10 histopathologists participated in the study. 
They were all lead regional histopathologists who regularly participated in the 
reporting of colonic polyps and cancers from the NHS BCSP.  
 
5.6.1 Inter-observer variation round 1 results 
5.6.1.1 Qualitative factors 
5.6.1.1.1 Shape of lesion 
The inter-observer agreement in deciding the shape of the lesion generated a 
κ value of 0.33 (95% CI 0.30 – 0.36, p < 0.001). Figure 5.3 demonstrates the 
breakdown of the shape of the lesion that the pathologist had decided on 
each case. 
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Figure 5.3: Overall results for each case in deciding the shape of the lesion 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 1 0 1 2 0 0 1 0 0 0 1 0 1 0 0 1
sessile 3 0 1 2 3 3 4 0 0 2 0 8 0 0 2 0 0 0 3 4 0 9 0 2 10 0 0 0 1 0 10 0 3 1 0 0 0 0 9 6 0
Semi-pedunculated 6 2 6 5 6 5 6 6 0 1 2 1 0 0 7 1 0 3 5 4 3 1 2 4 0 2 1 4 3 3 0 2 5 5 4 1 0 0 0 4 7
Pedunculated 1 8 3 3 1 2 0 4 10 7 8 1 10 10 1 9 9 6 2 2 7 0 7 3 0 7 9 5 4 7 0 7 2 4 6 8 10 9 1 0 2
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5.6.1.1.2 Grade of differentiation 
The overall κ score for the reporting of the grade of differentiation (where the 
three possible categories were non-poorly, poorly differentiated and not 
assessable) was 0.13 (95% CI 0.09 – 0.18, p < 0.001). Figure 5.4 
demonstrates the breakdown of the grade of differentiation for each case. 
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Figure 5.4: Overall results for each case in deciding the grade of differentiation. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
N/A 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 1 0 0 0 0 2 0 0 1 0 0 2 0 0 0 0 0 0 2 0 0 0 1 0
Poor 1 0 0 2 1 5 0 0 0 0 0 4 1 4 0 0 3 0 3 0 1 3 0 0 0 4 2 0 0 4 2 1 0 4 7 0 2 3 1 1 1
Non-Poor 9 10 10 8 9 5 10 10 9 10 10 6 9 6 10 10 6 9 7 10 9 7 8 10 10 5 8 10 8 6 8 9 10 6 3 8 8 7 9 8 9
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5.6.1.1.3 Lymphatic invasion 
The overall κ score for reporting the presence of lymphatic invasion was 0.08 
(95% CI 0.03 – 0.12, p<0.001). Figure 5.5 displays the breakdown of each 
case. 
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Figure 5.5: Overall results for each case in deciding the presence of lymphatic invasion
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 1 0 0 1 0 0 2 0 0 0 0 0 0 2 1 0 0 2 0
No 7 8 8 9 9 6 10 10 10 10 9 6 10 7 10 9 9 8 7 4 10 7 9 10 8 8 8 9 8 10 9 10 10 9 9 8 9 9 6 7 10
Yes 3 1 2 1 1 4 0 0 0 0 1 4 0 3 0 1 0 1 3 6 0 3 0 0 2 1 2 1 0 0 1 0 0 1 1 0 0 1 4 1 0
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5.6.1.1.4 Vascular invasion 
The overall κ score for reporting the presence of vascular invasion was 0.08 
(95% CI 0.03 – 0.19, p<0.001). Figure 5.6 displays the breakdown of each 
case. 
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Figure 5.6: Overall results for each case in deciding the presence of vascular invasion. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
NA 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 1 0 0 1 0 0 2 0 0 0 0 0 0 2 0 0 0 1 0
No 7 7 6 9 10 10 10 10 9 10 10 9 7 10 10 10 9 9 9 8 10 8 8 7 10 9 7 8 5 10 10 7 10 10 8 8 10 10 8 9 10
Yes 3 3 4 1 0 0 0 0 1 0 0 1 3 0 0 0 0 0 1 2 0 2 1 3 0 0 3 2 3 0 0 3 0 0 2 0 0 0 2 0 0
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5.6.1.1.5 Haggitt level 
The overall κ score for the reporting of Haggitt level (where the five possible 
categories were Haggit level 1 to 4 and not assessable) was 0.17 (95% CI 
0.15 – 0.19, p < 0.001). Figure 5.7 demonstrates the breakdown of the Haggitt 
level for each case.
  
152 
 
Figure 5.7: Overall results for each case in deciding the Haggitt level of invasion.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
NA 2 1 0 1 1 3 3 1 1 1 0 4 0 0 2 1 1 2 3 4 0 6 1 2 7 2 0 1 2 1 7 0 3 1 1 2 0 0 7 7 1
Haggitt 4 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 5 1 2 0 0 2 0 0 0 0 0 2 0 1 1 0 0 0 0 2 1 0
Haggitt 3 5 2 7 6 3 6 7 2 1 2 3 5 1 4 4 1 6 1 0 1 2 1 6 7 0 1 2 5 7 1 1 6 0 7 6 0 2 2 0 2 6
Haggitt 2 2 7 3 2 5 1 0 5 6 2 6 0 4 5 3 0 3 3 2 0 6 0 2 1 1 3 5 2 1 6 0 2 5 1 3 2 3 6 1 0 2
Haggitt 1 0 0 0 1 1 0 0 2 2 5 1 1 5 1 0 8 0 4 4 0 1 1 1 0 0 4 3 2 0 2 0 2 1 0 0 6 5 2 0 0 1
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5.6.1.1.6 Kikuchi Level 
The overall κ score for the reporting of Kikuchi level (where the four possible 
categories were Kikuchi level 1 to 3 and not assessable) was 0.05 (95% CI 
0.03 – 0.08, p < 0.001). Figure 5.8 demonstrates the breakdown of the 
Kikuchi level for each case. 
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Figure 5.8: Overall results for each case in deciding the Kikuchi level of invasion. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
NA 5 6 6 6 5 5 4 6 6 5 6 2 6 6 4 6 6 5 4 3 5 1 6 4 0 7 6 6 6 6 0 5 3 6 6 7 6 6 3 3 5
SM3 3 0 0 0 0 0 1 0 0 0 0 3 0 0 0 0 0 0 0 6 0 0 0 0 1 0 0 0 0 1 6 0 0 1 0 0 0 0 0 2 0
SM2 1 2 2 2 2 3 3 2 1 0 1 3 1 0 2 0 1 1 0 1 2 8 1 4 8 0 1 1 2 1 4 1 3 1 2 0 2 0 3 4 1
SM1 1 2 2 2 3 2 2 2 3 5 3 2 3 4 4 4 3 4 6 0 3 1 3 2 1 3 3 3 2 2 0 4 4 2 2 3 2 4 4 1 4
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5.6.1.1.7 Is the lesion fully excised? 
The overall κ score that was generated by the question posed (is the lesion 
fully excised?) was 0.49 (95% CI 0.44 – 0.53, p < 0.001). Figure 5.9 
demonstrates the breakdown of each case in relation to the question posed. 
  
156 
 
Figure 5.9: Overall results for each case in deciding whether the lesion is fully excised.  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
N/A 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 1 0 1 1 0 2 1 0 0 2 0 2 0 0 0 0 2 0 1 0 0 0
No 1 0 10 10 3 4 9 0 0 1 0 4 0 0 3 0 0 2 0 0 0 1 1 3 0 0 0 1 7 0 1 0 1 7 10 0 0 0 2 10 3
Yes 9 10 0 0 7 6 1 10 10 9 10 5 10 10 7 10 9 7 10 9 10 8 8 7 8 9 10 9 1 10 7 10 9 3 0 8 10 9 8 0 7
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5.6.1.1.8 Should the lesion have a radical resection? 
The overall κ score that was generated by the question posed (should the 
lesion have a radical resection?) was 0.18 (0.14 – 0.22, p < 0.001). Figure 
5.10 demonstrates the breakdown of each case in relation to the question 
posed. 
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Figure 5.10: Overall results for each case in deciding whether the lesion should receive a radical resection. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
NA 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 1 1 1 3 0 3 1 0 4 1 0 1 2 0 5 0 0 0 0 3 0 1 0 1 0
No 3 9 1 6 4 4 2 9 9 9 7 2 8 6 5 9 6 5 6 2 8 3 6 3 3 6 7 6 2 6 0 6 7 3 1 6 8 6 4 0 4
Yes 7 1 9 4 6 6 8 1 1 1 2 8 1 3 5 1 3 4 3 5 2 4 3 7 3 3 3 3 6 4 5 4 3 7 9 1 2 3 6 9 6
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5.6.1.2 Quantitative factors 
The quantitative factors that were studied in round 1 of the inter-observer 
study were the width of lesion, distance of the lesion to the nearest margin 
and the depth of invasion that gave ICC values of 0.73, 0.58 and 0.67 
respectively.  Figures 5.11, 5.12 and 5.13 display the distribution of values for 
each case assessed by the pathologist.
  
160 
 
Figure 5.11: Scatter plot showing the overall results for the measurements of the width of the lesion by each pathologist.   
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Figure 5.12: Scatter plot showing the overall results for the measurements of the distance of carcinoma to margin by each 
pathologist. 
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Figure 5.13: Scatter plot showing the overall results for the measurements of the depth of invasion by each pathologist. 
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Table 5.2 shows a summary of the agreement between the pathologist in 
assessing the qualitative and quantitative factors of the 41 pT1 CRCs for 
round 1 
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Qualitative / Quantitative 
Factors 
Kappa (κ) value / Intra-class Correlation 
Coefficient (ICC) value (95% 
confidence interval, p value) 
Interpretation of 
Kappa/Intra-class 
correlation value 
Shape of lesion κ = 0.33 (0.30 – 0.36, p < 0.01) Fair agreement 
Grade of 
differentiation 
κ = 0.13 (0.09 – 0.18, p < 0.001) Slight agreement 
Lymphatic invasion κ = 0.08 (0.03 – 0.12, p < 0.001) Slight agreement 
Vascular invasion κ = 0.08 (0.03 – 0.12, p < 0.001) Slight agreement 
Haggitt level κ = 0.17 (0.15 – 0.19, p< 0.001) Fair agreement 
Kikuchi level κ = 0.05 (0.03 – 0.08, p < 0.001) Slight agreement 
Is the lesion fully 
excised? 
κ = 0.49 (0.44 – 0.53, P < 0.001) Moderate agreement 
Should the lesion be 
fully resected? 
κ = 0.18 (0.14 – 0.22, p < 0.001) Slight agreement  
Width of lesion ICC = 0.73 (0.63 – 0.82, p < 0.001) Substantial agreement 
Distance to margin ICC = 0.58 (0.45 – 0.69, p < 0.001) Moderate agreement 
Depth of invasion ICC = 0.67 (0.55 – 0.78, p < 0.001) Substantial agreement 
Table 5.2: Summary of the qualitative and quantitative factors that were 
analysed in round 1 of the inter-observer study.  
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5.6.2 Inter-observer variation results round 2 
5.6.2.1 Qualitative factors 
5.6.2.1.1 Shape of lesion 
The overall κ score for the reporting of the shape of the lesion in round 2 
(where there were three possible categories [sessile, non-sessile and not 
assessable] compared to four possible categories [sessile, semi-
pedunculated, pedunculated and not assessable] in round 1) was 0.21 (95% 
CI 0.17 – 0.25, p < 0.001). Figure 5.14 demonstrates the breakdown of the 
shape of the lesion for each case in round 2. 
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Figure 5.14:  Overall results for each case in deciding the shape of the lesion in round 2. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
N/A 0 2 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 1 1 0 0 0 1 0 1 1 0 0 0 0 0 0 0 0 0 1 1
Sessile 1 1 0 1 3 2 0 2 2 0 2 0 0 4 2 2 8 1 4 0 2 6 3 0 1 1 4 2 0 2 0 2 1 9 3 0 4 5 7 2 4
Non-sessile 9 7 10 9 7 8 10 8 7 10 8 10 10 5 8 8 2 9 6 10 8 3 6 10 9 9 5 8 9 7 10 8 9 1 7 10 6 5 3 7 5
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Shape of lesion 
  
167 
5.6.2.1.2 Grade of differentiation 
In round 2, the pathologist had to grade the pT1 CRC into 3 categories (non-
poor, poor and not assessable). The overall κ score for the reporting of the 
grade of differentiation was 0.19 (95% CI 0.15 – 0.24, p < 0.001). Figure 5.15 
demonstrates the breakdown of the grade of differentiation for each case. 
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Figure 5.15: Overall results for each case in deciding whether the grade of differentiation of the pT1 CRC in round 2. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
N/A 0 2 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Poor 0 0 1 0 6 0 1 6 0 1 1 6 4 1 2 8 0 7 1 1 0 4 1 0 0 0 1 5 4 1 4 0 3 1 3 4 0 6 5 2 5
Non-poor 10 8 9 10 4 10 9 4 9 9 9 4 6 8 8 2 10 3 9 9 10 6 9 10 10 10 9 5 6 9 6 10 7 9 7 6 10 4 5 8 5
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5.6.2.1.3 Lymphatic invasion 
The overall κ score for reporting the presence of lymphatic invasion in round 2 
was 0.12 (95% CI 0.08 – 0.17, p<0.001). Figure 5.16 displays the breakdown 
of each case. 
  
170 
 
Figure 5.16: Overall results for each case in deciding the presence of lymphatic invasion in round 2. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
N/A 0 2 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Yes 3 0 0 0 1 1 0 0 0 0 0 0 0 0 2 0 0 1 0 1 0 0 1 1 0 2 6 5 3 2 2 0 0 0 2 1 0 1 0 0 3
No 7 8 10 10 9 9 10 10 9 10 10 10 10 9 8 10 10 9 10 9 10 10 9 9 10 8 4 5 7 8 8 10 10 10 8 9 10 9 10 10 7
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5.6.2.1.4 Vascular invasion 
The overall κ score for reporting the presence of vascular invasion in round 2 
was 0.19 (95% CI 0.14 – 0.22, p<0.001). Figure 5.17 displays the breakdown 
of each case. 
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Figure 5.17: Overall results for each case in deciding the presence of vascular invasion in round 2. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
N/A 0 2 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Yes 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 0 2 0 2 0 0 2 0 0 4 6 1 0 4 0 0 2 0 1 0 0 0 0 0 1
No 10 8 9 10 10 9 10 9 9 10 10 10 10 9 10 10 10 8 10 7 10 10 8 10 10 6 4 9 10 6 10 10 8 10 9 10 9 10 10 10 9
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5.6.2.1.5 Haggitt level 
The overall κ score for the reporting of Haggitt level in round 2 (where the five 
categories were similar in round 1) was 0.15 (95% CI 0.13 – 0.17, p < 0.001). 
Figure 5.18 demonstrates the breakdown of the Haggitt level for each case. 
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Figure 5.18: Overall results for each case in deciding the Haggitt level of invasion in round 2. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
N/A 1 2 0 0 1 1 0 2 3 0 2 0 0 3 1 2 5 1 2 0 1 3 1 0 1 1 2 1 1 2 1 1 1 5 1 0 2 1 3 1 2
Haggit 4 0 0 0 0 1 0 0 0 2 0 0 1 0 0 0 0 3 0 1 0 1 5 2 0 0 0 1 0 0 1 1 4 0 0 0 1 3 5 2 1 1
Haggit 3 1 2 5 8 4 6 0 8 3 3 4 8 1 3 2 3 2 8 5 3 1 2 5 6 5 2 5 5 1 5 2 1 6 3 7 8 3 2 4 5 6
Haggit 2 8 4 2 2 4 3 1 0 1 5 3 1 5 3 6 5 0 1 2 6 6 0 2 4 3 7 2 3 6 2 4 4 3 2 1 1 1 2 1 3 1
Haggit 1 0 2 3 0 0 0 9 0 1 2 1 0 4 1 1 0 0 0 0 1 1 0 0 0 1 0 0 0 2 0 2 0 0 0 1 0 1 0 0 0 0
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5.6.2.1.6 Kikuchi level 
The overall κ score for the reporting of Kikuchi level in round 2 (where the four 
categories were similar in round 1) was 0.07 (95% CI 0.04 – 0.10, p < 0.001). 
Figure 5.19 demonstrates the breakdown of the Kikuchi level for each case. 
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Figure 5.19: Overall results for each case in deciding the Kikuchi level of invasion in round 2. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
N/A 5 6 6 6 5 6 6 4 5 6 5 6 6 5 6 5 2 6 4 6 5 2 6 6 5 6 5 5 6 6 6 5 5 1 6 6 3 3 2 5 4
SM3 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 8 0 0 0 1 8 1 0 0 0 0 0 0 0 0 4 0 0 0 0 4 4 0 2 1
SM2 2 2 0 1 3 2 0 4 3 1 3 2 0 2 1 3 0 2 3 1 1 0 2 2 2 1 4 4 1 3 1 2 3 8 2 3 2 3 5 2 4
SM1 3 2 4 3 2 2 4 1 2 3 1 2 4 3 3 2 0 2 3 3 3 0 1 2 3 3 1 1 3 1 3 0 2 1 2 1 1 0 3 1 1
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5.6.2.1.7 Should the lesion have a radical resection? 
In round 2, the overall κ score that was generated by the question posed 
(should the lesion have a radical resection?) was 0.32 (95% CI 0.28 – 0.36, p 
< 0.001). Figure 5.20 demonstrates the breakdown of each case in relation to 
the question posed. 
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Figure 5.20: Overall results in round 2 for each case in deciding whether the lesion should receive a radical resection. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41
N/A 0 2 0 0 0 0 0 0 1 0 0 0 0 1 0 0 3 1 2 1 1 2 0 0 0 0 0 0 0 0 0 0 2 2 0 0 3 2 2 0 1
No 9 8 6 0 0 4 10 2 1 9 5 2 10 2 8 0 3 0 6 5 7 3 0 8 4 5 1 2 8 1 7 1 5 4 5 7 4 1 2 2 3
Yes 1 0 4 10 10 6 0 8 8 1 5 8 0 7 2 10 4 9 2 4 2 5 10 2 6 5 9 8 2 9 3 9 3 4 5 3 3 7 6 8 6
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5.6.2.2 Quantitative factors 
5.6.2.2.1 Width of lesion/ carcinoma 
The ICC score for width of lesion in round 2 was 0.95 (95% CI 0.92 – 0.96, p 
< 0.001) and the ICC score for width of carcinoma was 0.01 (95% CI -0.03 – 
0.08, p< 0.001). Figures 5.21 and 5.22 demonstrate the measurements of the 
individual cases by the pathologists. 
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Figure 5.21: Overall results for the measurements of the width of the lesion in round 2. 
0
5
10
15
20
25
30
35
0 5 10 15 20 25 30 35 40
W
id
th
 o
f 
Le
si
o
n
 
Cases 
Observer 1
Observer 2
Observer 3
Observer 4
Observer 5
Observer 6
Observer 7
Observer 8
Observer 9
Observer 10
  
181 
 
 
Figure 5.22: Overall results for the measurements of the width of the carcinoma in round 2. 
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5.6.2.2.2 Distance to margin 
In round 2, we had asked the pathologist to measure the distance of the 
invasive front of the cancer to the nearest margin twice. First, using their own 
method and secondly, measuring the distance to the margin based on 
recommendations generated from the first round of the inter-observer study. 
The ICC score for the distance to margin using the pathologist’s own method 
was 0.79 (95% CI 0.69 – 0.88, P < 0.001) and the ICC score for the distance 
to margin based on the recommendations was 0.88 (95% CI 0.81 – 0.93, P < 
0.001).  Figures 5.23 and 5.24 demonstrate the measurements of the 
individual cases by the pathologists.
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Figure 5.23:  Overall results for the measurements of the distance to margin based on the pathologist own method in round 2. 
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Figure 5.24:  Overall results for the measurements of the distance to margin based on round 1 recommendation. 
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5.6.2.2.3 Depth of invasion 
In round 2 of this study, we had asked the pathologist to measure depth of 
invasion based on 4 methods: epithelial surface to deepest tumour cell, virtual 
muscularis mucosae curved line method to deepest tumour cell, virtual 
muscularis mucosae straight line method to deepest tumour cell and from the 
muscularis mucosae that is visible to the deepest tumour cell. 
The ICC scores for depth of invasion from the epithelial surface, virtual 
muscularis mucosae curved line method and virtual muscularis mucosae 
straight line method was 0.86 (95% CI 0.79 – 0.91, p < 0.001), 0.78 (95% CI 
0.67 – 0.87, p < 0.001) and 0.40 (95% CI 0.25 – 0.62, p < 0.01) respectively. 
Figures 5.25, 5.26 and 5.27 represents the measurements of the different 
methods of depth of invasion for each case.  
The ICC score for depth of invasion from the muscularis mucosae that is 
visible to the deepest tumour cell was 0.29 (95% CI 0.04 – 0.95, p < 0.001). 
However, it should be noted in the majority of cases, the pathologists were 
unable to identify the muscularis mucosae. Figures 5.28 demonstrate the 
measurements of the depth of invasion from the muscularis mucosae. 
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Figure 5.25: Overall results for the measurements of the depth of invasion from the epithelial surface in round 2. 
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Figure 5.26: Overall results for the measurements of the depth of invasion from curved virtual muscularis mucosae in round 2. 
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Figure 5.27: Overall results for the measurements of the depth of invasion from virtual straight line in round 2. 
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Figure 5.28: Overall results for the measurements of the depth of invasion if the muscularis mucosae was present.  
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5.6.2.2.4 Area of submucosal invasion 
In round 2, we had asked the pathologist to measure the area of submucosal 
invasion.  The ICC for the area of submucosal invasion was 0.59 (95% CI 0.47 – 
0.72, p < 0.001).  Figure 5.29 demonstrates the measurements of the individual 
cases by the pathologists. 
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Figure 5.29:  Overall results for the area of submucosal invasion in round 2. 
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Table 5.3 summarizes the results from both round 1 and 2.  
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Qualitative/ Quantitative factors Round 1  Round 2 
Shape of lesion [κ (95% CI)] 0.33 (0.30 – 0.36) 0.21 (0.17 – 0.25) 
Grade of differentiation [κ (95% CI)] 0.13 (0.09 – 0.18) 0.19 (0.15 – 0.24) 
Lymphatic invasion [κ (95% CI)] 0.08 (0.03 – 0.12) 0.12 (0.08 – 0.17) 
Vascular invasion [κ (95% CI)] 0.08 (0.03 – 0.19) 0.19 (0.14 – 0.22) 
Haggitt Level [κ (95% CI)] 0.17 (0.15 – 0.19) 0.15 (0.13  - 0.17) 
Kikuchi Level [κ (95% CI)] 0.05 (0.03 – 0.08) 0.07 (0.04 – 0.10) 
Lesion fully excised? [κ (95% CI)] 0.49 (0.44 – 0.53)  
For full resection? [κ (95% CI)] 0.18 (0.14 – 0.22) 0.32 (0.28 – 0.36) 
Width of lesion [ICC (95% CI)] 0.73 (0.63 – 0.82) 0.95 (0.92 – 0.96) 
Width of carcinoma [ICC (95% CI)]  0.01 (-0.03 – 0.08) 
Distance to margin [ICC 
(95% CI)] 
Own method 0.58 (0.45 – 0.69) 0.79 (0.69 – 0.88) 
Based on 
recommendations 
 0.88 (0.81 – 0.93) 
Depth of invasion [ICC 
(95% CI)] 
Epithelia surface 0.67 (0.55 – 0.78) 0.86 (0.79 – 0.91) 
Virtual muscularis 
mucosae - Curve 
 0.78 (0.67 – 0.87) 
Virtual muscularis 
mucosae - Straight 
 0.40 (0.25 – 0.62) 
Visible muscularis 
mucosae 
 0.29 (0.04 – 0.95) 
Area of submucosal invasion (95% CI)  0.59 (0.47 – 0.72) 
Table 5.3: Summary of the results from both round 1 and 2 of the interobserver 
variation studies.  
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5.6.3 Further analysis of round 1 and 2 without non-assessable cases 
A further analysis had been carried out with the non-assessable cases omitted.  This 
was done to see whether there was an improvement in the kappa scores of the 
qualitative analysis of the lesions when the difficult lesions were omitted.  Tables 5.4 
and 5.5 show the comparisons between the cases in round 1 and 2 and the non-
assessable cases that were omitted.   
 
5.6.3.1 Round 1 result 
Shape of lesion 
In assessing the shape of the lesion, 30 out of the original 41 cases were included 
(11 non-assessable cases omitted).  The inter-observer agreement in deciding the 
shape of the lesion generated a κ value of 0.39 (95% CI 0.30 – 0.46, p < 0.001).  
Figure 5.30 demonstrates the breakdown of the shape of the lesion that the 
pathologist had decided on each case.  
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Figure 5.30: Overall results for each case in deciding the shape of the lesion in round 1 excluding the non-assessable cases.  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Sessile 3 0 1 2 3 3 4 0 0 2 0 8 0 0 2 0 3 4 0 9 10 0 0 10 3 1 0 0 9 6
Semi-pedunculated 6 2 6 5 6 5 6 6 0 1 2 1 0 0 7 1 5 4 3 1 0 1 3 0 5 5 4 0 0 4
Pedunculated 1 8 3 3 1 2 0 4 10 7 8 1 10 10 1 9 2 2 7 0 0 9 7 0 2 4 6 10 1 0
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Grade of differentiation  
For grade of differentiation, 33 cases were used (8 non-assessable cases omitted).  
The overall κ score for the reporting of the grade of differentiation was 0.16 (95% CI 
0.11 – 0.21, p < 0.001). Figure 5.31 demonstrates the breakdown of the grade of 
differentiation for each case.   
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Figure 5.31: Overall results for each case in deciding the grade of differentiation in round 1 excluding the non-assessable cases.  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Poor 1 0 0 2 1 5 0 0 0 0 4 1 4 0 0 3 0 1 3 0 0 2 0 4 2 1 0 4 7 2 3 1 1
Non-Poor 9 10 10 8 9 5 10 10 10 10 6 9 6 10 10 7 10 9 7 10 10 8 10 6 8 9 10 6 3 8 7 9 9
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Lymphatic invasion 
For lymphatic invasion, 33 cases were used (8 non-assessable cases omitted).  The 
overall κ score for the reporting of lymphatic invasion was 0.11 (95% CI 0.06 – 0.16, 
p < 0.0001).  Figure 5.32 demonstrates the breakdown of lymphatic invasion for each 
case.   
  
199 
 
Figure 5.32: Overall results for each case in deciding the presence of lymphatic invasion in round 1 excluding the non-assessable 
cases. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
No 7 8 8 9 9 6 10 10 10 10 9 6 10 7 10 9 7 4 10 7 10 8 8 9 10 9 10 10 9 9 9 6 10
Yes 3 1 2 1 1 4 0 0 0 0 1 4 0 3 0 1 3 6 0 3 0 2 2 1 0 1 0 0 1 1 1 4 0
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Vascular invasion 
For vascular invasion, 34 cases were used (7 non-assessable cases omitted).  The 
overall κ score for the reporting of vascular invasion was 0.08 (95% CI 0.03 – 0.13, 
p< 0.00001).  Figure 5.33 displays the breakdown of each case.   
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Figure 5.33: Overall results for each case in deciding the presence of vascular invasion in round 1 excluding the non-assessable 
cases. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
No 7 7 6 9 10 10 10 10 9 10 10 9 7 10 10 10 9 8 10 8 7 10 7 8 10 10 7 10 10 8 10 10 8 10
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Haggit level 
For Haggit level of invasion, 9 cases were used (32 non-assessable cases omitted).  
The overall κ score for the reporting of Haggitt levels was 0.04 (95% CI -0.03 – 0.10, 
p < 0.0001).  Figure 5.34 displays the breakdown of each case.   
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Figure 5.34: Overall results for each case in deciding the Haggitt level of invasion in round 1 excluding the non-assessable cases.  
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Kikuchi level 
For Kikuchi level of invasion, only 2 cases were used (39 non-assessable cases 
omitted).  The overall κ score for the reporting of Kikuchi levels was 0.12 (95% CI -
0.06 – 0.30, p <0.0001).  Figure 5.35 displays the breakdown of both the cases.   
 
 
Figure 5.35: Overall results for each case in deciding the Kikuchi level of invasion in 
round 1 excluding the non-assessable cases.  
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Is the lesion fully excised? 
In this section, 29 cases were used (12 non-assessable cases omitted).  The overall 
κ score for that was generated by the question posed was 0.12 (95% CI -0.06 – 0.30, 
p < 0.0001). 
 Figure 5.36 demonstrates the breakdown of each case in relation to the question 
posed. 
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Figure 5.36: Overall results for each case in deciding whether the lesion is fully excised in round 1 excluding the non-assessable 
cases.  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
No 1 0 10 10 3 4 9 0 0 1 0 0 0 3 0 0 0 3 0 1 0 0 1 7 10 0 2 10 3
Yes 9 10 0 0 7 6 1 10 10 9 10 10 10 7 10 10 10 7 10 9 10 10 9 3 0 10 8 0 7
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Should the lesion have a radical resection? 
In this section, 24 cases were used (17 non-assessable cases omitted).  The overall 
κ score that was generated by this question posed was 0.24 (95% CI 0.18 – 0.30, p 
< 0.0001). Figure 5.37 demonstrates the breakdown of each case in relation to the 
question posed. 
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Figure 5.37:  Overall results for each case in deciding whether the lesion should receive a radical resection in round 1 excluding the 
non-assessable cases. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
No 3 9 1 6 4 4 2 9 9 9 2 5 9 8 3 7 6 6 7 3 1 8 4 4
Yes 7 1 9 4 6 6 8 1 1 1 8 5 1 2 7 3 4 4 3 7 9 2 6 6
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Should the lesion have a radical resection? 
  
209 
5.6.3.2 Round 2 results 
Shape of lesion 
For the second round, 29 cases were used (12 non-assessable cases omitted).  The 
inter-observer agreement in deciding the shape of the lesion generated a κ value of 
0.30 (95% CI 0.25 - .035, p < 0.001).  Figure 5.38 demonstrates the breakdown of 
the shape of the lesion that the pathologist had decided on each case.  
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Figure 5.38: Overall results for each case in deciding the shape of the lesion in round 2 excluding the non-assessable cases. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Sessile 1 0 1 3 2 0 2 0 2 0 0 2 2 8 1 4 0 2 0 1 1 2 1 9 3 0 4 5 7
Non-sessile 9 10 9 7 8 10 8 10 8 10 10 8 8 2 9 6 10 8 10 9 9 8 9 1 7 10 6 5 3
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Shape of lesion 
  
211 
Grade of differentiation 
For grade of differentiation, 38 cases were used (3 non-assessable cases omitted).  
The overall κ score for the reporting of the grade of differentiation was 0.20 (95% CI 
0.15 – 0.25, p < 0.001). Figure 5.39 demonstrates the breakdown of the grade of 
differentiation for each case. 
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Figure 5.39: Overall results for each case in deciding whether the grade of differentiation of the pT1 CRC in round 2 excluding the 
non-assessable cases.  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38
Poor 0 1 0 6 0 1 6 1 1 6 4 2 8 0 7 1 1 0 4 1 0 0 0 1 5 4 1 4 0 3 1 3 4 0 6 5 2 5
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Lymphatic invasion 
For lymphatic invasion, 38 cases were used (3 non-assessable cases omitted).  The 
overall κ score for the reporting of lymphatic invasion was 0.14 (95% CI 0.09 – 0.18, 
p < 0.0001). Figure 5.40 demonstrates the breakdown of lymphatic invasion for each 
case.   
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Figure 5.40: Overall results for each case in deciding the presence of lymphatic invasion in round 2 excluding the non-assessable 
cases.  
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Vascular invasion 
For vascular invasion, 37 cases were used (4 non-assessable cases omitted).  The 
overall κ score for the reporting of vascular invasion was 0.23 (95% CI 0.18 – 0.28, p 
< 0.0001).  Figure 5.41 displays the breakdown of each case.   
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Figure 5.41: Overall results for each case in deciding the presence of vascular invasion in round 2 excluding the non-assessable 
cases.  
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Haggit level 
For Haggit level of invasion, 9 cases were used (32 non-assessable cases omitted).  
The overall κ score for the reporting of Haggitt levels was 0.24 (95% CI 0.17 – 0.31, 
p < 0.0001).  Figure 5.42 displays the breakdown of each case.   
 
 
Figure 5.42: Overall results for each case in deciding the Haggitt level of invasion in 
round 2 excluding the non-assessable cases.   
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Should the lesion be resected? 
In this section, 26 cases were used (15 non-assessable cases omitted).  The overall 
κ score that was generated by this question posed was 0.46 (95% CI 0.39 – 0.51, p 
< 0.0001). Figure 5.43 demonstrates the breakdown of each case in relation to the 
question posed. 
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Figure 5.43: Overall results in round 2 for each case in deciding whether the lesion should receive a radical resection excluding the 
non-assessable cases.  
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Tables 5.4 and 5.5 summarize the results from both rounds 1/2 and modified rounds 
1/2. 
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Qualitative/ 
Quantitative factors 
Round 1  Modified Round 1 Number of cases 
excluded 
Shape of lesion [κ 
(95% CI)] 
0.33 (0.30 – 0.36) 0.39 (0.30 – 0.46) 11 
Grade of 
differentiation [κ 
(95% CI)] 
0.13 (0.09 – 0.18) 0.16 (0.11 – 0.21) 8 
Lymphatic invasion 
[κ (95% CI)] 
0.08 (0.03 – 0.12) 0.11 (0.06 – 0.16) 8 
Vascular invasion 
[κ (95% CI)] 
0.08 (0.03 – 0.19) 0.08 (0.03 – 0.13) 7 
Haggitt Level [κ 
(95% CI)] 
0.17 (0.15 – 0.19) 0.04 (-0.03  - 0.10) 32 
Kikuchi Level [κ 
(95% CI)] 
0.05 (0.03 – 0.08) 0.12 (0.06 – 0.30) 39 
Lesion fully 
excised? [κ (95% 
CI)] 
0.49 (0.44 – 0.53) 0.12 (0.06 – 0.30) 12 
For full resection? 
[κ (95% CI)] 
0.18 (0.14 – 0.22) 0.24 (0.18 – 0.30) 17 
Table 5.4: Summary of the results from both round 1 and modified round 1 
(exclusion of non-assessable cases). 
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Qualitative/ 
Quantitative factors 
Round 2 Modified Round 2 Number of cases 
excluded 
Shape of lesion [κ 
(95% CI)] 
0.21 (0.17 – 0.25) 0.30 (0.25 – 0.35) 12 
Grade of 
differentiation [κ 
(95% CI)] 
0.19 (0.15 – 0.24) 0.20 (0.15 – 0.25) 3 
Lymphatic invasion 
[κ (95% CI)] 
0.12 (0.08 – 0.17) 0.14 (0.09 – 0.18) 3 
Vascular invasion 
[κ (95% CI)] 
0.19 (0.14 – 0.22) 0.23 (0.18 – 0.28) 4 
Haggitt Level [κ 
(95% CI)] 
0.15 (0.13 – 0.17) 0.24 (0.17  - 0.31) 32 
Kikuchi Level [κ 
(95% CI)] 
0.07 (0.04 – 0.10)  41 
For full resection? 
[κ (95% CI)] 
0.32 (0.28 – 0.36) 0.46 (0.39 – 0.51) 15 
Table 5.5:  Summary of the results from both round 2 and modified round 2 
(exclusion of non-assessable cases). 
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5.6.4 Results of intra-observer study 
Nine out of the 10 pathologists had participated in the intra-observer study. Tables 
5.6 and 5.7 summarises the results of the intra-observer study that was conducted in 
between both rounds of the inter-observer studies. The kappa scores for quantitative 
factors appeared to be more reproducible when compared to the qualitative factors. 
Kappa Scores (intra-observer) – Qualitative analysis 
Observer Shape 
of 
lesion 
Grade of 
differentiation 
Lymphatic 
invasion 
Vascular 
invasion 
Haggitt 
level 
Kikuchi 
level 
Lesion 
fully 
excised? 
For 
resection? 
1 0.46 0.18 0.64 0.48 0.30 0.42 0.13 -0.09 
2 0.38 0.25 0.22 0.17 0.17 -0.01 0.27 0.31 
3 0.37 0.26 0.38 0.44 0.17 0.58 0.54 0.16 
4 0.62 0.32 0.43 -0.05 0.27 0.28 0.58 0.56 
5 0.73 0.87 0.75 0.75 0.91 1.00 0.90 0.92 
6 0.35 0.42 0.43 0.43 0.47 0.64 0.61 0.54 
7 0.79 0.51 0.87 0.78 0.78 0.77 0.89 0.92 
8 0.48 0.37 0.23 0.08 0.41 0.65 0.69 0.49 
10 0.50 0.05 -0.03 0.5 0.51 -0.47 0.77 0.50 
Table 5.6: Summary of the results for the intra-observer variation study on the 
qualitative factors. 
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Intra-class correlation co-efficient [ICC] (95% confidence interval) – Quantitative 
analysis 
Observer  Distance to nearest 
margin 
Depth of invasion  Width of invasion 
1 0.88(0.79 – 0.92) 0.90 (0.83 – 0.94) 0.76 (0.46 – 0.89) 
2 0.66 (0.45 – 0.81) 0.60 (0.36 – 0.76) 0.37 (0.02 – 0.59) 
3 0.81 (0.66 – 0.89) 0.83 (0.69 – 0.91) 0.78 (0.59 – 0.88) 
4 0.86 (0.77 – 0.92) 0.78 (0.66 – 0.87) 0.79 (0.64 – 0.88) 
5 0.99 (0.98 – 1.00) 0.97 (0.95 – 1.00) 0.99 (0.97 – 0.99) 
6 0.96 (0.91 – 0.98) 0.87 (0.62 – 0.94) 0.80 (0.64 – 0.89) 
7 0.98 (0.97 – 0.99) 0.97 (0.95 – 0.98) 0.72 (0.56 – 0.83) 
8 0.95 (0.91 – 0.97) 0.58 (0.37 – 0.73) 0.80 (0.68 – 0.87) 
10 0.89 (0.81 – 0.93) 0.61 (0.41 – 0.75) 0.63 (0.45 – 0.76) 
Table 5.7:  Summary of the results for the intra-observer variation study on the 
quantitative factors. 
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5.7 Discussion 
The main aim of this study was to assess the inter- and intra-observer agreement in 
reporting features of malignant colorectal polyps by regional lead histopathologists 
participating in the NHSBCSP within the asymptomatic population. However, 
effective clinical management of these malignant polyps is dependent on the quality 
of the histological assessment and diagnosis of these lesions. 
The secondary aim of this study was to assess the reliability of measuring proven 
and novel qualitative factors of colorectal polyp cancers. The proven high risk 
quantitative and qualitative factors and new novel quantitative factors such as width 
of invading carcinoma were tested between lead consultant histopathologists who 
participated in the NHS BCSP. This study is different from other previous inter-
observer studies, as the novel quantitative factors mentioned above have not been 
previously assessed.   
 
5.7.1 Grade of differentiation 
The grading of CRC is often considered a simple task. However, studies have shown 
that this is not the case and there is often poor to fair inter-observer agreement in 
grading of CRC (Chandler’s study yielded a Kappa value of 0.351 and 0.358 for a 
three tiered and two tiered grading system respectively (Chandler et al 2008); 
Komuta’s study yielded a Kappa value of 0.163 for a two tiered grading system) 
(Komuta et al 2004). This was apparent in this study where the Kappa value for the 
grading of pT1 CRC was 0.13 and 0.19 in round 1 and 2 respectively.  There was no 
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improvement in the inter-observer agreement despite omitting the non-assessable 
cases in the modified round 1 and 2. 
One of the main reasons that CRC grading produces a large degree of inter-
observer variation is that grading is very subjective.  The subjectivity of grading 
occurs because of the creation of artificial boundaries across a continuum and 
tumour heterogeneity.  The intra-tumour variation that arises in a CRC makes the 
application of the simplest grading system difficult (Compton 2003).  For pT1 CRC, 
pathologists have been advised to grade the CRC based on the area of poorest 
differentiation (Loughrey, Quirke and Shepherd 2014). Here, subjectivity may arise, 
as the areas of poorest differentiation may be small and inconspicuous and often 
missed during microscopic examination.   
There are two recognized methods of grading CRC. The first method that is 
recommended by the WHO is to grade a tumour as a poorly differentiated CRC if the 
predominant proportion of the cancer displays poor differentiation (Halvorsen and 
Seim 1988). This method is currently employed for pT2 CRCs and above in the UK 
(Loughrey, Quirke and Shepherd 2014).  The second method is that a grade of poor 
differentiation should be applied when any area of the cancer is considered to show 
poor differentiation. The NHS BCSP recommends the second method for pT1 
cancers (NHS BCSP 2016). 
In this study, the group of pathologists did not feel that there was an optimal method 
in determining the grade of differentiation based on the three methods as described 
above. In conclusion, they agreed to continue using the standard method of grading 
the pT1 CRC based on the area of poorest differentiation in order to ensure that no 
poorly differentiated cancer was missed. 
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5.7.2 Haggitt and Kikuchi Classification 
The inter-observer agreement in classifying pT1 CRC in both Haggitt and Kikuchi 
classifications were poor in this study. The Kappa values for Haggitt classification 
were 0.17 and 0.14 in rounds 1 and 2 respectively. The Kappa values for Kikuchi 
classification were lower with 0.05 and 0.07 in rounds 1 and 2 respectively.   
One of the main issues that contributed to the poor inter-observer agreement was 
the shape of the lesion. The shape of the lesion normally dictates the use of either 
the Haggitt or Kikuchi classification: Haggitt for polypoid lesions and Kikuchi for 
sessile lesions. We found high inter-observer variation with defining the shape with 
Kappa scores of 0.33 and 0.21 in both round 1 and 2 respectively.  Interestingly, the 
Kappa scores did not improve in round 2 despite reducing the rating categories (4 
rating categories in round 1 compared to 3 rating categories in round 2).  The kappa 
scores did improve but only to a small degree when the non-assessable cases were 
omitted in both rounds (0.39 for round 1 and 0.30 for round 2). 
In the real world, colonic polyps come in a variety of shapes ranging from sessile to 
pedunculated and also a combination of both sessile and pedunculated (semi-
pedunculated).  This will only further complicate the Haggitt or Kikuchi classifications 
and increase the inter-observer variability.  
Another factor that may contribute to low Kappa values within the Kikuchi 
classification is the fact that pathologists were unable to give a Kikuchi class to 
lesions that lacked a muscularis mucosae. Again, the lack of a muscularis mucosae 
means that the reporting pathologist is unable to subdivide the submucosa since 
they do not know where to start measuring from.  Even when the non-assessable 
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lesions were excluded, Kappa values did not improve.  In this study, we also studied 
the inter-observer variation of pathologists reporting in the presence of a muscularis 
mucosae within the lesion and the results still generated a kappa score of 0.014.  
 
5.7.3 Lymphatic and vascular invasion 
Lympho-vascular invasion in CRC is considered a strong indicator for a poorer 
outcome and often influences the post-surgical treatment of the patient. This is the 
reason that the detection of lympho-vascular invasion is vital in providing a prognosis 
and also confirming the use of adjuvant therapy after cancer resection. However, the 
detection of lympho-vascular invasion is often difficult on a standard H & E slide. 
This was clearly evident from this study with poor inter-observer agreement for both 
lymphatic and vascular invasion in the two rounds.  Previous studies (Harris et al 
2008, Kojima et al 2013) have shown better inter-observer agreements but overall, 
the kappa values were still moderate at best.  
The use of immunohistochemical stains such as CD31 (used in identifying vascular 
endothelial cells) and D2-40 (used in identifying lymphatic endothelial cells) have 
aided the pathologist in identifying lymphovascular invasion in many malignancies.  
However, these immunohistochemical stains are not being used routinely in the 
identification of lymphovascular invasion in pT1 CRC and the literature is not 
supportive of substantial benefit for immunohistochemistry (Harris et al 2008, Kojima 
et al 2013).  There are a number of reasons why these stains are not used on a 
routine basis. Firstly, these stains add cost and are labour intensive for laboratories 
and the pathologist. Secondly, applying these special stains adds at a minimum 1 
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day and may delay the result. Thirdly, special lymphovascular stains such as CD31 
and D2-40 have not been shown to improve the inter-observer agreement in the 
identification of lympho-vascular invasion when compared to the standard H & E 
stains (Harris et al 2008, Kojima et al 2013).   
In performing this study, the general consensus between the pathologists was that 
they did not think the immunohistochemical stains for lymphatic and vascular 
invasion would be more beneficial or more predictive for LNM. It was agreed that 
these stains need further evaluation and to show significant benefit before they can 
be used routinely in the NHSBCSP. 
 
5.7.4 Depth of invasion 
Depth of invasion should ideally be measured from the bottom of the muscularis 
mucosae (the most superficial part of the lamina propria) to the deepest part of the 
tumour mass/ cell. This quantitative measurement should be reproducible and simple 
to perform. However, this is not always the case. 
The invading tumour often destroys the muscularis mucosae making it difficult or 
impossible to measure the depth of invasion from the muscularis mucosae. The 
other option in measuring the depth of invasion is to measure from the luminal 
surface to the deepest site of invasion. However, this may introduce two factors that 
can decrease the reproducibility of this method of measurement. Firstly, ulceration of 
the surface in some of the cancers may lead to an apparent thinning of the thickness 
of the lesion and may lead to an under estimation of the depth of invasion. 
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Conversely, some cancers exhibit exophytic adenomatous growth and this increases 
the tumour thickness and would lead to an overestimation of the tumour depth.  
In this study, we have investigated the reproducibility of the measurement of depth of 
invasion. The depth of invasion had produced moderate and almost perfect 
agreement in both round 1 and 2 respectively.  The reason behind the high levels of 
agreement in measuring depth of invasion in this study is that the participating 
pathologists mainly measured the depth from the epithelial surface of the lesion, as 
recommended by the Japanese, ignoring the muscularis mucosae (which was 
absent in most cases). Adopting this would inappropriately increase the resection 
rate using the Japanese definition of resection if invasion is >1mm. 
 In this study we also analysed the inter-observer variation of measuring the depth of 
invasion by generating different types of virtual muscularis mucosae. The first 
consisted of creating an imaginary muscularis mucosae which would have been 
present if it had not been destroyed by the cancer. This measurement performed 
nearly as well as measurement from the surface.  The second type of virtual 
muscularis mucosae is a straight line that connects the edges of the residual 
muscularis mucosae.  This method of creating a virtual muscularis mucosae has not 
been proven to be prognostic for lymph node metastasis and did not improve the 
degree of observer variation. However, the measurement of depth from the different 
types of virtual muscularis mucosae was undertaken to explore the different ways to 
overcome the problem that arises when measuring depth of invasion when a 
muscularis mucosae is not present.  
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5.7.5 Distance to margin 
The measurement of the distance from the invasive carcinoma to the resection 
margin produced reasonable inter-observer agreement. In round 1, an ICC of 0.58 
was obtained and this had increased to 0.77 in round 2 when the pathologists had 
been provided with further guidance.  
A perfect or almost perfect agreement is difficult to achieve in measuring the 
distance to the resection margin. This is due to the method by which the polyps are 
removed endoscopically within the bowel. The majority of polyps are removed by a 
diathermy snare or with a similar device. The diathermy produces a considerable 
amount of heat that burns and coagulates the resection margin of the polyp 
specimen. This introduces a number of artefactual changes. These changes include 
retraction of the resection margin into the tissue sample thereby reducing the 
distance of the resection margin. The heat that the diathermy produces also causes 
the resection margin to be “jagged”. The blood vessels and connective tissue within 
the submucosa coagulate at different temperatures and causes the coagulated blood 
vessels to stand proud of the rest of the tissue of the retracted diathermy margin. 
There may also be marked clefting along the sides of the coagulated blood vessels 
because of the differential shrinkage of the vessels and stroma leading to the 
splitting or fragmentation of the resection margin.  
The improvement in inter-observer agreement between the two rounds was achieved 
after a senior pathologist had made a simple but important recommendation after 
round one, which was then implemented, in round 2.  The recommendation 
suggested was to adopt a conservative approach when measuring the distance to 
the margin, ignore retraction artefact and only measure to the margin that they are 
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confident on.  This recommendation has now been introduced into routine practice 
within the NHSBCSP and confirmed in the latest revision of the pathology guidelines 
(NHSBCSP 2016). 
 
5.7.6 Width of lesion/carcinoma 
In this study, we have defined the width of a lesion as both the width of the 
carcinoma and adenoma component together. The ICC value for the width of lesion 
in both round 1 and 2 were in almost perfect agreement (0.728 and 0.949 
respectively).  
However, when the group of pathologists were requested to measure the width of 
the carcinoma only in round 2, the ICC value showed poor agreement (ICC value of 
0.01). The strong agreement of the ICC values in both rounds for width of the lesion 
could be attributed to the pathologist easily identifying the boundaries between the 
normal colonic mucosa and the carcinoma/ adenoma component. In contrast, the 
poor agreement obtained in measuring the width of carcinoma could be due to the 
difficulty in identifying the transition from the carcinomatous to the adenomatous 
component. This might be improved by better guidance and definitions.  This is 
important to test as this measurement performed well in predicting LNM as described 
in Chapter 2. 
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5.7.7 Decision to resect 
Pathologists currently play a major role in deciding the type of treatment a patient 
receives for their early colorectal cancer. The decision to resect the bowel containing 
the early colorectal cancer has important implications for the patient, surgeons and 
the NHS. Therefore, it is very important that the pathologist gets the decision right. 
There are several histopathological factors that can influence and guide a pathologist 
into making the correct decision. Examples of these histopathological factors are the 
grade of differentiation of the cancer, lymphatic and vascular involvement, the depth 
of invasion, the distance of the cancer from the excision margins and the size of the 
cancer. There are other clinical decisions that may affect the decision of resect the 
bowel containing the early colorectal cancer such as the pre-morbid state of the 
patient. However, the treatment decision is never straightforward requiring 
discussion in the multidisciplinary team. 
In this study, we aimed to assess the degree of inter-observer variability in making 
the decision to resect the bowel containing the early colorectal cancer. This was an 
artificial process as they were required to make a decision on only one slide and they 
did not have to define the basis of that decision.  In both rounds of the study, only a 
fair level of agreement could be achieved (0.265 and 0.30 in round 1 and 2 
respectively).  
The overall fair level of agreement in making the decision for resection could be due 
to summation of a number of different high risk factors that individually demonstrated 
poor or moderate inter-observer agreement and others such as incomplete excision 
that had better inter-observer variation helping to lift the agreement.  
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The fair level of agreement could also be down to the individual pathologist regarding 
different histopathological factors as high risk. In this study, there were no 
standardized criteria implemented in determining the decision for resection, however 
one would expect individual risk factors such as incomplete excision, poor 
differentiation, vascular and lymphatic invasion as well as sm3 invasion to lead to 
such a decision. The multiplicity of potential factors and their inter-observer variation 
must contribute to this issue.  If there is inter-observer variation in differentiation, 
lymphatic and vascular invasion then the ultimate decision to resect will vary widely.  
This is most likely the reason for only a fair level of agreement. 
 
5.7.8 Exclusion of non-assessable cases 
The decision was made to exclude the non-assessable cases in an attempt to 
reduce the number of cases when a feature might not be used e.g Haggitt vs Kikuchi 
in each qualitative analysis and thus, hopefully improve the inter-observer 
agreement.  Re-analysis of the inter-observer variation studies without the non-
assessable cases showed slight improvements or no change in the kappa scores 
with the decision for full resection in both round 1 and 2 showing the greatest 
improvement in kappa scoring (table 5.4 and 5.5).  However, for the classification of 
Haggitt levels and the assessment of the completeness of excision of the lesion in 
the modified round 1 showed a decreased kappa score.   
Despite the reduction in both the cases and categories in each qualitative analysis, 
no major improvement in inter-observer agreement was achieved.  This highlights 
the subjectivity of qualitative analysis of these lesions.  Therefore, either better 
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qualitative definitions and guidelines are needed in assessing these lesions to help 
reduce the inter-observer variability, however this may be in vain due to the 
subjective nature of many of the definitions or assessments.  If possible we need to 
move to reproducible quantitative assessments.   
 
5.7.9 Prospects of novel quantitative factors 
The findings of width of the invading carcinoma and area of submucosal invasion as 
a predictor for LNM is very promising as these two quantitative factors can be quickly 
and easily measured on standard H & E slides.  Additionally, there is no extra cost in 
measuring these quantitative factors.   
For the width of the invading carcinoma, unfortunately, there was great inter-
observer variation (ICC value – 0.01) between the pathologists in the inter-observer 
study.  This is a contrast to the inter-observer variation analysis (to assess the 
reproducibility of the quantitative factors in chapter 2) done between the main and 
senior author that produced an ICC value of 0.76.  Two issues could explain the 
discrepancy in the ICC values.  Firstly, the caseload for the inter-observer variation 
analysis between the main/senior author and the group of pathologists were 
different.  Secondly, the number of cases also varied: 10 cases were examined in 
the inter-observer variation analysis of the main/senior author compared to the inter-
observer variation analysis between the pathologist where 41 cases were examined.  
Despite the poor ICC values obtained in the inter-observer variation analysis 
between the pathologists for the width of the invading carcinoma, we feel that this 
quantitative factor is still a simple and valuable factor in the prediction of LNM and as 
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mentioned earlier, a better inter-observer agreement might be achieved in measuring 
this factor with better definitions and guidance.  Also, we need further studies since 
the width of carcinoma only missed only 1 case with a LNM that was identified by the 
area of submucosal invasion. 
The area of submucosal invasion had fared much better than the width of invasion in 
terms of inter-obsever agreement.  In this study, the area of submucosal invasion 
had produced a moderate agreement between the pathologists (ICC value – 0.59).  
One of the reasons that a better agreement could not be achieved in measuring this 
quantitative factor is the difficulty in identifying the muscularis mucosae if the 
muscularis mucosae had been destroyed by the CRC.   
It is worth mentioning that the ICC value obtained between the main and senior 
author is very encouraging (ICC value – 0.95).  This shows that with better 
definitions and adequate training, the inter-observer agreement for the area of 
submucosal invasion can be improved.  We feel that this is necessary as the area of 
submucosal invasion is an important quantitative factor in predicting LNM. 
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5.8 Conclusion 
The overall results from this study emphasises the urgent need to improve the level 
of agreement in reporting early CRCs especially the early CRCs identified within the 
NHS BCSP.  The areas that that needed improvement or replacement were mainly 
qualitative factors such grade of differentiation, lymphovascular invasion and level of 
invasion based on Haggitt and Kikuchi definitions.  Despite the quantitative factors 
faring slightly better than the qualitative factors in terms interobserver agreement, 
there is still a lot of work to be done to improve both these factors.  
The creation and implementation of the NHS BCSP EQA scheme has helped 
improve the quality of pathology and maintains a high quality level of reporting within 
the screening programme. However, the problematic areas must be further 
addressed and improved.  A move to quantitative factors, a robust multivariate model 
that gives recurrence risk for an individual patient, combined with better reporting 
guidelines and clarification of the diagnostic criteria paired with training and 
educational workshops are required.  We also agree with Turner et al that further 
development of pathology networks specialising in the assessment of complex or 
unusual lesions from the NHSBCSP along with further support via tele-consultation 
would help improve interobserver agreement (Turner et a 2013).  
We hope that these suggestions may improve the risk assessments and ensure a 
higher standard level of reporting and thus, reducing inter-observer variations 
between pathologists.  Nevertheless, the search for better predictors of metastasis 
must go on. 
 
  
238 
Chapter 6 Overall conclusions and future work 
 
6.1 The future of the NHS BCSP 
The introduction of the NHS BCSP has led to an increase in detection of CRC within 
the screened population.  The NHS BCSP has also increased the diagnosis of early 
and favourable staged CRC.  As of May 2016, 25,528 CRCs have been detected via 
FOBt and 248,109 high risk polyps were identified (P Quirke 2016, personal 
communication).  This has resulted in an increase in both local procedures and 
radical resections.  
The numbers of radical resections and local procedures are expected to further 
increase in the near future with the replacement of FOBt with faecal 
immunochemical testing (FIT).  FIT is an important technical improvement to the 
standard FOBt.  FIT works principally by the detection of the human globin protein by 
specific antibodies.  Whilst the haem component of haemoglobin is common to all 
species, globin is species specific and so FIT should not be subjected to interference 
by blood from normal dietary intake.  The Japanese have been using FIT in their 
bowel cancer screening schemes since the 1980s (Saito et al 2000, Ross 2010).  In 
the Netherlands, studies have shown that participation and detection rates for 
advanced adenomas and CRC were significantly higher for FIT when compared to 
FOBt (van Rossum et al 2008, van Rossum et al 2009).  Therefore, we may expect 
and increase detection of early CRC with the introduction of FIT.  
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The UK Flexible Sigmoidoscopy Screening Trial has shown that flexible 
sigmoidoscopy is a safe and practical screening test that offers substantial and long 
term benefits (Atkinet al 2010).  Together with the NHS BCSP, it is hoped that in the 
future, CRC would be discovered at an earlier stage and thus reducing stage 4 
diseases and improving outcomes in the treatment of CRC.  
 
6.2 The challenges of diagnosing and treating pT1 CRCs  
The management of patients with pT1 CRCs is highly dependent on the quality of 
the histological reporting of these CRCs. One of the challenges faced by pathologists 
is the inter-observer variability in the histological assessment of pT1 CRCs.  There is 
still a substantial degree of inter-observer variability in the histological assessments 
of high risk features such as grade of differentiation, lymphatic and vascular invasion 
and this was evident in this study. These findings are consistent with those of 
previous studies (Foss et al 2012, Turner et al 2013) and highlights that there is still 
room for improvement in the histological assessment and reporting of pT1 CRCs.  
This study also highlights the need for development of better definitions and 
clarification for the current histopathological reporting criteria of these high risk 
features and inclusion of these in NHS BCSP reporting guidelines leading to fewer 
discrepancies in histopathological reporting and improved patient management.   
Another challenge faced by the multi-disciplinary team is choosing the correct 
treatment for patients with early CRCs.   With the NHS BCSP in place, the huge shift 
towards early CRCs has had a major impact on the treatment that is provided for 
these cancers. The main goal of treatment in early colorectal cancer is to provide a 
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cure with no or minimal morbidity and mortality risk. Therefore, histopathological 
analysis plays an important role in deciding the type of treatment that can be offered 
to patients with pT1 CRCs.  Known subjective high risk histopathological features 
such as poor grade of differentiation, lymphatic and vascular invasion have already 
helped dichotomize patients into two main treatment groups; local procedure or 
radical resection.  In this present study, we have identified three further novel 
quantitative histopathological features that may be useful in the therapeutic decision 
making.  These three quantitative features are the width of invasion of the cancer, 
area of submucosal invasion and proportion of tumour stroma (PoTS).  Both the area 
of submucosal invasion and PoTS are independent prognostic markers for LNM in 
our studies.    
The width of invasion and area of submucosal invasion have been shown to be 
reproducible in this study (width of invasion: ICC score of 0.728 and 0.949 in round 1 
and round 2 of the inter-observer variation study; area of submucosal invasion: ICC 
score of 0.95 in the reproducibility test between main and senior author).  These two 
quantitative features are also applicable to all pT1 CRCs, even those of different 
shapes and therefore, could hopefully be used as a substitute for the Haggitt and 
Kikuchi classifications which require different assessment methods dependent on 
whether flat, raised or polypoid.  Another benefit of using these quantitative factors is 
that there will less subjectivity in assessing pT1 lesions compared to the well-known 
high risk qualitative factors such as grade of differentiation, lymphatic and vascular 
invasion. 
The PoTS is an interesting and new quantitative feature.  Our studies have shown 
that a high PoTS is a prognostic factor for LNM and could be useful in therapeutic 
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decision making.  However, this novel quantitative factor will need to be tested and 
validated in a larger series of pT1 CRC compared to other suggested factors.   
As shown in this study, screened pT1 CRC are smaller in size compared to 
symptomatic pT1 CRC.  Therefore, the treatment options for screened pT1 CRC will 
either consist of conservative or surgical management.  The conservative 
management includes watchful waiting and monitoring with radiological analysis 
(MRI).  Surgical management on the other hand includes local procedures (TEMS 
and EMR) or radical resection the cancer.  The main determinant for either treatment 
options is whether the pT1 CRC is at risk of LNM.  Thus, we hope that the findings of 
these new and novel quantitative features will help stratify screened pT1 CRC 
patients into the correct treatment groups and thereby minimizing mortality and 
morbidity.   
 
6.3 Future works 
Further studies are needed in screened and non-screened populations to validate 
these novel quantitative features.  The cut-off values of the novel quantitative factors 
were obtained by the ROC curves are a hypothesis and will need validating in 
multiple larger independent series of pT1 CRC.   
In regards to improving inter-observer variation between pathologists, clearer 
definitions and guidelines need to be developed, tested and validated ideally by a 
group of pathologist who are part of the NHSBCSP.  If possible grading should be 
automated or replaced, as this is an important feature predicting LNM. Poorly 
differentiated tumours must also be tested for deficient mismatch repair to exclude 
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this as a cause of the poor differentiation due to their lower metastatic potential 
(Braun et al 2008, Hutchins et al 2011, Smith et al 2013) 
Another phenotypic feature in CRC that needs further evaluation is tumour budding.  
Tumour budding has been recognized as an important additional prognostic factor.  
Tumour budding in CRC has been associated with poorer overall survival and 
increased risk of LNM and/or distant metastasis (Hase et al 1995, Nakamura et al 
2005, Lugli, Karamitopoulou and Zlobec 2012, Koelzer, Zlobec and Lugli 2014, 
Koelzer, Zlobec and Lugli 2016).  Tumour budding may help identify pT1 CRC that 
are high risk for LNM (Wang et al 2005, Yamauchi et al 2008, Tateishi et al 2010, 
Nakadoi et al 2012).  Tumour budding may also prove to be an additional indicator 
for neoadjuvant therapy in early rectal cancers (Morodomi et al 1989, Rogers et al 
2014).  
However, at this present time, tumour budding is not routinely used in the reporting 
of CRC.  The two main reasons are because there is no standardized method or 
definition in measuring tumour budding and the inter-observer agreement in tumour 
budding is still variable (Koelzer, Zlobec and Lugli 2016, Okamura et al 2016).  
Efforts have already been made to improve inter-observer agreement in assessing 
tumour budding but results are conflicting.  Kai et al (2016) showed that the use of 
cytokeratin immunohistochemistry (AE1/AE3 immunostain) improved the evaluation 
of tumour budding and reduced inter-observer variability by less experienced 
pathologists. However, Okamura et al (2016) showed that tumour budding detected 
by cytokeratin immunohistochemistry (CAM 5.2 immunostain) was not superior to the 
standard H & E stain.  The results of Okamura’s study is promising as there is no 
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need for extra staining of the specimen and the standard H & E staining would 
suffice. 
Hence, the assessment of the possibility of using tumour budding as a prognostic 
factor should be undertaken.  In particular, a standardized method and optimal 
scoring method should be established.   This has just been achieved at a recent 
consensus conference allowing the place of budding to be effectively tested (P 
Quirke 2016, personal communication) and compared to other factors and this is 
now on-going in our laboratory. 
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6.4 Conclusion 
These are exciting times for everyone involved in CRC screening and treating early 
CRCs.  The results of the NHS BCSP are very encouraging with the increased 
detection of early CRCs and improved outcomes.  Similarly, the goal of providing a 
more personalised treatment for patients based on the phenotypic features of their 
early CRC appears achievable with the promising novel high risk features identified 
in this study. This will not only be advantageous to patients in terms of reducing 
morbidity/ mortality and increasing cure rates but it will also reduce healthcare costs.   
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Appendices 
Appendix I: Invitation letter to 1st round of interobserver study 
 
Dear Colleague, 
 As you are aware from the committee meeting we are keen to investigate the 
reproducibility of the factors and measurements we are asking our colleagues to 
make on pT1 cancers. We would like you to undertake 10 key tasks on this occasion 
and we will ask you to repeat this in 6 months time. 
 These tasks are: 
1. To define the shape of the lesion (Pedunculated / Semi-pedunculated/ 
Sessile) 
2. To define the grade of differentiation 
3. To identify the distance of carcinoma to the nearest margin 
4. To identify the presence of lymphatic invasion 
5. To identify the presence of vascular invasion 
6. To state whether lesion can be assessed by Haggitt’s levels and identify the 
level of invasion( Level 1/ 2/ 3/ 4) 
7. To state whether lesion can be assessed by Kikuchi’s levels and identify the 
level of invasion (SM1/ SM2/ SM3) 
8. To measure the width of carcinoma 
9. To measure the depth of invasion of the carcinoma 
10. To state whether the lesion/ carcinoma is fully excised and/or should be 
resected 
 
The cases can be accessed on the website as below: 
http://www.virtualpathology.leeds.ac.uk/demo/et.php 
The findings will be anonymised and your data fed back against everybody 
else after the second round.  All participants will be included as authors. If you do not 
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have time to undertake this exercise, then we will have to exclude you from the 
authorship but we would like a high level of participation so as inform 
recommendations to the NHS Bowel Cancer Screening Programme.  
If you have any technical issues please contact Eu-Wing Toh 
(euwing@gmail.com) and if you have any matters of principle please contact me 
p.quirke@leeds.ac.uk 
 
Yours sincerely, 
 
Professor Phil Quirke 
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Appendix II: Invitation letter to 2nd round of interobserver study 
 
Dear Colleague, 
 Following on from the recent NHS BCSP committee meeting and the revised 
diagnostic criteria that we redeveloped we continue to be keen to investigate the 
reproducibility of the factors and measurements that we undertook on the last series 
of pT1 cancers. We would like you to undertake 11 key tasks on this occasion. 
 These tasks are: 
1. To define the shape of the lesion (Non-sessile/Sessile) and also 
measurements of the width and base of lesion in defining the shape of the 
lesion (appendix I). The width of the lesion in this context is the width of the 
adenoma and carcinoma component together 
2. To measure the width of carcinoma (carcinoma component only) 
3. To identify the distance of lesion to the nearest margin  based on your 
methods and the new method described by Dr Da Costa(see appendix II) 
4. To measure the depth of invasion of the carcinoma based on 4 methods (see 
appendix II) 
5. Area of invasion of carcinoma below the muscularis mucosae (see apendix III) 
6. To define the grade of differentiation (Non-poor/ Poor) 
7. To identify the presence of lymphatic invasion 
8. To identify the presence of vascular invasion 
9. To state the Haggitt’s levels ( Level 1/ 2/ 3/ 4) 
10. To state the Kikuchi’s levels (SM1/ SM2/ SM3) 
11. To state whether the lesion/ carcinoma should be resected and state why it 
should be resected 
We would like to request that all the tasks be answered to the best that is 
possible and please try not to give answers as ‘non-applicable’.  Similar to the 
previous studies, the findings will be anonymised and your data fed back against 
everybody in an upcoming meeting.  All participants will be included as authors. If 
you do not have time to undertake this exercise, then we will have to exclude you 
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from the authorship but we would like a high level of participation so as inform 
recommendations to the NHS Bowel Cancer Screening Programme.  
If you have any technical issues please contact Eu-Wing Toh  
euwing@gmail.com and if you have any matters of principle please contact me 
p.quirke@leeds.ac.uk 
Best wishes, 
 Eu-Wing Toh and Phil Quirke  
 
